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Abstract 
Current cancer diagnostic trajectories consist of clinical evaluation, various 
imaging techniques, histological assessments, biomarker assays and, if 
applicable, endoscopic investigations. Biomarker assays are known to focus on 
serum tumour markers, such as tumour proteins or tumour DNA. In recent 
literature a focus has emerged on the role of the immune system in cancer origin 
and development. In the immune system of healthy persons monocytes and 
macrophages play an important role in managing tissue homeostasis by 
patrolling, cytokine production and antigen presenting capabilities towards other 
immune cells. They form the first barrier of defence in the intestinal tract and are 
able to clear invasive pathogens. In patients with colorectal cancer (CRC) 
macrophages play an important role in tumour progression due to their plasticity. 
Subpopulations are formed with their own specific tasks based on tumour cell 
influences. Methods to diagnose or monitor CRC utilising the immune cell 
populations are new and challenging. CRC is the fourth most common form of 
cancer in the Netherlands after prostate cancer, breast cancer and melanoma. 
Key in diagnosis and treatment is the ability to detect primary and recurrent 
disease in time for curation. In this review the origin and role of macrophages in 
cancer is described, with a focus on the non-hereditary form of CRC. The 
available screening, diagnostic and monitoring methods for CRC are described 
to provide context for experimental diagnostic and monitoring methods including 
macrophage-assays. 
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1. Macrophages in (colorectal) cancer  
1.1 The monocyte phagocyte system 
Monocytes, macrophages and dendritic cells (DCs) are part of the mononuclear 
phagocyte system. Their progenitors (such as haematopoietic stem cells (HSC) 
and common myeloid progenitors (CMP)) have their origin in bone marrow1. 
Macrophages and DCs develop from monocytes as their direct precursor, both 
having their own specific functions within the immune system. Originally 
identified by the Russian immunologist Metchnikoff during the 1880's, 
macrophages (called phagocytes at that time) are ancient phagocytic cells, 
being part of the innate immune system. "Macrophage" literally means "large 
eating cell", one of its prime functions and a description of its morphology2.  
Macrophages are designated self and non-self identifiers. This enables them to 
not only discern host from foreign substances, but also to recognise host 
elements that have become "foreign", such as damaged or dying cells2. These 
dying cells can be part of stromal tissue consisting of tumour and immune cells3.  
1.2  Monocyte and macrophage activation 
Until a few years ago, two distinct pathways for macrophage activation were 
described in literature, the classic (M1) and alternative (M2) activation4,5. In 
cancer, activation status was thought to depend on the stage of tumour 
development6,7. M1-macrophages were considered pro-inflammatory, activated 
to react on infiltration or tissue damage by non-self entities. Sometimes M1-type 
reactions would be excessive, and therefore lead to prolonged inflammation. 
This results in (chronic) tissue-damage as found in diseases such as Crohn’s 
disease or ulcerative colitis. The widespread inflammation in turn would lead to 
extensive DNA-repair and inherent mutations, prone to become carcinogenic. 
The M2-macrophages were found to exhibit an immunosuppressive profile 
(T-cell inhibition and tumour growth promotion8). This has been proven present 
in human tumours such as ovarian carcinoma and glioma9,10. Recent literature 
describes more of an activation continuum where M1 and M2 are each the 
extremes. This continuum consists of macrophages flexibly categorised in 
classically activated, wound-healing and regulatory macrophages, dependent on 
their cell surface marker expression, cell function/secretions and signalling 
specifications11. Macrophage plasticity and diversity is currently investigated in 
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relation to inflammatory (colorectal) diseases and their proposed subsequent 
malignant evolution. It is thought that when monocytes are recruited locally they 
must undergo a rapid local education process to support homeostasis. 
Otherwise alternative fates are adopted, possibly promoting inflammation12. 
 
 
 
 
 
 
 
 
Figure 1.1 Macrophage with bluish core staining, showing a brownish prostate specific antigen 
(PSA) staining intracellularly (Leers et al 2008). The large irregular cell with multi-
lobulated core shows the distinct morphology of the macrophage. 
 
1.3  Monocyte heterogeneity; three distinct subtypes 
In humans, heterogeneity of monocytes can be immunophenotypical shown by 
the expression of CD14 (LPS-binding protein complex) and CD16 (Fcɣ-receptor 
type III). CD16 is a marker of monocyte activation. The simultaneous expression 
of CD14 with CD16 enables detection of differentiated activated monocytes 
resembling circulating and tissue macrophages13-15. It is known that CD16+ 
monocyte levels are elevated in metastatic gastric, colon and rectal cancer 
patients as well as in sepsis patients16. CD16+ monocytes account for 46%±22% 
in cancer patients versus 5%±3% for controls. It has been proposed that the 
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CD16+ population would offer a readily accessible, quantifiable means by which 
to identify and follow a host’s response to treatment17. The majority of 
monocytes are CD14++CD16- (classic monocytes, ~90% of the total monocyte 
population). The CD16+ monocytes can be subdivided into CD14+C16++ (non-
classical) monocytes and CD14++CD16+ (intermediate) monocytes. The latter 
mentioned subset (including atypical macrophages and dendritic cells)18 has an 
intermediate phenotype between the classical and non-classical monocytes with 
a higher antigen presenting activity and pro-angiogenic capacity (Figure 1.2)19,20. 
These intermediate cells show CD163 positivity concurrent with the classical 
monocytes, which differentiates them from the non-classical subtype. A low level 
of CD62L (L-selectin) is observed in non-classical monocytes combined with a 
low level of chemokine receptor 2 (CCR2), which is not seen in the classical and 
intermediate subtypes. This last finding has also been reproduced in mice, rats 
and pigs, suggesting a homology across species19. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Example of monocyte subsets gating strategy in humans as defined by flow cytometry 
(Ziegler-Heitbrock, 2014) 
 
Ziegler-Heitbrock et al. described in 1993 that CD14+CD16+ monocytes exhibit 
a higher level of class II antigen and a lower level of CD11b and CD33 antigens 
compared to the CD14++ monocytes. The CD14+CD16+ monocytes are 
therefore known as a more mature monocyte type. The consistency with tissue 
macrophages has been investigated by stimulation of peripheral blood 
mononuclear cells. This resulted in a higher class II antigen and lower 
CD11b/CD33 antigen expression confirming acquisition of features in common 
with mature tissue macrophages13.  
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In mice, macrophage cell surface expressions of CD11c and CD11b in 
combination with F4/80 antigen are characteristic for monocyte-derived 
macrophages residing in the lamina propria of the colon. Besides that, they 
express CD64 and CX3CR112. The latter enables (flow cytometrical) 
macrophage detection in mice-experiments using GFP-reporter gene insertion21. 
1.4  Monocyte and macrophage trafficking 
Investigation of macrophages using a murine model enables visualisation of 
macrophage movement, also known as trafficking. By means of GFP-labelling, 
trafficking has been shown in vivo in mice22,23. Patrolling monocytes were found 
to roll over the intraluminal vessel wall and subsequently extravasate. 
Monocytes, which extravasated into the gut, are shown to be able to retain their 
CD14/CD16 monocyte state and migrate further after internalising substances in 
the tissue. Migration towards lymph nodes has been reported24. In other 
situations, such as in atherosclerosis25 and clearance of photoreceptor debris 
following retinal injury26,27, it has been shown that macrophages are able to 
migrate out of the tissue they resided in, back into the blood stream. A 
postulated hypothesis is that monocytes indeed extravasate, possibly 
differentiate into macrophages and perform local phagocytosis at the edges of 
(invasive) tumour growth. Subsequent migration back into the blood stream or to 
lymph nodes and beyond has been investigated28,29 and was confirmed by our 
research group30.  
1.5  The origin of the tissue-macrophage 
In combination with other mononuclear phagocytes, macrophages maintain 
tissue integrity during the development, initiation and resolution of innate and 
adaptive immunity. The continuity of the population of macrophages was 
historically thought to be mainly dependent on replenishment out of the blood 
stream by differentiating activated monocytes. Recently, organ-resident 
macrophages were discovered to derive from fetal progenitors developing out of 
the yolk sac during embryogenesis in specific organs31. Under steady state they 
exhibit the capacity for local self-maintenance without significant input of 
circulating monocytes, as was found for liver Kupffer cells (KC), lung alveolar 
macrophages, peritoneal macrophages, epidermal Langerhans cells and brain 
microglia32-36. On the other hand, experiments on mouse-gut showed that 
macrophages were found to repopulate mainly out of HSC-derived (activated) 
Ly6C+-monocytes. After extravasation from the blood stream they complement 
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the resident macrophage population. As a result, this highly versatile 
macrophage compartment of the total immune cell population in the lamina 
propria is able to rapidly adapt to the unique and dynamic intestinal environment 
it encounters12.  
1.6  Tumour-associated macrophages (TAM) 
Macrophages present in malignant tumours are called tumour-associated 
macrophages (TAM)8. TAM, apart from other myeloid cells including neutrophils, 
eosinophils and dendritic cells, can represent up to 50% of the total tumour 
mass. This infiltration grade was thought to be an indication of anti-tumour 
immunity, by now it is clear that this function is suppressed in the tumour 
environment. Macrophage-mediated cancer cell phagocytosis can be 
reinvigorated by a therapeutic intervention blocking CD47, a "don't eat me" 
signal over-expressed in most cancer cells8,37. In breast, gastric, urogenital, 
glioma, cholangiocarcinoma, Hodgkin lymphoma and glioma high density TAM 
infiltration is associated with worse overall survival, enhanced tumour growth 
and metastases. Interestingly though, in CRC high density TAM infiltration is 
associated with better overall survival38. It is suggested that TAM ontogeny, 
phenotype, their products and activation state, are more informative for patient 
prognosis than their absolute number in and around tumours8,39  
1.7  TAM in stromal tissue 
The stromal border around CRC consists of different macrophage-phenotypes, 
among other cell types such as T-cells, fibroblasts, dendritic cells and infiltrating 
leukocytes. In literature, the tumour cell to immune cell interactions have been 
described as cancer immunoediting. This phenomenon has a much broader 
basis than macrophages alone40-42. This review will not further dwell on the 
origins, functions and interactions of the other mentioned cells in the stromal 
border or their role in cancer development in general40. Macrophages contribute 
to a tumour microenvironment suitable for either tumour progression or tumour 
regression, where the outcome is based on an environmental balance shift 
either way11,38. TAM were thought to predominantly lean towards a M2-like 
phenotype43-45, but recent research shows that a dynamic activation switch 
occurs among TAM as the tumour develops, shifting from M1-state through 
different sub-states towards M2. This finding may help explain the mixed 
activation state of TAM populations found in different murine and human 
tumours44,46,47. In chronic unresolved inflammation sites, macrophages in M1 
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status are considered more carcinogenic due to their ability to maintain and 
aggravate the inflammatory reaction. M2 macrophages (low IL-12 expression, 
high IL-10 expression and low tumouricidal activity) show more tumour 
promoting capabilities. These are based on trophic and wound healing 
properties, which promote angiogenesis and tissue remodelling8,48. Mouse 
studies show tumour progression to be associated with phenotypical switches 
from M1 to M2 macrophages49. Under tumour cell influence, macrophage-
induced angiogenesis is started when macrophages differentiate towards M2-
phenotype, the so-called angiogenic switch50. In hypoxic (tumour) areas, 
angiogenesis is promoted under influence of vascular endothelial growth factor 
(VEGF) produced by either CCL2- or HIF1α- recruited macrophages39,51. Tissue 
remodelling occurs under influence of matrix metalloproteinases (MMPs). These 
are produced by TAM under influence of signals from surrounding cells, 
including tumour cells, (e.g. MMP2 and MMP9).  
1.8  Cancer metastases, the role of the macrophage 
Tumours consist of several different ecosystems, such as cancer nests, 
peritumoural stroma, perivascular regions and hypoxic regions. This results in a 
complex, developing organoid structure. The macrophage phenotype differs 
within these different areas, displaying distinct functions8. For proteolytic 
destruction of the matrix macrophages produce MMPs, (serine) proteases and 
cathepsins. Macrophages facilitate tumour cells to migrate through the dense 
stroma and to ultimately escape the basement membrane confinement (48). 
Metastases in breast cancer are attributed to perivascular macrophages 
producing endothelial growth factor (EGF) attracting macrophage-colony 
stimulating factor-producing cancer cells. This results in a coordinated migration 
and intravasation of cancer cells at macrophage dense sites. This migratory 
nature of perivascular macrophages is seen in vascular dense areas as opposed 
to limited TAM migration in avascular regions52,53. This combination of tumour 
cells and vessel-associated macrophages forming metastasis-favourable sites 
based on attracting cancer cells has been directly visualised in a murine model. 
It is hypothesised that these (vessel associated) TAM are able to promote 
migration and intravasation by chemotactically attracting tumour cells, and 
enabling them to enter the bloodstream52,53. The colony-stimulating factor 1 
(CSF-1)/EGF paracrine loop, existing between tumour cells and macrophages, 
facilitates tumour cell migration along fibrous strands (fibrillar collagen I) in the 
stromal tissue towards blood vessels. Once the tumour cell arrives, the vascular 
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macrophages facilitate further migration into the bloodstream54,55. In mice 
bearing mammary tumours, EGF or CSF-1 inhibition and genetic TAM-reduction 
effectively reduces circulating tumour cells48. In CRC mice models a collective 
invasion of sheets of cells are found instead of single cell invasion as in breast 
cancer. In CRC an immature myeloid cell population surrounding the invasive 
front is described. These immature myeloid cells produce MMP type 9 (MMP9) 
and type 2 (MMP2), which are required for tissue remodelling, and subsequent 
tumour cell invasion possibly resulting in metastases56. This macrophage-MMP9 
production also reduces DCs ability to migrate and release anti-tumour activity57 
in combination with the hypoxic environment. Upregulation of macrophage-
VEGF and basic fibroblast growth factor (bFGF) keeps T-cells from invading 
tumour environments by inhibiting adhesion molecule expression on endothelial 
cells58. These are only a few examples of the total arsenal of the 
immunosuppressive repertoire regulated by tumours, orchestrating TAM to 
perform as is wanted. They use macrophage-capabilities, along with capabilities 
of other immune cells, to disrupt a healthy immune response. This review further 
confines itself to considering the role of the monocyte-macrophage continuum in 
cancer metastasis. 
1.9  Hybrids, the macrophage-cancer cell connection 
Another hypothesis states that macrophages are able to become malignantly 
invasive by integration of malignant DNA into the macrophage-host DNA. This 
process is called in-vivo fusion, which permanently transduces and transcribes 
macrophage-foreign DNA into the host cell59-61. Macrophages are also thought to 
either fuse with tumour cells, or to transfer migrational abilities onto them. The 
resulting hybrid cells exhibit metastatic abilities62-64. The specific macrophage 
traits such as aerobic glycolysis (the Warburg effect65-70), migratory and 
secretory abilities are retained after tumour cell macrophage fusion71. The 
hybrids use an autophagy-lysosomal pathway for sequestration and digestion of 
external food sources that are internalized via phagocytosis or other endocytic 
processes. These hybrids escape from regular immuno-surveillance by following 
this fusion/adoption pathway. Finally, a theory of tumour budding has been 
described in relation to metastases. Tumour budding is defined as single cells, 
or small clusters of up to 5 cells that are present in the peritumoural stromal 
tissue, (migrated) ahead of the invasive tumour front72,73. The buds show 
upregulation of metalloproteinases, urokinase receptors and cathepsin, which 
may contribute to increased migratory capacity and stromal invasion. 
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Furthermore, they exhibit a low proliferative activity, which is in line with their 
migratory phenotype. Their production of MMP2, MMP7 and MMP9 are 
indicative of their matrix remodelling capabilities74. 
1.10  Macrophage diagnostics? 
The tumour budding observation could lead to metastases screening being 
based on an evaluation of the budding cells in the tumour biopsy or surgical 
resection specimen. Defining whether these cells are in fact hybrids or cells with 
incorporated tumour DNA could have prognostic value. For example, Kinouchi et 
al described the favourable disease free survival (DFS) in patients showing 
CD14+ macrophages at the invasive front. Better overall survival was found for 
the CD14high group opposed to the CD14Low group75. They also described 
dense infiltration with CD40+ TAM to indicate a favourable prognosis76. The 
Immunoscore for CRC by Galon77-79 investigates specific T-cell densities that 
has been claimed to have prognostic value. Including more cell types is thought 
to increase the performance of the score. The Klintrup-score80-82 focuses on the 
influx of more immune cells (such as neutrophils, granulocytes, lymphoid cells 
and macrophages) in the central tumour and its invasive border in postoperative 
specimens. Both the Immuno-score and Klintrup-score are based on 
pathological specimen as is the tumour budding evaluation. Although all of the 
above scores can inform clinicians about prognosis, the scores have no 
contribution to screening or follow-up settings because of the need for tissue 
investigation. Screening, monitoring or follow-up could become feasible if such 
an assay would require only minor invasive sampling of other materials, such as 
blood or excrements. To deliver additional value, any form of screening needs to 
be as little invasive as possible. When investigating (additional) discriminative 
power of a diagnostic technique, calculating the area under the curve (AUC) 
based on receiver operating characteristics analysis is an accepted instrument83. 
An example of a low-invasive diagnostic technique is the investigation of 
cytokine footprints. This technique uses a panel of cytokines to detect different 
inflammatory and neoplastic diseases. Kantola et al, investigated CRC patient 
discrimination from healthy individuals, resulting in an AUC of 0.890 based on 
these cytokine footprints. Regrettably, this trial omitted the comparison with 
groups consisting of patients with inflammatory or infectious diseases84. To use 
macrophages in a diagnostic setting, a peripheral blood based assay that covers 
a wide spectrum of colorectal diseases is needed. Subsequent introduction in 
the clinical setting is only possible after thorough validation. 
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2.  Colorectal cancer  
2.1  Epidemiology and risk factors 
CRC is currently the third most prevalent cancer worldwide. Combining new 
cases in men and women, CRC is even the second most common form of 
cancer after lung cancer85. In 2012, 13408 new cases of CRC were diagnosed in 
the Netherlands86,87, 447.000 in Europe88 and 1.4 million worldwide86,89. The 
expectation is that the incidence will rise to 2.4 million cases worldwide in 2035 
88,89. Annual mortality in the Netherlands has continued to rise from around 4200 
in 2002 to over 5000 patients in 201286. Men are slightly more prone to develop 
CRC than women and most cases present themselves after the age of 55 
years87. Age is the number one risk factor for development of sporadic CRC and 
over 90% of all CRC-cases develops after the first 50 years of life. Family 
history, inflammatory bowel disease, obesity, adult attained height, tobacco and 
alcohol abuse, high stress and western diet have also proven to be risk factors88-
95. Physical activity, fruit and vegetable consumption and food high in dietary 
fibre are considered protective against developing CRC94,96,97. One in every 
three CRC-cases in the Netherlands concerns rectal cancer87. The lifetime risk 
in the Netherlands to be diagnosed with rectal cancer for a 35-year old male with 
a life expectancy of 85 years is 2.20 percent and for a female this percentage is 
1.36 percent86. 
2.2  Patient populations and pathogenesis 
CRC consists of hereditary (familial adenomatous polyposis (FAP), hereditary 
non polyposis CRC (HNPCC or Lynch’s syndrome), MYH-associated polyposis 
(MAP), Peutz-Jegher’s syndrome, juvenile coli (JPS)) and the non hereditary 
form, the sporadic CRC, which is the most common CRC type98. This review 
focuses on this last form of CRC. The sporadic cancer cases find their origin in 
evolving polyps from adenoma via dysplasia to carcinoma. The differentiation 
from adenoma to carcinoma takes about 10 years on average and is most often 
caused by multiple somatic mutations and genetic instability (such as MSI and 
various oncogene mutations)90,99. Epigenetic evaluation may lead to distinction 
between CRC types to identify favourable genetic profiles for certain treatment 
options. Currently only a few genomic markers are useful for prognosis. These 
include APC, MLH1 and MSH2, the latter two being known as mismatch repair 
(MMR) proteins. All three markers indicate a very high risk of CRC and guide 
surveillance frequency and prophylactic surgery recommendations100. In general, 
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sporadic CRC with defective mismatch repair (dMMR) has a favourable 
prognosis compared to CRC with a germ line origin. Sporadic cancer cases are 
also detected in inflammatory bowel disease patients (IBD; Crohn's disease 
(CD) and ulcerative colitis (UC)). Although the CRC incidence in the IBD group 
equals 3 cases per 1000 patient years, risk does increase with disease duration 
and extent. Cumulative risk after 10 years of UC equals 1.6% and increases to 
18.4% after 30 years of disease. In the IBD-patient group, CRC occurs mostly 
due to malignant epithelial changes during chronic and continuous re-
epithelisation processes as a response to repeated mucosal inflammation. In 
about 50% of the IBD-patient CRC-cases it concerns an interval-CRC, 
diagnosed or missed between initial screening and regular follow-up moments99. 
CRC-development in IBD patients may also follow the serrated neoplastic 
pathway, as an alternative origin of neoplasia101,102. 
2.3  Carcinoembryonic antigen in colorectal cancer 
In 1965 Gold and Freedman discovered the protein carcinoembryonic antigen 
(CEA)103,104, a presumed colorectal-specific tumour marker at that time. First 
CEA was thought to be present only in fetal tissues in various stages of 
gestation105. In the years following its discovery it became clear that the CEA-
antigen was found in other epithelial malignancies (e.g. lung, pancreatic, gastric, 
female reproductive tract105 and breast106 cancer) as well as in specific parts of 
normal tissue of the stomach, tongue, oesophagus, cervix, prostate and colon. 
Antibodies targeted against CEA were developed, but appeared to cross-react 
with normal antigens and CEA-related antigens. CEA is part of a 29-member 
family of genes and pseudogenes. Normal antigens consist of members such as 
CEA gene family members (CGMs) and pregnancy-specific β-1 glycoprotein 
(PSGs). CGM2 is closest in relation to CEA because of its presence in epithelial 
cells and no presence in granulocytes. Crossreacting antigens consist of non-
specific crossreacting antigens (NCAs), biliary glycoproteins (BGP), membrane-
associated tissular antigen (MTA) and isomeric carcinoembryonic antigen 
(CEA-S)107-109. Therefore the use of very specific CEA-antibodies, from the 
epitope groups 1-3 (Gold 1-3), is recommended107. Furthermore, elevated CEA-
levels can be detected in selected benign situations such as an exacerbation of 
ulcerative colitis, (premalignant) adenomatous polyps108 and people who smoke 
tobacco. Serum CEA determination should therefore never be considered as a 
diagnostic assay on its own. Nowadays, it is common knowledge that CEA is a 
part of the intestinal barrier in the normal colon, with a limited tissue expression 
 Macrophages in colorectal cancer: current diagnostic opportunities 
   21 
1 
compared to malignancies110. In the colon CEA functions as a homophilic and 
heterophilic cell adhesion molecule with a heavily glycosylated protein structure 
containing a number of multi-antennary carbohydrate chains. CEA (and NCA) is 
presented on top of the columnar epithelial cells and released intra-luminally by 
the goblet cells in the mucinous layer on top of the glycocalyx. The apical 
glycocalyx is the microvillus region on top of the mature enterocytes, also called 
the "fuzzy coat". New glycocalyx is continuously formed at the apical surface of 
these mature enterocytes. Replacing the microorganism-saturated 'old' 
glycocalyx is regulated by inflammatory cytokines. Direct interactions of CEA 
with microorganisms have been described, preventing the microorganisms from 
reaching down to the microvilli of the epithelial cells to invade them. CEA is able 
(together with BGP and NCA) to bind and trap these microorganisms, and 
furthermore is thought to have a signalling function to the CEA-expressing cells 
below109.  
 
 
 
 
 
 
 
 
Figure 1.3  CEA-excretion in normal colon and colon cancer. A: CEA is released into the colon 
lumen (CL) by polarised columnar epithelial cells and not into the blood capillaries (BC). 
B: CEA is released by non-polarised neoplastic cells into tumour gland lumen (TGL), 
located deep inside tumour glands. CEA enters the blood stream via access to lymph 
and blood vessels through intercellular spaces (Hammarström 1999).  
 
The applicability of CEA in a diagnostic or screening setting is limited to an 
additional role besides the primary assessment of clinical symptoms, imaging 
techniques and colonoscopy with biopsy111-114. Current clinical applications are 
surveillance for local recurrence or (hepatic) metastasis, prognosis of especially 
stage II patients after CRC-resection and monitoring of advanced disease114,115. 
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Other biomarkers for CRC screening, prognosis or response such as TIMP-1116 
and Septin 9117-119, are not commonly implemented. Emerging CRC biomarkers 
include multi-gene profiles, CA-19.9, stool DNA-profiles and transcription factor 
AP-2 epsilon (TFAP2E) hypermethylation120. The latter is used for chemotherapy 
response prediction114. 
2.4  Currently available screening methods for CRC 
Currently, the gold standard for CRC diagnosis remains colonoscopy combined 
with biopsy, after which collected tissue is subject to pathology evaluation85. 
Colonoscopy is not without risks (e.g. perforation (0.07%), bleeding (1.34%)). 
Besides this, it is also uncomfortable for patients. Even high quality imaging 
techniques in current settings are not able to fill in the need for tissue or cell 
collection. Moreover, (additional) radiation burden remains and costs are 
relatively high. Detecting aberrant DNA methylation in faecal DNA in CRC or 
advanced adenomas has a sensitivity of 46 to 77% for detecting early stage 
CRC. It was recently added to cancer-screening guidelines of the ACS and is 
currently under investigation in the Netherlands (see below). This technique is 
superior to the faecal occult blood test (guaciaFOBT or gFOBT). Faecal 
Immunochemical Test (FIT or iFOBT) has many advantages over gFOBT, such 
as better analytical sensitivity and specificity and adjustable cut-off 
concentration. It has therefore become the preferred faecal test85,114. Positive 
outcomes in all FOBT-test types need diagnosis confirmation by colonoscopy. In 
screening, colonoscopy is the gold standard, although this has never been 
evaluated in a large randomized controlled trial85. Currently a large population-
based screening trial has started in the Netherlands. It is planned to include 
891.203 persons above 50 years old in 2013-2014. The screening program is 
aimed at diagnosing CRC and advanced adenomas (AAD). Eligible persons are 
invited for iFOBT-screening and in case of a positive result (iFOBT result above 
cut-off value), a routine colonoscopy is offered. In this trial so far n=11.430 
colonoscopies have been performed. Preliminary results show a CRC/AAD 
detection ratio of 35.5 per 1000 (equals 1 in 28) in 129.395 screened 
participants until now121. iFOBT showed a 59.8% false-positive rate (meaning no 
CRC or AAD) at colonoscopy. In 31.9% of the persons with positive iFOBT-tests 
colonoscopy did not reveal any adenomas at all. In 60.1% of the persons who 
underwent colonoscopy a form of adenoma was discovered, some of which 
were eligible for surveillance colonoscopy programmes.  
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Molecular tumour features of the serrated pathway might be involved in CRC 
development within 5 years after colonoscopy122. Drawbacks are that 
colonoscopy does not prevent deaths in general and has a 1 in 3 chance of 
false-positive outcomes. Besides the high costs, risks of screening are 
overdiagnosis, negative psychosocial consequences, somatic complications, the 
use of invasive follow-up procedures and surveillance withdrawal because of 
adverse effects. Maybe most relevant when considering screening, is that it is 
offered to mostly healthy individuals without a wish to solve a health problem. 
The interventions can cause serious harm with only modest or no reduction in 
cancer related mortality. Therefore a benefit for some will come at the expense 
of harm to others123. 
2.5  New diagnostic techniques 
Recently new minimal invasive techniques such as liquid biopsy and detecting 
tumour related material in macrophages were investigated. The first technique, 
liquid biopsy, is a method to detect circulating tumour DNA (ctDNA) and 
circulating tumour cells (CTC) in peripheral blood124. Both are shedded from the 
tumour into the blood stream. Regular tissue biopsies are not reflective of the 
whole spectrum of aberrant cells in for instance breast cancer; the assessment 
of tumour heterogeneity is proposed to be more accurate using liquid 
biopsies125. These techniques show it is possible to monitor genes and changes 
thereof, associated with certain treatment sensitivity, such as anti-EGFR-
treatment. Changes in gene-expression (such as KRAS, BRAF, PIK3CA and 
EGFR) indicate possible treatment failure and enable treatment alteration126-128. 
The challenge with ctDNA and CTC analyses is that it is mostly investigated in 
metastatic disease cases, where the load of CTCs and ctDNA is the 
highest129,130. In early disease stages this is not the case. Detection of tumour 
related material in macrophages has been investigated in prostate cancer, using 
commonly known tumour markers (such as prostate specific antigen (PSA)) in a 
new way, showing possibilities in detecting prostate cancer already in early 
stages30,131. Both described techniques are currently under further investigation 
and the latter is being investigated in relation to CRC132. 
2.6  Validation of new diagnostic techniques 
Investigating diagnostic methods also implies validating them. Besides validity, 
steps necessary to ensure reliability and efficacy of tumour marker data in the 
overall care and management of patients need to be investigated. Laboratory 
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assay validation consists of a pre-analytic, analytic and post-analytic 
phase133,134. During the pre-analytic phase test ordering, sample collection, 
transport and storage conditions, laboratory sample delivery and preparation 
and handling before analysis are assessed. The analytic phase consists of 
choice of method, standardisation, calibration and precision assessment. Post-
analytical phase assessment includes result presentation, result interpretation 
and comparison to other clinical and laboratory data and finally using the 
collected data in disease management. If the assessed items show good 
reproducibility, a test can be considered properly validated134. Biological 
variation within and between patients is an item not automatically investigated 
using the above definition of validity analysis. This type of variation is important, 
although not always part of regular investigations in experimental (tumour 
marker) assays. For example, total variation up to 35% (biological and 
analytical) within a patient in sequential leucocyte analyses is not uncommon135. 
Normally, such a variation is clinically investigated to exclude serious underlying 
pathology. Variability in tumour marker assays is common as well. Therefore, in 
serum tumour marker analysis a baseline level increase of 25-30% occurring 
twice in a row is considered clinically relevant111,136. Additional diagnostic 
investigation for detection of recurrent or metastatic disease is warranted when 
such an increase is discovered. 
3.  Clinical application of macrophage-diagnostics 
in colorectal cancer  
3.1  Screening and diagnostic application in colorectal cancer 
Based on the work of Herwig et al.28,29,137 and Leers et al.30 on PSA detection in 
macrophages in prostate cancer patients, the concept of the method was 
adapted to CRC in 2008 using CEA as tumour marker-directed primary antibody. 
In a pilot study CRC patients were investigated for presence of monocytes/ 
macrophages exhibiting intracellular (tumour-related) debris, such as CEA on 
the debris. The pilot study reported that it was possible to intracellularly detect 
CEA in activated macrophages. It further showed a discriminating potential for 
distinguishing CRC patients with AJCC stages I-IV from healthy individuals and 
patients with benign inflammatory disease132. This technique is potentially of 
value in different settings for diagnostic or screening purposes, in follow-up after 
CRC surgery and to monitor treatment effects. A thorough elementary 
investigation was started to gain better understanding of the cellular basis138,139, 
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the technique pit-falls140 and possible clinical implications in therapy monitoring 
(unpublished results).  
Screening for CRC is a hot topic in medicine as mentioned in paragraph 1.3. In 
order to add an experimental method to current standard diagnostic trajectories 
in CRC a series of steps needs to be taken. Validation of such an assay is key. 
Kievit et al.112 described the additional value of regular CEA-analysis in the 
follow-up setting. They showed clearly it only has benefit in specific patient 
groups and only in follow-up setting, not in a diagnostic setting. 
3.2  Monitoring neoadjuvant treatment in rectal cancer 
Monitoring inflammation based on monocyte levels has been done earlier in 
different settings such as erysipelas and pneumonia141,142. Applying 
inflammatory monitoring in rectal cancer should be based on the inflammatory 
component in the tumour and its surroundings. Elevation of the level of 
inflammatory cells in the peripheral blood could reflect the presence of a local 
immune reaction. Using a macrophage assay in a neoadjuvant treatment 
monitoring setting could facilitate optimisation of treatment by treatment 
alteration. At this moment rectal cancer patients are only monitored for this 
purpose in trial setting, mainly focussing on imaging techniques for this purpose, 
such as PET-CT and MRI. Both are used for staging and restaging purposes, 
important for preoperative assessment of tumour regression after neoadjuvant 
radiochemotherapy143. Monitoring treatment efficacy using blood biomarkers, 
such as CEA and IL8, complimentary to imaging techniques was recently 
published by Buijsen et al.144. They showed response predicting capabilities for 
serum-based biomarkers in relation to pathological complete response (pCR) as 
the outcome measure.  
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4.  Aim of this thesis  
This body of knowledge and the results of a pilot study, investigating the 
feasibility of detection of CEA in activated macrophages, evolved into a PhD-
trajectory that has finally resulted in this thesis. The aim of this PhD trajectory 
consisted of multiple parts that are described in the following paragraphs. The 
role of macrophages in CRC, in cancer in general and their possible diagnostic 
applications has been investigated. 
4.1  Macrophages in CRC 
To investigate if phagocytes could internalise tumour-related material by 
immunophenotypical detection of it, we conducted two studies using the CRC-
model as our investigational platform. A wider arsenal of tumour-related material 
was investigated beside CEA, including TKTL1, M30 and CK. Confirmation of 
the presence of the above-mentioned tumour-related material and the possible 
location inside the phagocyte has been described in chapter 2 and 3 using light 
microscopy and electron microscopy respectively. 
4.2  Proof of principle 
The internalisation of tumour related material by macrophages causing a form of 
concentration of this material inside the macrophage was translated from the 
prostate cancer method29,30,131,137,145 into a CRC method. CEA, the most 
common tumour-marker for CRC, was investigated using this experimental 
method. The detailed results of this proof of principle investigation are described 
in chapter 4. 
4.3  Validation of diagnostic test 
Validation of tumour related material detection in macrophages is a major 
portion of this thesis. It has been referred to as epitope detection, because a 
wider arsenal of tumour related material (TKTL1, M30, CK and CEA) has been 
investigated to prove that its reproducibility isn't limited to CEA. Without a proper 
validation trajectory, clinical application of a new (macrophage) assay in any 
form is not possible111,133,136,146. The validation trajectory has proven that a 
macrophage assay for diagnostic purposes is technically feasible140, as has 
been described in chapter 5.  
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4.4  Early clinical application of an experimental diagnostic test 
To investigate possible clinical application a population of rectal cancer patients 
was chosen for three reasons. Firstly, in our institution this population is carefully 
monitored during pre-operative radiochemotherapy using established modalities 
such as blood biomarkers, PET-CT and MRI144,147-151. This created the 
opportunity to investigate the performance of a newly developed test in this 
carefully controlled disease-environment. Secondly, it was possible to evaluate 
the new test’s performance in comparison to the above-mentioned modalities 
and to investigate possible additional value to response prediction models. 
Thirdly, the population was chosen due to the expectation that neoadjuvant 
treatment causes the highest possible yield of shedding of tumour related 
material. This means that the new diagnostic tool should be able to detect 
baseline levels and baseline level changes during treatment. This could then be 
evaluated in relation to different relevant definitions of outcome in this 
population. The results of this early diagnostic application have been described 
in chapter 6. 
4.5  Discussion, future developments, challenges and 
recommendations 
In the discussion all results are discussed using literature describing possible 
explanations for the results and their value. Also additional (non published) 
findings will be discussed. Finally, future developments, challenges and 
recommendations for future research are postulated. 
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Abstract 
Introduction 
The presence of carcinoembryonic antigen (CEA)-containing activated macrophages has 
been demonstrated in peripheral blood from patients with colorectal carcinoma. 
Macrophages migrate from the circulation into tissue, phagocytose debris and return to 
the bloodstream. Hence it seems likely that activated macrophages containing tumour 
debris i.e. tumour marker are present in the stroma of colorectal carcinoma. After 
phagocytosis, they could follow a haematogenic or lymphogenic route to peripheral blood.  
 
Aims 
To assess the presence of tumour marker containing activated macrophages in the 
stroma of colon carcinoma and in regional lymph nodes.  
 
Methods 
From 10 cases of colon carcinoma, samples of tumour tissue and metastasis-free lymph 
nodes were cut in serial sections and stained for CD68 to identify macrophages and for 
CEA-, cytokeratin- or M30-presence. Slides were digitalised and visually inspected using 
two monitors, comparing the CD68 stain to the tumour marker stain to evaluate the 
presence of tumour marker positive macrophages.  
 
Results 
Macrophages containing tumour marker could be identified in tumour stroma and in 
metastasis-free regional lymph nodes. The distribution varied for the different markers, 
CEA-positive macrophages being most abundant.  
 
Conclusions 
The presence of macrophages containing tumour marker in tumour stroma and lymph 
nodes from patients with colon carcinoma could be confirmed in this series using serial 
immunohistochemistry. This finding supports the concept of activated macrophages, after 
phagocytosing cell debris, being transported or migrating through the lymphatic system. 
These results support the potential of tumour marker containing macrophages to serve as 
a marker for diagnosis and follow-up of colon cancer patients. 
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1. Introduction 
Activated (CD14+/CD16+) macrophages containing carcinoembryonic antigen 
(CEA) and prostate-specific antigen (PSA) have been identified in peripheral 
blood from respectively colorectal and prostate cancer patients, using flow 
cytometry1,2. In melanoma-associated macrophages, melanin-containing 
melanosomes have been described, both at the tumour site as well as in 
regional lymph nodes3,4. The CD14+/CD16+ subpopulation of monocytes 
resembles tissue macrophages in many ways5. Activated blood-borne 
monocytes/ macrophages are able to migrate into tissues and replenish tissue-
specific macrophages, phagocytosing substances (e.g. cell debris) at the site in 
both tumour environment as well as in non-neoplastic conditions6-9.  
This pilot study intends to evaluate the concept of tumour marker containing 
macrophages in colon carcinoma tissue and regional metastasis-free lymph 
nodes, using double monitor comparison of immunohistochemistry on serial 
sections to visualise macrophages and tumour markers CEA, cytokeratin and 
M30. 
2. Materials and methods 
2.1 Patient and sample selection 
For this pilot study, ten patients recently operated for colon carcinoma 
(confirmed on histopathological evaluation) were included. Age, tumour 
localisation, tumour size and tumour stage according to the American Joint 
Committee on Cancer (AJCC) were retrieved from medical records. For each 
case, original histopathological reports and H&E stained sections were reviewed 
and the carcinoma sample showing most invasive growth was selected. In one 
case, the initial diagnostic biopsy was selected for analysis because it showed 
more invasive growth than the tumour in the colon resection specimen. In one 
case two separate tumours were found in one resection; we chose to evaluate 
the more invasive tumour. For each tumour sample, from the same surgical 
specimen 2 regional lymph nodes free of metastasis were selected. All selected 
samples were evaluated for presence of tumour marker containing 
macrophages.  
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2.2 Immunohistochemistry 
All paraffin-embedded colon carcinoma samples and lymph node samples were 
serially sectioned in four consecutive 3 µm slides. Sections were deparaffinised 
with xylene and rehydrated through graded ethanol. For each sample sections 
were stained with anti-CD-68, anti-CEA, anti-cytokeratin and anti-M30 antibodies 
respectively.  
Antigen retrieval was performed in different ways for the different antigens. For 
CD68 and M30, specimens were placed in 0,01M citrate buffer at pH 6.0, 
incubated for 20 minutes at 98°C and allowed to cool in buffer. For CEA, 
specimens were placed in EDTA buffer at pH 9.0, incubated for 20 minutes at 
98°C and allowed to cool in buffer. For cytokeratin, specimens were incubated 
with 2 ml pepsin 1mg/ml in 0,1M HCl at 37°C for 15 minutes, then cooled and 
rinsed in tap water. 
Next, slides were incubated with Dako Dual Endogenous Enzyme Block (Dako) 
for 5 minutes to block endogenous peroxidase.  
These steps were followed by incubation with primary antibodies. For detection 
of macrophages, anti-CD-68 (clone PG-M1, Dako Cytomation, Denmark) 
commonly used as a marker of monocyte-macrophage lineage cells10-12, was 
used. To visualise the presence of CEA, clone II-7 was used. This clone is 
monospecific for CEA13. Mouse monoclonal anti-cytokeratin (clone MNF 116, 
Dako) was used to visualise cytokeratins, commonly found in the cytoskeleton of 
mammalian cells and many carcinomas. Anti-M30 Cytodeath (clone M30, 
Peviva, Sweden) was used to visualise M30, an antibody that recognises a 
neoepitope of cytokeratin 18 exposed after caspase-mediated cleavage during 
early apoptosis (14). Antibodies were diluted in Dako Chem Mate Antibody 
Diluent (Dako). Antibody dilutions used were 1:100 for anti-CD68 and anti-M30, 
and 1:200 for anti-CEA and anti-cytokeratin.  
Antibody binding was visualized using the Dako Autostainer by means of the 
Dako EnVision Detection System, Peroxidase/diaminobenzidine (DAB, Dako) kit 
for CD68, CEA and cytokeratin and aminoethylcarbazole (AEC Single Solution, 
Zymed, USA) for M30. Slides were incubated with Envision HRP rabbit/mouse 
solution (Dako) for 30 minutes and were incubated with DAB (CD68-, CEA-, and 
cytokeratin-staining) or AEC (M30-staining) for 5 minutes twice, yielding a 
respectively brown or red substrate at the site of the target antigen. Finally, all 
slides were counterstained with haematoxylin and coverslipped.  
 Activated macrophages containing tumour marker in colon carcinoma 
    41 
2 
2.3 Scoring of immunohistochemistry 
Slides created were digitalised using the 3DH/Zeiss Automatic Brightfield Scan 
microscopy scanner (Zeiss, Germany) and viewed in MIRAX Viewer 
(3DHISTECH, Hungary) version 1.12.22.1.  
Digital slides were evaluated using a double-screen setup, allowing for 
simultaneous viewing of the CD68 stain on one screen and one of the tumour 
marker stains from the same case on the other screen. Identical areas were 
identified and here we searched for morphologically macrophage-like cells that 
stained positively on the CD68 stain and also on the tumour marker stain, 
illustrated in Figure 2.1. Tumour marker containing macrophages were digitally 
annotated. Annotations were made in different colors for the respective tumour 
markers. All slides were evaluated by one observer. In case of doubt a second 
independent observer assessed the unresolved cases. If interpretation still 
remained unclear, the original section was reviewed in conventional microscopy. 
Ambiguous structures were not marked as positive.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 A. CD68 stain of tumour sample; B. corresponding CEA stain of the same sample. 
Tumour cell clusters are visible (arrows) with diffuse staining around tumour cells. An 
example of a CEA containing macrophage with granular staining can be seen to the 
right of the tumour cells (circle and arrowhead); the CD68 stain shows the presence of 
macrophages around the tumour and diffusely in the tumour stroma whereas the tumour 
cell cluster is negative 
 
A B
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2.4 Analysis 
Primary tumour: the area with the highest density of tumour marker positive 
macrophages was identified. In this area, the number of tumour marker positive 
macrophages per 2 square mm was counted. For each tumour stage and the 
total group, medians with ranges were determined.  
Lymph nodes: the surface area of every lymph node was measured and the 
number of tumour marker positive macrophages per 2 square mm was recorded 
for each lymph node. For each tumour stage and the whole group, medians with 
ranges were determined. 
3. Results 
3.1 Baseline characteristics 
From 10 patients 10 tumours and 20 lymph nodes were analysed. The median 
age of patients included in this study was 74 years (range 57-90 years). The 
male:female ratio was 1:1. Three AJCC stage I tumours were included, one 
stage II tumour and six stage III tumours. No stage IV tumours were included in 
the study. Patient and tumour characteristics are summarised in Table 2.1.  
 
                               Table 2.1 Patient and tumour characteristics (n=10). 
Gender 
   male 
n= 
5 (50%) 
Age 
   total 
   male 
   female 
Median in years (range) 
73 (57-90) 
68 (57-82) 
78 (61-90) 
Tumour stage (AJCC) 
   I (T1-2, N0) 
   II (T3-4, N0) 
   III (any N+) 
   IV (any M+) 
n= 
3  
1  
6  
0  
 
3.2 Digital images 
The setup with two monitors, displaying the CD68 and a tumour marker stain 
facilitated the examination of the different staining patterns in the same area. By 
annotating the identified macrophages with different colours for each marker on 
the CD68 image, differences or similarities in distribution of different markers 
could readily be identified. 
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3.3 Tumour stroma 
In 10/10 cases, activated macrophages positive for CEA, cytokeratin and M30 
could be identified. Results are summarized in Table 2.2.  
 
Table 2.2 Median number of tumour marker positive macrophages in tumour stroma per 2 square 
mm in the area of highest density grouped by AJCC stage, with ranges. 
Tumour stage (AJCC) M30 Cytokeratin CEA 
I (n=3) 3 (1-9) 11 (4-21)   362 (93-498) 
II (n=1) 2 13 265 
III (n=6)   3 (2-10) 10 (4-14) 100 (4-344) 
All (n=10) and range   3 (1-10) 11 (4-21) 199 (4-498) 
 
 
CD68-positive macrophages were encountered in different places. The highest 
concentrations were found in desmoplastic stroma in the periphery of the 
tumour. Macrophages were also found directly adjacent to tumour glands, in the 
lumina of tumour glands, in blood vessels and in lymphatic vessels. To a lesser 
extent, macrophages were found in the lamina propria and submucosa of the 
adjacent normal colon.  
A substantial number of activated macrophages showing positivity for CEA could 
be identified. CEA-positive macrophages were found in all abovementioned 
localisations of the macrophages. One slide showed a CEA-positive 
macrophage in a blood vessel wall, suggesting migration of macrophages after 
phagocytosis (Figure 2.2). Most positive activated macrophages showed 
intracellular deposits of CEA (Figure 2.1). In a number of tumours, we observed 
diffusion of the staining directly adjacent to the tumour epithelium, in an area 
with a high density of activated macrophages (Figure 2.1). These macrophages 
were considered positive. Two stage III tumours were found to be partially CEA-
negative but still contained a number of CEA-positive macrophages.  
Cytokeratin positive macrophages were present in smaller numbers than CEA-
positive macrophages (Table 2.2) and in the serial sections; they were not 
present at the same location.  
M30 tumour cell positivity was found in all tumours, especially within the lumina 
of tumour glands and in areas of apoptosis. M30 positive activated macrophages 
were sporadically found in tumour stroma. Since this study assessed properties 
of tissue-associated macrophages, only these cells were evaluated. The number 
of macrophages positive for M30 was substantially lower than for CEA and 
cytokeratin (Table 2.2).  
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Although this study does not allow any definitive conclusions, the results shown 
in Table 2.2 suggest that for higher tumour stages, the number of tumour-marker 
containing macrophages in tumour stroma decreases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 A. CD68 stain of a blood vessel (outlined) next to tumour tissue; B. CEA stain of the 
same blood vessel. Intramural macrophages are present; two macrophages are positive 
in the CEA stain (arrowheads, circles). CEA reactivity is also visible at the luminal 
borders of this vessel. 
 
3.4 Lymph nodes 
We evaluated 20 lymph nodes from the same 10 patients. In 19/20 lymph nodes, 
macrophages containing tumour marker could be identified. In one case, M30 
containing macrophages could not be identified. Results are summarized in 
Table 2.3. 
 
A B
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Table 2.3 Median number of tumour marker positive macrophages in lymph nodes per 2 square 
mm grouped by AJCC stage, with ranges.  
Tumour stage (AJCC) M30 Cytokeratin CEA 
I (n=6) 0,7 (0,2-1,0) 3,1 (0,3-5,7)   9,5 (1,4-65,7) 
II (n=2) 0,6 (0,5-0,7) 5,7 (2,6-5,7) 1,4 (1,4-1,4) 
III (n=12) 0,8 (0,0-5,8) 1,4 (0,6-5,9)   3,3 (0,6-53,9) 
All (n=20) and range 0,8 (0,0-5,8) 2,3 (0,3-8,7)   4,3 (0,6-65,7) 
 
 
CD68-positive macrophages were found along the lining of the medullary 
sinuses and in lymphatic nodules. In smaller amounts, macrophages were found 
in cortical sinuses, medullary chords and within the cortical parenchyma.  
Similar to our findings within the tumour stroma, CEA containing macrophages 
were found in relatively large numbers when compared to M30 and cytokeratin. 
Macrophages with CEA positivity showed a characteristic granular cytoplasmic 
staining and were almost exclusively found along the lining of the medullary 
sinuses (Figure 2.3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 A. CD68 stain of a lymph node with widespread macrophage distribution; 
B. corresponding CEA stain. CEA-containing macrophages can be seen along the lining 
of and are limited to the medullary sinuses. Granular staining is visible in a number of 
macrophages (example at arrow) 
 
 
Cytokeratin containing macrophages, though fewer in number, showed a less 
restrictive distribution. These macrophages were found within the sinuses, and 
in the subcapsulary sinuses, medullary chords and cortex parenchyma as well. 
Within lymphatic nodules, cytokeratin containing macrophages were only 
sporadically seen. Some perivascular elements showed cytokeratin positivity but 
A B
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could be differentiated from macrophages based on morphological 
characteristics and a lack of corresponding CD68 staining.  
M30 containing macrophages were found in similar locations as cytokeratin-
containing macrophages. In contrast to cytokeratin and CEA, these 
macrophages were also found in lymphatic nodules. M30 positive macrophages 
were found only sporadically compared to CEA- and cytokeratin-positive 
macrophages (Table 2.3). 
4. Discussion 
To the best of our knowledge this is the first report on the possible route of 
transportation followed by tumour associated fragments from the tumour site to 
the blood stream, supported by morphological and immunohistochemical 
observations. We propose that circulating tumour marker containing 
CD14+/CD16+ macrophages1,2 may have ingested this material at the tumour 
site. 
The exact route macrophages follow after phagocytosing tumour material is 
unclear. In a mouse model of retinal injury, Joly et al demonstrated the migration 
of blood borne macrophages into an area of injury. Microglia, the retinal resident 
tissue macrophages, showed trafficking abilities towards the injured retinal side, 
and adopted signs of phagocytosis. In reaction to the injury, both at the site of 
injury and healthy tissue, the number of macrophages rose by influx via blood 
vessels, adding extra phagocytic capacity to the injured site. Macrophages 
loaded with debris attaching to and crossing into capillaries suggest a route back 
into the circulation15. Their findings also give support to the hypothesis that 
tissue associated macrophages can engulf tumour particles and transport them 
to vascular structures.  
Blood-borne activated macrophages containing tumour material as found in 
earlier studies1,2 have likely obtained tumour material while residing in stromal 
tissue at the tumour site and afterwards migrated towards the circulation. In this 
series, macrophages were found mostly at the margin of the tumour and also in 
the tumour stroma, consistent with earlier findings16. We identified a tumour 
marker containing macrophage in a blood vessel wall in one section, supporting 
the hypothesis of haematogenic migration. According to anatomical venous 
outflow, cells entering blood vessels will travel through the portal vein towards 
the liver. Examining (peroperative) portal blood and liver tissue from patients 
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with colon carcinoma could provide more insight into the mechanisms involved 
in this process.  
However, from the assessment of regional lymph nodes we can conclude that 
TM-containing macrophages also travel through the lymphatic system towards 
regional lymph nodes. In case reports of malignant melanoma, melanin-
containing macrophages have been demonstrated in sentinel lymph nodes, even 
without the presence of tumour in the lymph nodes4,17. TM-containing 
macrophages were more readily identified in lymph nodes than in blood vessels 
in this study. This may suggest a preference for these cells to travel via 
lymphogenic route. Although both a lymphogenic and haematogenic route are 
possible travel itineraries for TM-containing macrophages our results seem to 
concur with the observation of metastases being present in lymph nodes more 
frequent than in organs reached through a haematogenic route such as liver, 
lungs or the skeletal system.  
 
Macrophages are versatile cells that can exhibit different functional phenotypes. 
Macrophages have been divided into the M1 and M2 type. M1 macrophage 
activity includes pro-inflammatory functions, including the capacity to kill 
microorganisms and the production of proinflammatory cytokines. M2 
macrophages are involved in immunosuppression, tissue remodelling, 
angiogenesis and scavenging of debris, including apoptotic cells18,19. The 
division in M1 and M2 type macrophages may not be absolute20, enabling 
macrophages to switch from one function type to another or assuming 
characteristics of more than one type at a time. Tumour-associated 
macrophages (TAM) may play an important role in tumour progression, 
angiogenesis, metastatic ability and remodelling of the extracellular matrix21. 
Wyckoff et al.16 found that macrophages only phagocytosed labelled sugars 
while in the stroma of a tumour, as opposed to while circulating in the blood. 
This may indicate a phenotype difference between blood borne and tissue-
associated macrophages, possibly under influence of cytokines and (tumour-
derived) growth factors22-24. Nuclear condensation as seen in blood-borne 
tumour marker containing macrophages1 could indicate macrophages may have 
reached the end of their life cycle and initiate apoptosis after fulfilling their role in 
tumour stroma. A vitality stain could demonstrate whether blood-borne 
macrophages containing tumour material are indeed in the process of apoptosis.  
Tumour marker containing in macrophages showed a typical granular staining 
pattern. In 2010, Lazova et al.3 described melanoma-associated macrophages 
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containing coarse melanin in a similar staining pattern. Electron microscopy and 
immunohistochemistry showed that these melanosomes were contained in 
autophagosomes and/or autolysosomes in the macrophage cytoplasm. This may 
also be the case with CEA in colon carcinoma-associated macrophages.  
 
Pawelek et al.25 have postulated the fusion of tumour cells with bone marrow 
derived cells as a possible explanation for tumour progression and metastasis. 
Such hybrid cells have been identified in vitro and in sporadic cases in vivo. The 
presence of tumour marker in macrophages could be a characteristic of tumour-
macrophage hybrid cells. Electron microscopy may be of use to further evaluate 
the interaction between macrophages and tumour material.  
 
We found substantial differences between the various tumour markers in the 
densities of tumour marker containing macrophages. This gives rise to a number 
of hypotheses. Firstly, there may be a relation between the presence and 
distribution of the investigated substances in the tumour and the possibility to 
find loaded macrophages. Rupa et al described the amount of M30-positive cells 
in colorectal adenocarcinomas to be 5-17%, with a mean of 11,1%26, while 
almost all colorectal carcinoma epithelial cells exhibit cytokeratin and CEA 
positivity. Therefore, the argument of varying presence of tumour marker might 
be true for CEA compared to M30 but is not likely to be true for CEA compared 
to cytokeratins. Secondly, the stability of the substance may play a role. CEA is 
an extremely stable molecule that can even survive perchloric extraction, while 
cytokeratins are easily damaged by electrical or chemical agents. Thirdly it might 
be that the high level of glycosylation of CEA facilitates the interaction with 
tissue macrophages compared to cytokeratins. Fourthly, a macrophage does not 
only phagocytose substances. Phagosomes fuse with lysosomes containing 
various enzymes, which may degrade antigens, making them unrecognisable to 
our antibodies. A combination of all abovementioned mechanisms – availability, 
selective phagocytosis, molecule stability and degradation – is also possible.  
 
Although we did not apply double staining procedures, the serial section 
approach consistently showed different areas of distribution for macrophages 
with the three antigens investigated in this pilot study. This was observed both in 
the tumour stroma but even more prominent in the lymph nodes. Cross-reaction 
with the non-specific cross-reacting antigen (NCA), a macrophage component, 
might make interpretation more difficult; however, clone II-7 was one of the 
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highly CEA specific antibodies in a comparative study on multiple CEA 
antibodies13. Also, the fact that CEA positive macrophages were not found in all 
lymph nodes and their distribution in the lymph node was limited to a subset of 
cells gave further support to a meaningful interpretation of this observation. 
The use of double chromogenic stains does not seem to be an alternative, 
because we attempt to stain different structures both located in the cytoplasm of 
a single cell. Using direct fluorochrome labelled antibodies and confocal laser 
scanning microscopy may be a better option to answer the question of 
colocalisation of different substances in the same macrophages. Considering the 
typical granular staining of intra-macrophage tumour marker, the observed 
anatomical distribution of tumour markers and macrophages, and morphological 
characteristics of macrophages, serial section immunohistochemistry seems 
adequate for this pilot experiment evaluating whether or not tumour marker 
containing macrophages are present in colorectal tumour stroma and lymph 
nodes.  
5. Conclusion 
In this study we were able to identify tissue-associated macrophages both in 
tumours and in their lymphatic draining area. Serial sectioning and 
immunohistochemistry is a relatively simple method to identify tumour marker 
containing macrophages.  
Macrophages containing tumour material are present in the stroma of colon 
carcinoma and in regional metastasis-free lymph nodes. The number of tumour 
marker positive macrophages varied between cases as well as between the 
different tumour markers. The distribution of tumour marker positive 
macrophages is different for the various markers used in this study. 
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Abstract 
Introduction 
Carcinoembryonic Antigen (CEA) can be detected in activated macrophages (AM) in 
colorectal cancer (CRC) using flow cytometric analysis and light microscopy. The aim of 
the present study was to investigate the exact localization of the CEA-antigen on or in 
macrophages using transmission electron microscopy (EM) and immuno-electron 
microscopy (IEM). Besides, further insight in the macrophage role and its trafficking 
abilities in colorectal cancer patients is pursued, aiding to clarify more of the previous 
study findings.  
 
Methods 
Samples from vital tumour tissue and surrounding stromal tissue were collected from 
patients with colorectal carcinoma (n=5). Samples were separated in two series. Series 1 
was processed for regular EM to review the morphology and identify macrophages. 
Series 2 was used to visualize CEA in macrophages with IEM using gold-conjugated 
protein A indirect immunolabelling. Furthermore, a second series of five different patients 
near-tumour lymph nodes were analysed by EM and IEM in the same way as described 
above.  
 
Results 
Using EM and IEM phagocytes, resembling macrophages, could be identified with 
intracellular CEA-positive gold particles connected to cell-debris in the cytoplasm. 
Secondly, anti-CEA-protein-A-gold-particles connecting to cancer-specific villi on the 
outside of cancer cells were detected. The initial lymph node assessment showed no 
CEA-positivity despite using multiple staining protocols. 
 
Conclusion 
In five patients the EM-aided morphology analysis provided a detailed structure of 
macrophage-resembling phagocytes, not only aiding to the recognition of macrophages 
using EM, but also providing insight in the possible locations of internalized CEA. Some 
intracellular vesicles e.g. lysosomes indeed showed cell debris. Using IEM, large multi-
lobulated cored phagocytic cells (possibly macrophages) with CEA-positive cell-parts 
were visualised in some of the patients. These findings support our hypothesis of 
phagocytosis of CEA-containing (tumour) material by macrophages in tumour tissue and 
their surroundings. The uptake is not generally present in all macrophages, consistently 
with the findings in peripheral blood. The investigated lymph-node-group showed no 
positivity, possibly due to technical error(s) in sampling, storage, preparation or due to the 
selection itself. These findings were not in line with previous light microscopy findings, 
needing further future investigations.  
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1. Introduction  
In earlier studies shedded tumour material was shown to be internalised by 
macrophages in prostate cancer1-3 and colorectal cancer patients4. This 
observation could be qualified and quantified as PSA-positive and CEA-positive 
respectively by using multi-colour flow cytometry after applying standardised 
staining procedures. These internalised cytoplasmic materials could also be 
visualised with light microscopy after PSA-2 and CEA-staining cytospins (Figure 
3.1A (reprinted with permission)4), made of these flow cytometry samples. 
Macrophages appeared to internalise CEA-positive material from stromal or 
tumour tissue, subsequently, to return to the peripheral blood stream4,5 using a 
route that is still unclear. In a second study using light microscopy it was shown 
that in the tumour-stromal surroundings of CRC-patients not only CEA-positive 
macrophages are present, but also CK-positive, M30-positive and TKTL1-
positive macrophages6. In further experiments (Figure 3.1B) the targeted 
CD14+CD16+ monocytes could be flow cytometrically sorted (FACSAria, BD) 
and visualised and photographed using light microscopy (LM). Thus, evidence of 
irregularly shaped cells with large lobular nuclei, resembling tissue monocytes or 
tissue macrophages7 was confirmed.  
 
To further investigate our hypothesis it is important to know whether the 
internalised material is still expressing CEA or whether it is the cell-surface itself, 
expressing CEA-epitopes after an internalisation process. Using light 
microscopy it remains uncertain what cell area or cell part is exactly positive for 
this staining. Electron microscopy may be able to provide answers to this 
question if immunolabelling by antibodies can be transferred from flow cytometry 
to the EM modality. This paper describes the study protocol investigating the 
visualisation of internalised CEA-positive material in macrophages using 
transmission electron microscopy (TEM) and (cryo) immuno electron microscopy 
(IEM), and the first results thereof. 
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Figure 3.1 A) cytospin of CEA in macrophages (CEA-IM); an earlier published picture made of a 
cytospin of all cells from flow cytometry samples with brownish staining for CEA and 
H&E staining for nuclear material. Large irregular cells with lobular nuclei clearly 
staining positive for CEA could be identified beside other cell-types. B) Flow 
cytometrically sorted (FACSAria, BD) CD14+CD16+ cell population showing only these 
large irregular cells with lobulated nuclei. The cells were sorted from samples of the 
standardised CEA-IM assay after regular workup for flow cytometry and Giemsa-stained 
after sorting and air-drying. 
 
2.  Background  
2.1 Macrophage and monocyte origin 
For a long time the kinetics of monocyte travel and differentiation to 
macrophages were thought to be based on a theory of Furth and Cohn, research 
from the 1960's. After spending some days in the bloodstream these monocytes 
would migrate into tissues replenishing the tissue-resident macrophage 
population8. Another theory of local macrophage renewal by proliferation was 
recently shown to be plausible. This was proven for particular tissue-
macrophages such as the brain microglia or the skin Langerhans cells9,10. 
Macrophages are also proven not be depending on monocytes for 
replenishment in pancreatic, hepatic, pulmonary, splenic, peritoneal and bone 
marrow tissue11,12. On the other hand, also in the intestine influx of blood-borne 
monocytes and subsequent differentiation into tissue macrophages (CX3CR1hi-
type) appears to take place13. These cells (re)populate the intestine besides the 
already present self-replenishing resident macrophages (HLA+CD68+25F9+ 
type). Although earlier research stated that intestinal macrophages would have 
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lost their CD14- and CD16-epitopes14,15, this statement refers to the resident 
intestinal tissue macrophages, not to the migrating blood-borne monocytes. 
2.2  Monocyte and macrophage internalisation process 
Macrophages are known for ingesting (invading) cells or cell-parts thereof and 
presenting parts of them on their cell-surface for signalling functions to other 
immune cells16 like such as T-cells17. They are also known for internalising cell 
debris after cell decay through endocytosis after which digestion takes place in 
lysosomes. If internalisation and subsequent digestion were not the mechanism 
involved but rather internalisation and cell-surface expression a signalling 
function would be more likely than a scavenger function. Re-localisation of non-
differentiated monocytes after finalizing an internalisation process to regional 
lymph nodes has recently been confirmed18.  
2.3  Applicability to this protocol 
Our theory of extravasation of blood-borne monocytes into stromal areas around 
tumours and performing internalisation and digestive tasks fit in the above 
literature description on origin and function. In our hypothesis and in recent 
literature macrophages5 and/or activated monocytes19 have the ability to return 
to the blood stream, also after internalising cell debris. Alternatively, they could 
be able to travel to adjacent lymph nodes18.  
3.  Materials and methods  
3.1  Tissue sampling 
After obtaining medical ethical approval and informed consent, two groups of 
five patients were included. This setup was chosen to first determine the ability 
to apply the immunochemistry with anti-CEA to the epitopes after (cryo)fixation 
before starting tissue sampling of lymph node material. From the first patient 
group tissue samples were taken from CRC tumour-specimens within minutes 
after resection. Each specimen was inspected by a pathologist for optimal tissue 
sample selection. Sampling was performed from vital tumour tissue as well as 
from surrounding stromal tissue. Subsequently the tissue samples were fixed 
using two fixation strategies: one for morphologic imaging purposes (1 mm3 
tissue-pieces fixed in 2,5% glutaraldehyde (GA) in 0,1M phosphate buffer (PB) 
until slide preparation, (see further details in section 2.2.1)), another for (cryo) 
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immuno-EM purposes ((1 mm3 tissue-samples fixed for a maximum of 
60 minutes in GA 0,2% + paraformaldehyde (PFA) 2% in 0,1M PB pH 7.4, 
followed by transition to 1% PFA in 0,1M PB pH 7.4 until further processing (see 
for further details in section 3.2.3)).  
After microscopic histopathological evaluation of CRC resection specimen, extra 
LM sections were processed to evaluate the best EM-sampling areas (see 
section 3.1.1). From the second group of five patients samples of lymph node 
were extracted within minutes after resection and stored as described above, 
again combined with routine pathological analysis providing extra LM sections to 
evaluate the best EM-sampling areas (see section 3.1.1). 
3.1.1  Light microscopy area selection 
Extra sections of regular pathological analyses were used to evaluate the best 
EM-sampling areas for both series. These sections were digitalised using a 
Mirax scanner (3D-Histech, Hungary). Areas of interest were marked by one of 
the researchers (Pannoramic Viewer, 3D-Histech, Hungary) and confirmed or 
adjusted by a pathologist. Areas of interest were defined as containing tumour 
tissue as well as surrounding stromal tissue for series one and specific lymphoid 
node areas for series two. The probability of finding macrophages containing 
internalised shedded tumour-cell remnants was considered the highest in these 
areas. The marked areas were used to aid search guidance for the electron 
microscopist. 
3.2  Electron microscopy 
3.2.1  Slide preparation for morphology evaluation using TEM 
Tissue samples of both series of 5 patients were fixed in 2.5% glutaraldehyde in 
0.1 M phosphate buffer solution and embedded in Epon (LADD, US). The tissue-
blocks were cut into 80 nm sections for transmission electron microscopy (TEM) 
and photographed in the CM100 transmission electron microscope (Philips). The 
embedding process contained several steps. First, the samples were put in 
0.1 M phosphate buffer (PB) for 30 minutes, after which 1% osmium tetroxide 
was added for 60 min. Second, after rinsing for 45 min in 0.1 M PB for 45 min 
the tissue was dehydrated in a series of increasing ethanol concentration (70%, 
90%, 100%, 100%). The tissue was then routinely processed for embedding in 
Epon resin. From these Epon blocks 1 μm sections were cut and stained with 
toluidine-blue (Merck) to enable light microscopical navigation to the areas of 
interest prior to the EM search according to the earlier LM-defined areas of 
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interest. Then the ultrathin sections of 80 nm were cut and stained with uranyl 
acetate and lead citrate before evaluation and picturing in the CM100 
transmission electron microscope (Philips).  
3.2.2  Slide evaluation and cell selection using TEM 
An experienced electron microscopist evaluated the prepared sections using 
TEM and identified phagocytes (monocytes and macrophages) through pre-
determined cell aspects such as cell size, cell shape, nuclear lobulation and the 
presence of lysosomal organelles in the cytoplasm. 
3.2.3  Slide preparation for Immuno-EM (IEM) and staining protocols  
Tumour-, stromal- and lymphoid tissue samples were prepared according to the 
Tokuyasu-method20,21. In short, the tissue samples were extracted from the 
storage solution (PFA in PB), rinsed with 0,15% Glycine in PBS 0,1 M, followed 
by immersion steps in gelatine 2%, 5% and 10% respectively for 15-30 minutes, 
leaving it to harden in the refrigerator. Before cutting, 1% PFA+0.1 M PB pH 7.4 
was applied (for minimal 1 hr) and the tissue blocks were cut on ice in 1 mm3 
blocks and transferred to 2.3 M sucrose solution for overnight incubation (19.68 
gram sucrose in 25 ml 0,1M PB pH 7.4) for cryo-protection. Pieces were taken 
out of sucrose solution and pinned. The sucrose surplus was removed and 
subsequently stored in nitrogen ready for further staining after cutting.  
 
In a first try-out, an anti-CEA/protein A-Gold labelling was applied. Using an 
ultramicrotome 80nm sections were cut and placed on a 75 mesh copper grid. 
The sections were placed in a droplet of methyl-cellulose/2.3 M sucrose solution 
after which a cell staining protocol was started. The ultrathin sections were 
removed from the methyl-cellulose/2.3 M sucrose solution and placed in 2% 
gelatin in PBS in a petri dish for 10 minutes at 37°C, followed by 2 times 
2 minutes of 0,15% glycin in PBS, and subsequently by 0,1% Bovine Serum 
Albumin (BSA)/PBS for 2 minutes. Primary incubation was then performed in a 
solution containing an antibody directed against the CEA-antigen (IgG1, clone 
II-7, 270 mg/l; Dako, Glostrup, Denmark) which was added for at least 
20 minutes followed by 4 times 2 minutes rinsing with 0,1% BSA/PBS. This was 
followed by secondary incubation with protein A-gold22 in 1% BSA/PBS for 
20 minutes. Rinsing with 0,1% BSA/PBS twice for two minutes was followed by 
rinsing twice for two minutes using only PBS. Rinsing using GA 1% in PBS for 
5 minutes was used for protein stabilisation after which six times rinsing for one 
minute with demineralized water (Milli-Q) was applied. The grid was moved to an 
iced bath containing 1.8% methylcellulose/0.4% Uranyl acetate (MC/UA) for 
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5-10 minutes. After rinsing it in ice-cold 1.8% MC/0.4% UA, the grid was 
removed and the surplus of MC/UA was diminished to a film layer using filtration 
paper. The sections were finally air-dried. 
 
In a second try-out the primary antibody directed against CEA was used in 
combination with a 25 nm-gold conjugated goat-anti-mouse antibody against 
IgG1 as a secondary antibody (Aurion, Wageningen, The Netherlands). The 
same preparation protocol was used as in the first try-out.  
 
In order to establish that the EM-determined phagocytes were indeed 
macrophages simultaneous labelling for CEA and a macrophage marker in the 
same cells was attempted. For that purpose the same markers were used as in 
previously published peripheral blood analyses4. Anti-CD14-APC (clone Mø P9, 
25 μg/ml; B&D) and anti-CD16-FITC (clone NPK15, 125 μg/ml; B&D) were used. 
Staining performance of both anti-CD14- and anti-CD16-antibodies was tested 
on CRC-tissue and evaluated by LM first. Only the anti-CD16-FITC-antibody 
was proven to be possibly applicable in the 25nm-gold-conjugated goat-anti-
mouse-antibody protocol. The anti-CD14-antibody was not used for EM-
purposes due to LM-staining issues reported in de results-section 4.2.3. 
3.2.4  Slide evaluation and cell selection using IEM 
The same experienced electron microscopist evaluating the TEM-slides 
evaluated the IEM-slides searching for the same large irregular cells with lobular 
nuclei and lysosomal sub-cellular organelles. Single staining for CEA and CD16 
was assessed by searching for 25 nm gold spheres suggesting presence of the 
CEA or CD16 epitope.  
4.  Results  
4.1  Light microscopy 
4.1.1  Area selection 
Using regular light microscopy areas of possible macrophage infiltration were 
digitally tagged. This resulted in multiple slides per patient with several areas to 
investigate using TEM and IEM. In Figure 3.2 an example of an area of interest 
is shown within a light blue square. These selected area were all evaluated and 
confirmed by a pathologist. Parts of the selection were cut out from the tissue 
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samples and prepared for electron microscopy evaluation (see section 3.2.1 and 
3.2.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 An example of a selected area where phagocytes most likely reside (light blue 
rectangle) and where electron microscopical evaluation could detect internalised 
tumour-related material (arrows). The red area marks vital CRC tissue, the yellow area 
marks a part of the stromal tissue area. 
 
4.2  Electron microscopy 
4.2.1  Cell identification by TEM based on morphology 
Multiple phagocytes were identified in both tumoural and stromal areas (Figure 
3.3) in the first group. The TEM-determined phagocytes were used for 
comparison in the evaluation of the (cryo)-immuno-EM sections.  
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Figure 3.3 TEM-based selection areas of (A) tumour- and (B) stromal tissue respectively. In both 
areas phagocytes reside. They can be identified by size, shape, cytoplasmic vacuoles 
and a lobular nuclear configuration. In section A the total disruption caused by tumoural 
growth is obvious. In the lower left and center of the section two very irregularly shaped 
cells can be identified between tumour tissue. In the center the cell resembles a 
neutrophil while the one in the lower left corner seems to be a monocyte or a 
macrophage. In section B a stromal section is captured, showing connective tissue 
fibers in the upper part of the section and two parts of a nucleus derived from a 
macrophage in the right en lower center part. The macrophage almost extends over the 
complete section under the diagonal line, which can be drawn starting beside the 
connective tissue fibers top-center to the left edge (see marking).  
 
In Figure 3.4 an example of a phagocyte is photographed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 A phagocyte (white marking) containing an internalised nucleus (N) inside a vesicle (V) 
surrounded by cell organelles in the cytoplasm. The ingested nucleus seems to be 
degrading, characterized by indentations of nuclear surface. 
 
4.2.2  Phagocyte selection by IEM based on CEA-positivity 
Using the results of the TEM the concurring cell types were searched in the IEM-
slides stained with anti-CEA (according to the protein-A-protocol). Due to 
another fixation process the morphology of the cells in IEM was changed, 
resulting in more difficulty to find the proper cells than in the TEM procedures. 
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Despite this, also in the IEM-slides phagocytes were found. Some but definitely 
not all showed a positive staining with anti-CEA. Next to the positive staining of 
phagocytes, many tumoural villous cell linings showed positivity as well (Figure 
3.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 This section is selected from a colorectal cancer tumour site. Tumour tissue is seen on 
both sides of the villous cell lining. On top of the villous lining gold spheres confirm 
presence of CEA (white arrows). Also some concentrated gold spheres can be found 
deeper into the tumour tissue on the left side below the largest darker area. Further 
scattered over the total section some gold spheres can be identified. These gold 
spheres indicate the presence of CEA in the tumour tissue. 
 
In several slides CEA-positive material was detected inside phagocyte-like cells. 
In Figure 3.6 an example is shown.   
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Figure 3.6 Example of a phagocyte (white irregular marking) characterised by appearance of an 
irregular shaped cell containing a multi-lobulated irregular nucleus (by two light grey 
irregular circles, possibly explained by dissection plane), showing multiple cell-part-
remnants like some villi-parts (1) and gold spheres collected on a part of a nucleus (2). 
The villi suggest being a part of gastro-intestinal lining, possibly tumour epithelium. The 
nuclear remnant appears to be surrounded by a vesicle wall (3), possibly a layer of 
phagocyte cell wall, which is internalised after egulfment of the remnant. Other localized 
collections of gold spheres can be objectified suggesting presence of CEA in 
internalized tumour material (4). Not being obviously encapsulated in a vacuole it could 
resemble part of Golgi apparatus transporting some tumour related material in a further 
digested state where the edges of the material are not as sharp anymore. 
 
4.2.3  Phagocyte selection by IEM based on double staining 
Immunochemical staining of CRC-tissue for CD14 or CD16 to identify (activated) 
monocytes respectively was attempted in sections evaluated by LM to predict 
feasibility of these immunochemical stainings in EM. The LM sections showed 
positive staining on macrophages with the antibody directed against CD16 (data 
not shown) However, staining with antibodies against CD14 did not deliver any 
positive results in LM. The antibody directed against CD14 appeared not to be 
suitable for fixed tissue samples and was therefore not attempted in EM. The 
staining with the anti-CD16-antibody was attempted solitary in EM at first. These 
sections did not show any positive results, not even after applying different 
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concentrations of anti-CD16-antibody. Visualising CEA-positive tumour related 
material by double staining for CEA along with CD14 and/or CD16 (concurring 
with the flowcytometric blood-analysis of activated CD14+CD16+ monocytes) 
was not attempted due to these negative results.  
5.  Discussion  
5.1  Main findings 
This study shows the ability to detect phagocytes that have internalised tumour 
related cell remnants (e.g. tumour lining or nucleic material) in both stromal and 
tumour tissue using transmission and immuno-electron microscopic techniques. 
The cells presented can be recognised as tissue macrophages or tissue 
monocytes due to their specific morphology. The presence of CEA-positive 
internalised material proves the ability of the phagocytes to retain CEA-positive 
material at least for some time to be able to stain and visualise this material. The 
assumption that phagocytes (e.g. macrophages) digest all internalised material 
completely, prohibiting detection of internalised material, seems not to apply to 
this chosen setup within the set timeframe. The localisation of the tumour related 
material is inside the cytoplasm of the phagocytes, most likely in a lysosome, 
vacuole-like structure or Golgi apparatus, but definitely not on the cell surface of 
the phagocyte. An example of CEA-positivity on the cell surface is clearly seen 
on top of tumour-villi.  
In addition to these key-findings this study identifies concurrent results with flow 
cytometrical analysis as the experiments show varying results between 
patients4. Only two out of five patients showed positive staining for CEA in 
several slides in the first series (using the protein-A-protocol), which is 
concurrent with findings in earlier immunohistochemical LM-studies6. In different 
areas different staining patterns occur, seemingly random, possibly based on 
occasional phagocyte presence.  
Peripheral blood analyses show mostly reproducible results between and within 
patients and healthy controls. From these studies it is known that only a minor 
fraction of the extracted CD14+CD16+ blood monocytes are positive for 
internalised tumour material23. Considering these facts, tissue specimens from a 
larger cohort of CRC-patients could provide more representative outcomes 
preventing possible selection bias. In the next sections we describe the need for 
technical improvements. 
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5.2  CRC tissue extraction 
A challenge in sample preparation consisted of time-to-fixation after tissue 
specimen extraction. The time frame of transport of the tissue from the operating 
room (OR) to the pathology department took around 10 minutes where 
immediate tissue selection and extraction by a dedicated pathologist was 
available. This time frame is acceptable due to the toughness of the CEA-
epitope that will remain available after even a longer period of time. 
5.3  LM area selection 
Controlled area selection of probable macrophage-rich tissue using LM allowed 
a reduction of the search area, allowing quicker results and reducing possible 
erroneous cell identification. Transferring identification criteria of macrophages 
from LM to TEM and further to IEM facilitated identification of phagocytes in the 
changed morphology of the (cryo)-EM. The outcomes of each series were 
discussed and agreed on between the main researchers. However, transferring 
the preferred search area from one modality to the next remains a weak spot as 
one is not able to search exactly the same area because of possible tissue loss 
in cutting consecutive sections. 
5.4  Antibody challenges in IEM 
Epitopes in blood monocytes remain stable within 6-8 hours for staining using 
CD14, CD16, and CEA-antibodies23. In tissue, this will be similar when tougher 
fixation with GA and PFA would not be necessary for overall preservation. 
However, the evaluation of feasibility of using same CD14- and CD16-antibody 
as in flow cytometry was negative for the antibody against CD14 when staining 
LM sections of formalin fixed CRC-tissue. This is most likely due to protein 
cross-linking, which occurs during the fixation protocol. The fixation leads to 
disruption of the targeted epitope. The CD14-antibody used in the flow 
cytometric studies by our group is indeed designed for fresh or fresh frozen cell 
labelling. Because even tougher fixation protocols are applied in EM (with also 
aldehyde-derived fixatives), the application of this antibody becomes less 
feasible in EM. The use of the CD16-antibody instead for detection of phagocyte 
activation status remains an option, but can be debated. This antibody is 
directed against the Fcɣ-receptor IIIb, This transmembrane receptor is not only 
present on monocytes, but also on neutrophilic granulocytes, natural killer cells 
and mast cells. Whilst neutrophils are known for phagocytic capacity, the 
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neutrophil cell morphology differs substantially from macrophages24 preventing 
recognition mistakes. The ability to identify activated phagocytes internalising 
CEA-positive cell material could have enabled to point out CEA-IM with more 
confidence. In LM the anti-CD16-antibody was properly visible (data not shown), 
but in TEM the anti-CD16-antibody did not provide any positive results, possibly 
due to the more aggressive tissue fixation protocol with glutaraldehyde. The 
proposed double staining using an anti-CD16-antibody conjugated to 15 nm gold 
spheres and an anti-CEA-antibody conjugated to 25 nm gold spheres was never 
attempted due to the EM-results of the CD16-staining in tissue in the second 
series. Activation of monocytes could therefore not be confirmed by using the 
antibody against CD16. Only morphology and CEA-positivity could be used for 
proper identification of the monocytes.   
One could have opted for other markers like CD68 or CD11b to identify 
macrophages. Sadly these markers have not been applied in our flow cytometric 
assays before, therefore being second choice for now. Also the M1 or M2 
macrophage-markers CD86 or CD163 respectively could provide answers in cell 
recognition in future experiments, but the experiences of these markers on the 
specificity to the targeted cells in flow cytometric assays should be gathered 
before application in EM. 
Protein A-Gold labelling as detection method exhibits some known pitfalls25, e.g. 
nonspecific staining which in turn might lead to false-positive identification of 
CEA-IM. For that reason, the second strategy using a goat-anti-mouse anti-
IgG1-antibody conjugated with gold spheres should exclude this nonspecificity. 
A new series of sections of the proven CEA-positive tissue-samples from the 
first round (protein-A-series) combined with the second series (consisting of 
mere lymph-node-material) did not show any positivity in either section for CEA 
as well as CD16 using this new strategy. Firstly these outcomes prompted for 
critical evaluation of the new technique and secondly the outcomes of the first 
series using the protein-A protocol were questioned. Could every positive 
immunolabelling in the first series be due to coincidence or nonspecific staining? 
Was the second technique not suitable for the used tissue-samples or antibodies 
or were applied sampling logistics prohibiting proper results? Further 
improvement of the double immunostaining could provide these answers, after 
further optimising the sampling logistics and re-assessing staining protocols. 
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5.5  Future studies and conclusion 
Future studies applying other specific markers for the flow cytometrical detection 
of monocytes/macrophages (e.g. CD64, CD68, CD11b etc) as well as optimized 
EM fixation and staining strategies could further clarify the variable observations 
of CEA-positive material in macrophages and provide answers to questions 
remaining after the first part of this explorative study.  
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Abstract 
Background 
Serum tumor markers show low sensitivity, making them unsuitable for early detection of 
cancer. Activated macrophages (AM) from peripheral blood can accumulate tumor marker 
substances and facilitate early detection in prostate cancer. Here it was investigated 
whether carcinoembryonic antigen (CEA) containing macrophages (CEACM) can be used 
to detect colorectal cancer (CRC) at earlier stages than can serum CEA.  
 
Materials and methods 
Peripheral blood was collected from patients with CRC (n=48), inflammatory colorectal 
disease (n=5) and from healthy controls (n=18). After separating and labeling AM with 
CD14-APC/CD16-FITC, AM were intracellularly labeled with anti-CEA antibody and flow 
cytometrically analyzed. Serum CEA and C-reactive protein (CRP) were measured.  
 
Results 
The fraction-size of CEACM discriminated between controls and CRC patients, 
irrespective of AJCC-stage (AJCC stage I–IV, p=<0.0001). Serum CEA values were 
significantly elevated in AJCC stage II, III and IV (p=0.02, 0.006 and <0.0001, 
respectively). Combining CEACM with CRP-levels separated CRC from inflammatory 
colorectal disease.  
 
Conclusion 
CEACM combined with CRP appears to have diagnostic potential in early CRC. 
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Introduction 
Early detection of cancer in general is assumed to improve the possibilities for 
curative interventions and for this reason many efforts have been undertaken to 
achieve this goal. When Gold and Freedman presented carcinoembryonic 
antigen (CEA)1, people had great expectations but in time learned that CEA 
serum assays cannot be used for the detection of colorectal cancer (CRC). Both 
sensitivity and specificity of this marker were insufficient to support this. This 
applies in general for all known tumor markers, with exception of human 
chorionic gonadotropin (HCG) and lactate dehydrogenase LDH2,3. Recently we 
improved the method published by Herwig et al.4 and demonstrated that 
activated macrophages, expressing both CD14 and CD16 on their membranes 
had ingested prostate-specific antigen (PSA)-containing material. The size of the 
fraction of PSA-containing macrophages correlated well with the presence of 
prostate cancer5. Activated macrophages can also be found as tissue 
macrophages in the interstitial space of many tissues and in particular in the 
stroma of neoplastic proliferations6. These cells have the capacity to migrate 
from peripheral blood and accumulate substances in tumor tissue and 
tumorsurrounding tissue7,8. If they can phagocytize PSA in prostate cancer, it 
could be hypothesized this mechanism also applies to other tumor markers in 
other types of tumors and may achieve increased diagnostic sensitivity as well. 
Although not specific, CEA is present in high amounts in CRC-tissue9. For this 
reason we have selected CEA as a candidate to test this hypothesis for 
colorectal cancer. We initiated a prospective study where we compared the 
presence of CEA in activated macrophages in different stages of cancer and 
inflammatory disease with serum CEA values and the level of CRP. 
Materials and methods 
Specimen collection: Medical ethical approval was obtained. Patients were 
included after histological confirmation of cancer on endoscopic biopsies was 
obtained and after informed consent. Consecutive inclusion was performed in 
the outpatient clinic or preoperatively on the ward. Classification in AJCC staging 
groups9,10 was based on histopathological evaluation. Control persons were 
selected and included by matching the participating cancer patients for age and 
gender and if possible for social and environmental influences (e.g. spouses). 
Table 4.1 displays included patients and healthy controls. Two EDTA tubes, two 
serum tubes and one heparin tube of venous blood were collected. The heparin 
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tube was used for determination of CRP. One serum tube provided a serum 
CEA level within three hours after the vena puncture, the other serum tube was 
centrifuged at 4°C and the supernatant was stored at minus 70°C for future 
analysis. One of the EDTA tubes was used for a complete blood count (CBC). 
The remaining EDTA-tube was kept at room temperature (RT) and processed 
for flow cytometry within 24 hours after vena puncture.  
 
Table 4.1 Patient and control group demography. 
Group Frequency Mean age 
(years, (group range)) 
No. Female 
(% in group) 
Controls 18 55.28   (45-76)   8 (44.4%) 
Benign inflammatory disease   6 59.50   (25-81)   3 (50.0%) 
Malignant 48 70.48   (55-88) 24 (50.0%) 
Total 77 65.94   (25-88) 39 (50.3%) 
 
 
Mononuclear cell separation and immunocytochemical staining: One 3ml EDTA 
blood sample per patient was transferred into a CPT-tube (Becton Dickinson 
(B&D), Franklin Lakes, NJ, USA). A 20-minute centrifugation of the blood 
sample at 1650 x g isolated the mononuclear cells in a dense layer between the 
Ficoll-Hypaque density layer and the serum. This suspension of single cells was 
transferred into 100 μl aliquots containing ± 106 cells. To label the macrophages, 
directly conjugated monoclonal antibodies were added simultaneously. 
Allophycocyanin (APC)-conjugated monoclonal antibody against CD14 (clone 
Mϕ P9, 25 μg/ml; B&D) combined with a fluorescein isothiocyanate (FITC)-
conjugated monoclonal antibody against CD16 (clone NPK15, 125 μg/ml; B&D) 
were added and the cells were incubated in the dark at room temperature for 
15 minutes. A Fix & Perm strategy (GAS004, Caltag; InVitrogen, Carlsbad, CA, 
USA) was performed after a single 2 ml phosphate-buffered saline (PBS) wash 
procedure. The fixation step consisted of the addition of 100 μl fixation reagent A 
for 15 minutes at RT and two 2 ml PBS wash steps afterwards. The 
permeabilization step was subsequently performed by adding 100 μl 
permeabilization reagent B in the presence of 20 μl biotinylated anti-CEA-
antibody (clone II-7, 270 mg/l; Dako Cytomation, Glostrup, Denmark), added for 
intracellular staining. Biotinylation and subsequent blocking was performed by 
using an Animal Research Kit (ARK, Dako Cytomation); calculating the needed 
biotin and blocking-reagent was based on the use of pure anti-CEA antibody 
Ig-concentration. A 15-minute incubation in the dark at RT preceded two 
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washing steps with 2.0 ml PBS. This was followed by incubation of the cell-pellet 
for 15 minutes at RT with phycoerythrin-conjugated streptavidin (streptavidin-
rPE, 0.5 mg/ml; CAT No. 349023; B&D).  
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Parental gating structure. Parental gating, starting at the level of mononuclear cells, 
resulted in a stepwise separation of sub populations of cells with accumulated 
complexity of phenotypical characteristics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Gated sample of colorectal cancer patient (top row) and healthy control (bottom row). 
Parental gating is shown starting second plots from the left and in the two consecutive 
plots towards the right in both rows. More purple colored dots resembling CEACM are 
visible in the last, right most plot of the colorectal cancer patient compared to the 
healthy control. 
 
 
After another two 2.0 ml PBS wash-steps, the cell-pellet was resuspended in 
0.5 ml PBS and ready for measurement. A negative control (NC) was prepared 
by incubating cells with non-relevant mouse immunoglobulins which were 
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directly labeled with -FITC (10.0 μl IgG1, κ-FITC, clone G18-145; B&D 
(Pharmingen)) and -APC (2.5 μl IgG1, κ-APC, clone G18-145; B&D 
(Pharmingen)) to reveal background staining by the directly conjugated primary 
antibodies. Streptavidin-rPE was included in the negative control for detection of 
possible endogenous biotin binding.  
 
Flowcytometrical analysis: The prepared samples were analyzed with a 
FACScanto flow cytometer (B&D). Excitation of the cells was performed by a 
488 nm, air-cooled solid-state argon laser followed by a 17 mW 633 nm 
helium/neon laser. A 530-nm band pass filter enabled FITC-fluorescence 
detection, a 575 nm ± 13 (mean ± SD) band pass filter provided PE-
fluorescence detection and APC-fluorescence was assessed by using a 660 nm 
± 10 (mean ± SD) band pass filter. Seven-color setup beads (BD FACS; B&D) 
were used on weekly basis for optimal device performance. Automatic 
compensation settings were obtained by using the FACScanto software (BD 
Biosciences). At least 30000 events were counted for each sample. APC, FITC 
and PE signal-data were recorded with logarithmical amplification. BD 
FACSDiVa software (B&D) was used for analysis of the acquired data; the flow 
cytometrist was blinded for any clinical information. 
 
Gating procedure: Mononuclear cells were selected by drawing a gate in the 
forward scatter (FSC) / side scatter (SSC) plot to separate them from 
lymphocytes. Parental gating, starting at the level of mononuclear cells, resulted 
in a stepwise separation of sub populations of cells with accumulated complexity 
of phenotypical characteristics (Figure 4.1). Within the population of 
mononuclear cells, CD14-positivity identified the monocytes. In the following 
step, CD14/CD16-positive activated macrophages were gated within the 
monocyte fraction. Finally, step 3 resulted in identification of the fraction of CEA-
containing cells within the activated macrophage fraction (see Figure 4.2). 
 
Biochemical assays: Serum CEA levels were determined on an Advia Centaur 
Immunochemistry Analyzer (Bayer Healthcare, Diagnostics Division, Tarrytown, 
NY, USA). The CEA-assay on the Bayer Advia Centaur was a 2-sided dual 
monoclonal sandwich immunochemiluminescent assay (reference values of 
<5.0 μg/l (non-smoking population) and <10.0 μg/l (smoking population) were 
considered normal). Serum CRP levels were tested by particle-enhanced 
immunoturbidimetric assay (CRPLX, Tina-quant, Roche Diagnostics GmbH, 
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Mannheim, Germany) (reference value of <10.0 mg/l was considered normal) on 
a E170 Modular Analytics System (Roche Diagnostics, Hoffmann-LaRoche Inc, 
Basel, Switzerland). 
 
Cytospin preparations and immunocytochemistry: After preparation of the 
cytospins, immunocytochemistry was performed for the detection of the CEA-
antigen, using the same monoclonal antibody as described above. For this 
purpose, an indirect streptavidin-biotin method was performed. 
Statistical analyses: SPSS Statistical software, version 16 for Macintosh (SPSS 
Inc., Chicago, Illinois, USA) was used for the statistical analysis. The Mann 
Whitney U test was used for analysis of differences. A p-value of less than 0.05 
was considered statistically significant. Graphpad Prism, version 4.0 for 
Macintosh (Graphpad Software Inc., San Diego, California, USA) was used for 
creating graphs. 
Results 
The size of the fraction of activated macrophages did not differ between the 
investigated patient groups with CRC (Figure 4.3). However, we observed that 
AJCC stage III (mean±SD: 32.68%±11.46) shows significantly higher fractions of 
activated macrophages compared to healthy controls (20.57%±8.12, p=0.008), 
stage I and stage II colorectal cancer (21.20%±8.46, p=0.028 and 
21.10%±11.66, p=0.005). In all patient groups with CRC (AJCC-stage: 
mean±SD) CEACM was significantly higher (stage I: 15.93%±10.61, stage II: 
17.63%±12.76, stage III: 15.91%±7.73, stage IV: 16,54%±8,03, all p<0.0001) in 
comparison to healthy controls, (2,86%±1,19) (see Figure 4.3). The differences 
calculated comparing malignant disease with benign inflammatory disease were 
not significant; the difference between healthy controls and benign inflammatory 
disease (15.72%±22.85) was significant (p=0.005). The pre-operative CRP 
levels of patients with benign inflammatory disease (165.67 mg/l ±48.38) did 
significantly differ from patients with colorectal cancer (stage I: 3.80 mg/l ±3.63, 
stage II: 14.75 mg/l ±17.85 and stage III: 11.75 mg/l ±15.90; p-values of 0.024, 
0.034 and 0.034 respectively). Combining the measurements of activated 
macrophages, CEA-containing activated macrophages and pre-operative CRP-
levels provides a patient group-specific marker profile also separating benign 
inflammatory disease from cancer (Figure 4.3). 
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Figure 4.3 Patient group profiles showing fractions of activated macrophages, fractions of CEA-
containing activated macrophages and pre-operative CRP levels. Clearly the distinction 
between the healthy group and the benign group as well as all malignant groups can be 
made by measuring CEACM. CRP adds the ability to significantly differentiate between 
the benign inflammatory patient group and AJCC groups I-III. 
 
Serum CEA analysis (Figure 4.4): The standard serum CEA assay showed 
significantly elevated values in AJCC stage II to IV CRC (stage II: 6.36 μg/l 
±13.49, stage III: 6.51 μg/l ±8.77 and stage IV: 95.18 μg/l ±176.31; p-values of 
0.02, 0.006 and <0.0001 respectively) in comparison to healthy controls 
(1.45 μg/l ±0.70). In AJCC stage I (2.10 μg/l ±2.05), the serum CEA value did not 
significantly differ from that of healthy controls. In most of the investigated 
patients (including CRC patients), the serum CEA assay showed outcomes 
lower than reference values, together with high variance within the CRC groups. 
 
Photographic proof of CEA-containing macrophages: Immunocytochemical 
staining procedure of cytospins prepared from the monuclear cell fraction after 
CPT-tube centrifugation showed presence of vesicles staining positive for CEA 
in the peripheral zones of the cytoplasm of macrophages with large irregular 
nuclei (Figure 4.5). 
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Figure 4.4 Comparison of the fraction of CEA-containing activated macrophages with serum CEA 
levels in AJCC staging groups. Cut-off values of 5.0 and 10.0 μg/l (healthy and smoking 
respectively) of the serum CEA assay have been displayed by vertical continuous lines. 
The graph shows almost only higher staging groups being detected by the regular 
serum CEA-assay, but not in most cases. The flow cytometrical assay shows much 
better distinction between early cancer groups and the healthy controls. The horizontal 
dashed line could be used as a cut-off value for distinction between healthy controls 
(≤4.25-4.85%) and malignant disease (>4.25-4.85%) depending on diagnostic demand. 
Sensitivity and specificity in this cut-off value range varied between 100.0-97.9% and 
83.3-100.0% respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Cytocentrifuged sample stained for CEA prepared from an analysis sample used for 
flow cytometry. Visible are the bluish staining for the cell nucleus and the brownish anti-
CEA staining inside intracellular vesicles containing CEA. 
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Discussion 
Serum tumor markers were initially thought to be the ideal instrument for early 
detection of malignant tumors. However, low serum concentrations as a result of 
dilution effects in the total blood volume in combination with a majority of smaller 
primary tumors soon showed that only high-stage tumors or recurrent disease 
remained candidates for the use of these biomarkers11,12. Various committees 
tried to postulate guidelines for the use of tumor markers based on meta-
analyses of international research in randomized controlled setting. The 
European Group on Tumor Markers (EGTM)11, the National Academy of Clinical 
Biochemistry (NACB)13, the European Society for Medical Oncology (ESMO)14 
and comprehensive cancer centers provide guidelines and quality-assessments 
for the analysis process using serum tumor markers. In the current situation, 
these guidelines leave the clinician with a tool hardly applicable for use in major 
patient groups, leaving room for improvement. At the moment, the only 
application of serum CEA in CRC treatment guidelines is the use of this value in 
the follow-up of CRC. Not as a solitary marker, but as a small part of an 
intensive periodical follow-up strategy also containing modern imaging 
techniques, endoscopy and physical examination. It has been shown from meta-
analysis that intensive follow-up strategy gains 7% in mortality reduction15-17. 
 
The results of both our present study and earlier publications5 illustrate how 
intrinsic functions of a part of an organism such as tissue macrophages may be 
used to establish a test that provides insight in the state of health of the entire 
organism. 
  
One of the hypotheses postulated (also by Gordon et al) is migration of 
macrophages to draining lymph nodes and no further. Apart from apoptosis, 
necrosis, autolysis and ingestion by other macrophages (also outside lymph 
nodes), they may release material for cross presentation by dendritic cells. In 
view of the similarity of activated macrophages in the peripheral blood to tissue 
macrophages18, we postulate that the success of our method used here is based 
on a special condition. Activated macrophages are attracted to the tumor stroma 
and find themselves in close proximity to the damaged tissue. The accumulation 
of cell constituents inside these activated macrophages leads to concentration. 
Once saturated, the activated macrophages reach the peripheral blood and are 
sampled via venipuncture. A second concentration step is built into our assay, 
namely when the buffy coat is selected. The labeling of the activated 
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macrophages with CD14/CD16 can be regarded as an additional selective step. 
The last step, where the relevant tissue component is labeled and detected, thus 
receives a huge boost in sensitivity, which might explain the surprisingly good 
separation of controls from even AJCC stage I tumors. When comparing serum 
CEA with the fraction-size of CEACM in all patient groups (Figure 4.4) again the 
potential diagnostic power of this new assay even in AJCC stage I is shown. In 
most cancer cases the new assay produced an elevated signal, whereas the 
serum CEA assay lacked this ability. At the time of writing reference values have 
not been established. However, our present data seem to provide a preliminary 
cut-off value of 4.25% (Figure 4.3) to distinguish healthy controls (≤4.25%) from 
malignant cases (>4.25%). Using this cut-off, 100.0 % sensitivity and 83.3% 
specificity was reached, already in AJCC stage I. Increasing the cut-off value to 
4.85%, the sensitivity decreased to 97.9%, but the specificity increased to 100%. 
The cut-off value should be chosen according to the diagnostic demand. These 
characteristics are better than the calculated sensitivity and specificity of 
currently used diagnostic possibilities16. These proposed preliminary cut-off 
values are of course dependent on the chosen gating strategy and may become 
different in future. 
 
It appeared in our study that non-malignant disorders of the colorectal mucosa 
also resulted in increased fractions of CEACM. The inflammatory mechanism is 
not confined to tumorous development alone, but applies to all inflammatory 
processes in the body. Wherever tissue damage occurs, irrespective of the 
origin or the cause, the body reacts by starting this inflammatory reaction. The 
presence of CD16-positive monocytes, becoming CEA-positive, after cell-
damage in the colon-model indicates this inflammatory process has occurred. 
During an inflammatory process (or exacerbation thereof) in the colon the 
normal lining of the colon will be shedded and the CEA, commonly present in 
healthy and inflamed colon, will shed as well. The macrophages in the colon-wall 
will be able to phagocytize the shedded gut-wall as well as the shedded CEA. 
These macrophages are hypothesized to return to the blood pool. For 
differentiation between benign inflammatory and malignant colon disease the 
combination with an inflammatory marker, CRP appeared to be a good option. 
High CRP levels are associated with active inflammation and/or tumor necrosis 
in higher disease stages, whereas stage AJCC I and II in general show no signs 
of inflammation (low CRP values). The percentage of activated macrophages in 
AJCC stage III is elevated in comparison to the lower disease stages and stage 
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IV disease. A possible explanation for this may be that lymph node involvement 
in stage III disease stimulates the immune system, whereas in stage IV disease 
the immune system may be suppressed or exhausted. 
  
Differences in macrophage involvement may also be due to the macrophage-
activation state and macrophage reactions on entering this state. Upon an 
encounter triggering the macrophage, two possible reactions have been 
postulated in literature, the M1 and M2 reaction6,19. Phagocytosis for instance is 
performed by the M1-state macrophage, but angiogenesis is stimulated by M2-
state macrophages20. Phagocytosis of tumor remnants or even living tumor cells 
is of course desirable but angiogenesis to support tumor proliferation is 
obviously not. Furthermore, the substances a macrophage encounters differ 
depending on macrophage and location. The differences described above may 
explain why not all macrophages extracted from peripheral blood contain the 
same substances and also not the same amount thereof. 
 
It can be concluded from data measuring M30, an apoptosis marker21, in 
activated macrophages in CRC patients (manuscript in preparation) that this 
technique of detection of ingested substances in activated macrophages is 
applicable to whatever is technically detectable inside these tissue 
macrophages. This enhances the diagnostic applicability by a natural, pre-
analytical concentration step. A multi-marker strategy for solid tumors could be 
combined with this flow cytometrical approach, similar to the flow cytometrical 
analysis of patients with suspicion for bone marrow-associated malignancies. 
 
Determining the patient profile (Figure 4.3) considering inflammatory serum 
parameter levels and perhaps multiple flow cytometrically obtained 
tumormarker-containing macrophage fractions leads to a more broad collection 
of cross-related information. This information may be suitable for predicting the 
origin of disease and enabling earlier detection of primary disease, at least 
providing incentive for additional invasive diagnostic procedures. In the context 
of activated macrophages, there may be a new diagnostic role for CEA in the 
early detection of colorectal malignancies. 
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Abstract 
Introduction 
We have recently described epitope detection in macrophages (EDIM) by flow cytometry. 
This is a promising tool for the diagnosis and follow-up of malignancies. However, 
biological and technical validation is warranted before clinical applicability can be 
explored.  
 
Methods 
The pre-analytic and analytic phases were investigated. Five different aspects were 
assessed: blood sample stability, intra-individual variability in healthy persons, intra-assay 
variation, inter-assay variation and assay transferability. The post-analytic phase was 
already partly standardized and described in an earlier study. 
 
Results 
The outcomes in the pre-analytic phase showed that samples are stable for 24 hours 
after venipuncture. Biological variation over time was similar to that of serum tumour 
marker assays; each patient has a baseline value. Intra-assay variation showed good 
reproducibility, while inter-assay variation showed reproducibility similar to that of to 
established serum tumour marker assays. Furthermore, the assay showed excellent 
transferability between analyzers.  
 
Conclusion 
Under optimal analytic conditions the EDIM method is technically stable, reproducible and 
transferable. Biological variation over time needs further assessment in future work. 
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1. Introduction  
Current diagnostic serum assays for assessing tumour markers lack sensitivity. 
Their use is mostly confined to follow-up strategies, and they are always applied 
in combination with other diagnostic techniques1. 
Recently, both Herwig et al. and our own group explored the possibility of using 
macrophages from peripheral blood samples to detect tumour markers in 
patients with proven cancer of the prostate or colon2,3. This flowcytometry-based 
technique enables assessment of internalized tumour-related material in 
activated tissue associated macrophages, using multi-color fluorochrome 
labelling. Both the sensitivity and specificity of this approach were better than 
those of regular serum assays3,4. Technical validation of this new epitope 
detection assay was required to assess its possible position in future clinical 
applications5,6. When technical validation and optimization is completed, a next 
step will be assessment of the test reference range in larger patient populations. 
To our knowledge, hardly any literature describes validation strategies for flow 
cytometrical detection of intracellular tumourmarkers (TM), in contrast to serum 
tumour marker assays7-9. To that end, a validation approach similar to clinical 
chemical assays seemed warranted. This paper describes validation 
experiments in the pre-analytic and analytic phases for the epitope detection in 
macrophages (EDIM)-assay. The post-analytic phase (part 1: result-
presentation, part 2: interpretation and comparison with other clinical or 
laboratory data and part 3: using the data in managing of disease) is 
standardized for part 1 and 23,4. Part 3 is not subject of investigation in this 
validation-project. 
2. Materials and methods  
2.1 Experiment overview 
After obtaining medical ethical approval and informed consent, a total group of 
222 CRC in- and outpatients (35-84 years) and 23 healthy volunteers (49-58 
years) were included. The total number of CRC-patients was included in subsets 
from 2008 to 2010; each subset was intended for a different validation part. Per 
subject, three EDTA blood samples were drawn in a single draw per subset. All 
blood samples were prepared and measured according to standard operating 
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procedure (SOP) as described earlier3. The total SOP consists of three parts: 
the pre-analytic, the analytic and the post-analytic phase SOP.  
The pre-analytic phase SOP describes the sample preparation performed using 
CD14APC and CD16FITC-labeling (Becton Dickinson (BD), San Jose, USA) for 
cell characterization based on cell surface bound epitopes. This was followed by 
a Fix&Perm-strategy for labelling of epitopes intracellularly. For this purpose 
highly specific non-labeled primary antibodies directed against different TM10-13 
were biotinylated and made detectable by a conjugation step using streptavidin-
rPE (BD) fluorochrome labelling. The TM assessed were Carcinoembryonic 
antigen (CEA, clone II-7, DAKO, Glostrup, Denmark), Transketolase-like 1 
(TKTL1, R-Biopharm, Darmstadt, Germany), Cytokeratin-18 (CK 8/18, CAM5.2, 
BD) and M30 (M30-CytoDEATH-biotin, Peviva, Bromma, Sweden). 
The analytic phase consists of the actual measurement on the flow-cytometer(s). 
The post-analytic phase SOP describes a series of parental gating steps. Briefly, 
mononuclear cells are selected based on their characteristic Forward (FSC) and 
Side Scatter (SSC) properties. From this population activated macrophages 
were selected in two steps based on CD14 and CD16 positivity. Using this 
CD14+CD16+ population, the fraction tumour marker positive activated 
macrophages were selected based on the intracellular PE-labeled tumour 
marker expression (Figure 5.1). 
2.2 Instrument details 
The flow cytometers used in this validation study were the FACScanto I and 
FACScanto II (BD). Both machines were stationed in the same hospital, but in 
separate departments. Flow cytometer setup of both FACScanto machines was 
as described in earlier studies3: excitation of the cells was performed by a 488 
nm, air-cooled solid-state argon laser followed by a 17 mW 633 nm helium/neon 
laser. A 530-nm band pass filter enabled FITC-fluorescence detection, a 575 nm 
± 13 (mean ± SD) band pass filter provided PE-fluorescence detection and APC-
fluorescence was assessed by using a 660 nm ± 10 (mean ± SD) band pass 
filter. The second machine was set up and calibrated exactly like the first using 
standard seven-colour set-up beads (BD). Automatic compensation settings 
were obtained by using the FACSDiva software (BD). The SSC-settings were 
adjusted likewise on both machines, also assuring optimal capture range for 
high cell-complexity. On both machines, identical analysis templates were used, 
and the settings for FSC and SSC were chosen to enable optimal gating 
possibilities3. 
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Figure 5.1 Parental gating strategy steps (R1 to R4-gates) for epitope detection in macrophages 
(EDIM): In the FSC/SSC-plot (top-left) the mononuclear cells are selected based on 
higher cell-size and complexity than lymphocytes and RBC. From this subpopulation the 
CD14+ monocytes are selected in the CD14/SSC-plot (top-right) using a fixed cut-off for 
CD14-positivity of above 5000. In the CD14/CD16 plot (lower-left), using the negative 
control (mFMO), the CD14+CD16+ activated macrophages are selected from de CD14+ 
population from the 2nd plot. Again using the mFMO in the CD14/Epitope-rPE plot 
(lower-right) the CD14+CD16+epitopePE+ cells are selected from the CD14+CD16+ 
population identified in the 3rd plot. In this experiment the epitope was a tumour-marker 
used for tumour-marker detection in a colorectal cancer patient, therefore the term “ 
CRC-Patient-CEA” is used in the title above the plots. 
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2.3 Data analysis details 
FACSDiva software v6.1.2 (BD) was used for analysis of flow cytometric data 
files. MS Access 2003 SP2 (Microsoft Corporation, Redmond, USA) was used 
for data-storage, IBM SPSS-statistics 19 for mac (IBM, Armonk, USA) and 
Graph-pad Prism v5.0 (GraphPad Software, La Jolla, USA) were used for 
statistical analysis and creating graphs. In the sample stability assessment the 
Median Fluorescence Intensity (MdnFI) was chosen to assess epitope 
degradation because it is presumed to be the most robust (Shapiro and 
Roederer, 2008). Throughout the rest of the experiments the fraction 
CD14+/CD16+/EDIM+ monocytes e.g. CEA-IM, TKTL1-IM, CK-IM or M30-IM is 
the primary outcome measure of the EDIM-assay; further referred to as outcome 
EDIM-assay. Intra-class correlation coefficient (ICC), of which a value of 1.0 
indicates perfect agreement, was used to assess inter-assay, intra-assay, 
transferability and intra-individual variations. 
2.4 Pre-analytic investigation phase details 
2.4.1  Sample stability assessment 
Sample stability over time from venipuncture to start of preparation was 
assessed by storing multiple freshly drawn blood samples of 5 CRC-patients at 
room temperature (RT) and preparing them at time-points 0, 6 and 24 hours. 
Median fluorescence intensity is preferred for analysis using a logarithmic 
scaling14.  
2.4.2  Biological variation 
Biological variation was assessed by repeatedly measuring samples from the 
same healthy person(s) over a number of weeks and months. Firstly, we 
assessed the variability in 6 persons during four weeks with two blood draws per 
week, providing 8 consecutive outcomes in a relatively short time. Secondly, we 
assessed the outcome-variability in (the same) six persons 10 times during 40 
weeks. Combined with the measurements of the first 4 weeks, a 44-week 
measurement window is created. Besides biological variation inter-assay 
variability over a longer period is automatically assessed. All variables except 
time-point of venipuncture were kept static over this period. 
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2.5  Analytic investigation phase details 
2.5.1  Intra-assay variability  
The intra-assay variability was tested by repeated measurements of the same 
sample on a FACS-canto I flow cytometer (BD). 90 CRC-patient samples were 
measured two consecutive times. 
2.5.2  Inter-assay variability 
Inter-assay variability was first assessed by preparing two different samples of 
the same patient, independently of each other, followed by measurement on one 
single flow cytometer. A single sample, prepared out of 3 ml EDTA whole blood, 
is able to provide 2 to 3 consecutive measurements. Therefore we were 
restricted to 2 measurements per sample.  
2.5.3  Transferability  
The transferability of the EDIM-assay from one flow cytometer system to another 
comparable system was assessed by comparing EDIM-assay outcomes. A set 
of samples was measured on two flow cytometers (BD) (a FACS-canto I and a 
FACS-canto II) within two hours of each other. The machines were stationed in 
separate laboratories; different operators performed the flowcytometric analysis. 
3. Results  
3.1  Pre-analytic investigation phase 
3.1.1  Sample stability assessment 
Five tubes per single blood sample were analyzed using the EDIM-assay. The 
graphs show increase in cell size and diminishing of cell complexity over time. 
The expression of CD14, CD16 and EDIM changes, showing a general increase 
in the spread for CD16 and EDIM and an increase followed by a decrease of 
spread for CD14 (Figure 5.2). This variation did not interfere with the gating 
strategy. Statistical analysis is not feasible in a low number of measurements. 
3.1.2  Biological variation in time of CEA-IM (within healthy persons)  
Figure 5.3 shows the mean±SD of the fraction (%parent) CD14+/CD16+/EDIM+ 
monocytes using the CEA-antibody (CEA-IM) outcomes during a period of 308 
days in 6 healthy persons.  
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Figure 5.2 Sample stability assessment investigating stability of cell characteristics and 
mononuclear cell antibody binding sites in 5 CRC-patients. Samples were stored at 
room temperature on the bench and assessed at zero, six and twenty-four hours after 
venipuncture. 
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Figure 5.3 Combination of biological and inter-assay variation; showing 8 measurements over a 
period of four weeks, combined with 12 measurements over an additional period of 10 
months of the fraction (%parent) CEA-containing activated macrophages (CEA-IM) 
using the EDIM-method. The group mean ± SD is 17.28±12.11. 
 
3.2  Analytic investigation phase 
3.2.1  Intra-assay variability 
90 single blood samples of CRC patients were drawn. 90 series of 5 analysis 
tubes (CEA, TKTL1, M30 and CK) and a negative control (FMO) were prepared 
(450 analysis tubes). All tubes were measured twice on the same machine 
(resulting in 450 data file-pairs). In 57 pairs, one or both tubes were disqualified 
due to technical failures (mostly inadequate event-numbers in either or both 
tubes; adequate event-numbers were defined as a minimum of 30.000 
mononuclear cell events) and excluded, leaving 393 pairs for evaluation. The 
ICC of CEA-IM was: 0.902; of TKTL1-IM: 0.933; of CK-IM: 0.873 and of M30-IM: 
0.652. The FMO itself showed an ICC of 0.836 (Figure 5.4). 
3.2.2  Inter assay variability 
Twenty-nine double blood samples from 29 CRC patients were used for inter-
assay variability assessment. We prepared 145 pairs of analysis tubes (29 x 2 
series x 5 analysis tubes (CEA, TKTL1, M30 CK and FMO). In 7 pairs, one or 
both tubes were disqualified due to technical failures (mostly inadequate event-
numbers in either or both tubes; adequate event-numbers were defined as a 
minimum of 30.000 mononuclear cell events) and excluded, leaving 138 pairs for 
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evaluation. The ICC of CEA-IM was: 0.653; of TKTL1-IM: 0.539; of CK-IM: 0.479 
and of M30-IM: 0.391.The FMO had an ICC of 0.847 (Figure 5.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Agreement of duplicate EDIM Measurements: Using the EDIM method the 
reproducibility of duplicate tumourmarker measurements of all including CEA-IM is 
graphically shown (n=393). The positioning on the 45-degree axis shows good 
agreement (ICC=0,652 - 0,933) of both the original and duplicate measurement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Agreement of double EDIM Measurements: Using the EDIM-method the reproducibility 
of all double tumourmarker-epitope measurements (n=138 pairs) is graphically shown. 
The positioning on the 45-degree axis shows moderate to good agreement 
(ICC=0,391-0,847) of both the first and second sample. These ICC’s show less 
agreement than the intra-assay variability assessment. 
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3.2.3  Transferability 
Two series of duple samples of CRC patients were drawn, prepared, measured 
and analyzed on two different flow cytometers. In the first series 150 data files 
were acquired, the second series provided 120 data files. The outcomes showed 
excellent reproducibility between analyzers in both series. ICC of CEA-IM in 
series 1 was: 0.988, and in series 2: 0.975. ICC of TKTL1-IM in series 1 was: 
0.987 and in series 2: 0.989. ICC of M30-IM in series 1 was: 0.984 and in series 
2: 0.986 (Figure 5.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Agreement of flow cytometer data pairs: Reproducibility of 2 series of duplicate samples 
(series 1: n=150, series 2: n=120) on two different flow cytometers measuring the 
epitopes CEA, TKTL1 and M30. All measurement-couples appear on or near the 45-
degree axis. Sub-zero outcomes originate from correction of assay-outcome for control-
outcome, caused by assay-values not being high enough to overcome background-
values (corrected for control negative value-range: -0.2 to -8.0). These have all (n=21) 
been re-corrected to a value of 0. All duplicate measurements show excellent ICC’s 
(0,975-0,989), meaning the assay is transferable between analyzers. 
 
4.  Discussion  
According to Sturgeon et al. of the European Group on Tumor Markers (EGTM), 
the pre-analytic and analytic phases of investigating an assay should be 
standard for serum tumour marker assays15,16. It seems logical to apply their 
approach to our assay. Reproducibility is considered good when intra-assay 
variability is <5%CV and inter-assay variability is <10%CV in automated assays. 
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However, these values of intra-assay or inter-assay variability are often 
unachievable in experimental assays that are performed manually15.  
Our group published pilot-results on epitope detection in macrophages in 2008 
and 20093,4 showing the ability to distinguish healthy controls from prostate and 
colorectal cancer patients using PSA-IM and CEA-IM respectively. Provided 
optimal technical analytical conditions are ensured, the EDIM-method is stable, 
reproducible and transferable, yet the pre-analytic (non-technical) phase 
requires attention. The assessments of sample stability and biological variation 
over time have only provided visual results, which have not yet been supported 
by statistical analysis in our group due to small numbers. The group of Feyen et 
al on the other hand have proven good reproducibility in co-operation with 
various laboratories (CV’s 4.9-9.1%)5.  
 
The sample stability study showed changes in the binding capacity of cell 
surface directed antibody-fluorochrome-conjugates (CD14-APC and CD16-
FITC) on activated macrophages within 24 hours after venipuncture. Besides 
these observations, the cell size and complexity changes during time on the 
bench were also recorded. The observed variability within the five subjects may 
be due to several reasons: external antibody binding could be nonspecific and or 
there could be alterations in binding capacity of the binding sites. Both 
hypotheses may be consistent with commonly known changes observed in cell 
size and complexity during cell degeneration.  
The parental gating strategy based on CD14 and CD16-labeling remained intact 
during analysis, retaining the ability to correctly characterize the cell population 
of interest e.g. activated macrophages. The observation of more or less stable 
internal cell staining within twenty-four hours suggests that intracellular staining 
is less sensitive to cell degradation. We suggest that this is due to capturing of 
the stained tumour-related material inside phagosomes protecting against 
external influences. This is in accordance with earlier observations of 
internalized PSA and CEA in macrophages using cytospins in combination with 
immunocytochemistry, which showed granular staining and loss of integrity of 
the cell membrane3,4. Considering the outcomes of the sample stability test 
above, starting preparation is recommended within 6-8 hours after venipuncture. 
In our validation studies, 91% of all samples were not only prepared, but also 
analyzed within eight hours.  
The second pre-analytic aspect, biological variation, showed that the baseline 
mean value of the fraction of CEA-IM in six healthy persons over 44 weeks was 
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17.28% (SD=12.11). Due to a pre-analytic error, which was noted in the 
laboratory journal, an outlier occurred in all persons at 168 days that is clearly 
distinguishable in the graph. The variation that was found is not surprising when 
considering that leucocyte levels in peripheral blood samples of healthy persons 
vary between 8.9%CV and 15.7%CV within subjects, to 34.6%CV between 
subjects17. Baseline levels per individual must be established before interpreting 
solitary assay-outcomes, which is in accordance with the current best practice of 
serum tumour marker assays. An increase in serum tumour marker levels 
compared with a baseline of more than 25-30% that occurs twice in a row is 
considered clinically relevant in CRC7,18.  
During the 44-week assessment a problem occurred due to changes in LOT-
numbers of Streptavidin-rPE, leading to shifts in fluorescence staining, and 
ultimately also in different outcomes in measurements, which were correctable 
by titration. This underlines the high impact of lot-to-lot variation in similarity with 
conventional serum tumour marker assays. 
At the start of the validation process of this new assay, small adaptations to the 
original protocol were made3,4. The stopping gate was changed to a total of 
10.000 events specific for mononuclear cells, instead of a total of 30.000 random 
events. In addition, another type of negative control was introduced; a 
fluorescence-minus-one (FMO) which had been modified (mFMO). Because our 
assay is based on a multicolour-, streptavidin-based immunocytochemistry 
method control of background fluorescence is of utmost importance. The results 
of our previous work were based on using a regular isotype contro3,4. However, 
we sometimes experienced inexplicable shifts in the EDIM-negative population 
for rPE-staining. A possible explanation could be the presence of endogenous 
biotin, which led to aspecific binding of streptavidin-rPE. It is known that it is very 
difficult to find an isotype control that truly matches the background staining19. 
Another limitation of an isotype control is that they do not account for 
fluorescence spillover from other channels. For that reason, we chose a 
modified FMO. This is a sample that includes all of the antibody conjugates 
except the biotin-labelled EDIM- directed antibody. This sample is finally 
incubated with rPE-conjugated streptavidin. Because we used high-quality 
fluorochrome-labelled antibodies at appropriate concentrations, the background 
staining due to nonspecific antibody binding is minimal. The major source of 
background staining is due to fluorescence spillover. Because of this, the use of 
FMO controls is recommended19. 
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In the analytic phase, the intra-assay variability showed good results, 
demonstrating that it is possible to re-measure the prepared sample without 
significant deviations in outcome. The inter-assay variability shows mild to good 
agreement, while agreement on intra- and inter-assay may facilitate broader 
deployment options of the assay. The ICC-results in both intra-assay and inter-
assay assessments were fairly similar. The ICC’s of M30-IM were lowest in both 
intra-assay and inter-assay assessments. This seems to be in line with recent 
results of our group20 in which M30-IM were the least common in CRC-tissue-
analysis as well. The CEA-IM, TKTL1-IM and CK-IM ICC’s showed results in the 
same range within intra-assay and also within inter-assay assessment. This 
indicates that reproducibility within one blood sample is good, but between two 
sequential blood samples the variability is higher. This is in accordance with 
earlier intra- and inter-assay findings in sequential analysis of serum tumour 
markers8 in ovary cancer. Tuxen showed intra- and inter-assay variability of 
serum-CEA being very dependent on analytical and intra-individual variability, 
with intra-individual variability up to 58%. Finally, in both intra- and inter-assay 
assessment practically identical mFMO ICC’s were recorded, proving that 
variation in background-signal is very low. On 2 different flow cytometers 
agreement within 1 sample is good. Between sample agreement within one 
patient, measured on two flow-cytometers can differ from significant to mild. 
Besides the analytical and intra-individual variability described, the variability 
observed can also be due to the kind of cell separation tubes that are used. 
Further assessment of cell separation techniques is needed to rule out possible 
variability issues. 
Transferability was investigated by measuring each selected sample within a 
certain time frame on two different flow cytometers within the same institute, but 
in different laboratories. This provided excellent results, proving the assay 
performs well when the setup procedure is performed according to the SOP in 
another laboratory.  
 
In the post-analytic phase earlier established gating strategies were utilized 
using the mFMO as a blank. By comparing blank to sample outcomes all 
outcomes were obtained3,4. 
 
The clinical applicability of this assay-type in cancer diagnostics has been 
described in different publications6,21. The EDIM-test has been shown able to 
detect different biomarkers for the characterization of malignancy, based on the 
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detection of abnormal apoptosis, proliferation and anaerobic glucose metabolism 
(e.g. TKTL-1). TKTL-1 expression correlates with invasive growth and 
metastasis6,21. The applicability of the assay means a step forwards in detection 
and surveillance options for clinicians, which in turn may lead to earlier and 
different treatment than was available up until now. 
 
In summary, the EDIM-assay is a technically reproducible, stable and 
transferable assay. This article describes the validation of an experimental assay 
detecting tumour markers in macrophages. This assay exploits the natural 
concentration provided by the immune system. Our approach was shown to be 
stable during analytic procedures and partly during pre-analytic procedures.   
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Abstract 
Introduction 
Response prediction and response evaluation are key objectives of the monitoring of neo-
adjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC) patients. 
These outcomes could enable early treatment alteration during the first two weeks of 
chemoradiotherapy. In non-responders a tool to aid the decision to perform surgery 
earlier is desirable. Intra and peritumoural inflammation prohibits proper response 
evaluation by PET-CT, and is therefore not robust enough. This study evaluates the 
additional value of a panel of serummarkers and experimental flow cytometrical assays to 
PET-CT values alone in the efficacy assessment of chemoradiotherapy. These values are 
assessed in relation to tumour regression (TRG) and tumour response (ypTN). The 
immune cell influx (INF) is investigated separately to assess reflection of biological 
changes during nCRT by blood biomarker levels and or PET-CT values. 
 
Methods 
One-hundredsixteen LARC patients were included. Peripheral blood samples were drawn 
and PET-CT analyses performed at baseline, 15 days and 90 days after initiation of a 
50.4 Gy chemoradiotherapy protocol. Additional blood sampling was performed at day 7 
in a subset of patients. In the peripheral blood samples carcinoembryonic antigen (CEA), 
leucocytes and c-reactive protein (CRP) were measured using routine serum assays. 
Flow cytometrical assays measured the fractions of monocytes, activated macrophages 
and CEA-containing macrophages (CEA-IM). All blood biomarkers provided time point-
values and ∆values between time points. PET-CT measurements provided maximum 
standard uptake value (SUVmax), SUVmean and metabolic tumour volume (MTV) data. 
Results were analysed in patient subsets based on ypTN, TRG and immune cell influx-
score (INF). AUCs were calculated using ROC-curve analyses to assess outcome 
discriminative capabilities for TRG and ypTN. Added value to existing response prediction 
models at t=0, t=15 and t=90 was assessed. INF was investigated to assess the 
biological effects of nCRT treatment during the treatment period. 
 
Results 
Of 116 included patients 94 qualified for analysis of which 23 (24.5%) developed a 
ypT0N0 and 55 (58.5%) were good responders (ypT0-2N0). In univariate analysis serum 
CEA was predictive at t=0 using TRG 1-2 and ypT0N0 as outcome measure with AUC of 
0.656 (p=0.011) and AUC 0.600 (p=0.09) respectively. MTV at t=0 was predictive for 
TRG 1-2 (AUC=0.666, p=0.008), ypT0N0 (AUC=0.750, p=0.001) and ypT0-2N0 
(AUC=0.674, p=0.005) respectively. Other blood biomarkers at various time 
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points/periods showed trends towards predictive cut-off value 0.6. Combining PET-CT 
with baseline blood biomarker values increased the AUC from 0.74 to 0.75 in the first 
prediction model (t=0) of pCR. The second blood biomarker enhanced prediction model 
(t=0-15 days) showed an AUC of 0.72 for PET-CT alone and an AUC of 0.94 for PET + 
biomarkers predicting pCR. A third blood biomarker enhanced prediction model (t=0-90 
days) showed an AUC of 0.75 for PET-CT alone and 0.76 for PET-CT + biomarkers 
predicting pCR. Biological changes in the tumour (and surroundings) were reflected best 
by the MTV. MTV was predictive for low immune-cell influx (INF 0-1) at t=0-15 days and 
t=15-90 days (AUC=0.78 (p=0.002) and AUC=0.72 (p=0.078). 
 
Conclusion 
Serum CEA and MTV showed significant discriminating abilities on t=0 investigating the 
outcome measure TRG1-2. Recently published results predicting pCR (ypT0N0) outcome 
at t=0 using serum CEA have now been confirmed in this different patient population 
investigating ypT0N0 as well as TRG1-2. TRG1-2 therefore seems equal to ypT0N0. 
Using a blood biomarker enhanced pCR-prediction model shows an AUC of 0.94 in a 
prediction model applied in the first 2 treatment weeks of chemoradiotherapy. Therefore, 
treatment alteration based on pCR outcome prediction in the first two treatment weeks 
seems feasible. Confirmation of these findings in a prospective trial using a larger cohort 
in another population area would be necessary to exclude study bias. 
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1. Introduction  
Neoadjuvant chemoradiotherapy (nCRT) is widely used in patients with locally 
advanced rectal cancer (LARC). Besides decreasing local recurrences, 
downsizing and downstaging can be accomplished. Complete pathological 
response (pCR) is seen in 12-27%1 and some recent studies suggest that these 
patients can be offered a wait-and-see-policy2-4. Good responders (>50%) show 
reduction in both tumour size and lymph node positivity (down-staging), leading 
to possibilities for less invasive surgical intervention. Absence of such reactions 
(non-responders) could warrant earlier surgery, or exposure to higher or 
prolonged doses of radiation and/or chemotherapy5,6. 
Evaluation of response status for treatment alteration purposes is only possible if 
the response status can be properly determined. One of the promising imaging 
modalities is (FDG) PET-CT. PET-CT pre- and post-treatment has shown 78% 
sensitivity (range 75-82%, 95% CI) and 66% specificity (range 62-69%, 95% CI) 
in response prediction1. Maximum standardised uptake value (SUVmax) and 
response index (RI) at day 15 are stated as the most promising predicting 
factors1. MRI, regular CT and endorectal ultrasound (ERUS) proved to be 
inferior to PET-CT, but equally capable in predicting non-responders7,8. PET-CT 
is currently the imaging modality of choice in current clinical trials for response 
monitoring and prediction.  
Recently it was shown that the accuracy level of an established response 
prediction model based on clinical parameters and FDG PET-CT-information 
could be enhanced using blood biomarkers9. Buijsen et al. focussed on the 
additional value of multiple pre-chemoradiotherapy blood biomarker values. 
They reported serum carcinoembryonic antigen (CEA) and osteopontin as 
significant predictors for pCR after univariate analysis. For good tumour 
response (ypT0-2N0), CEA, interleukin 8 (IL-8) and osteopontin were the 
strongest predictors. The prediction model accuracy was increased to 0.81 for 
pCR and to 0.78 for tumour response. However, interpretation of the results in 
relation to TRG and INF was not performed. 
Blood biomarker variation during nCRT has had little attention up until recently. 
In previous studies we investigated a flow cytometrical assay which detects 
intracellular accumulation of tumour related material in macrophages in 
peripheral blood of CRC patients. Intracellular detection in macrophages of CEA 
(CEA-IM) attributed to early stage CRC diagnostics. Additional CRP-
 Predicting response using blood biomarkers and PET-CT during neoadjuvant chemoradiation 
     111 
6 
measurements effectively distinguished CRC from inflammatory bowel 
diseases10,11. 
Treatment result assessment using PET-CT and blood biomarkers investigating 
tumour response and (peritumoural) inflammation is not generally implemented 
and remains under investigation9. Tumour response can be assessed on the 
basis of the following outcome measures: tumour regression grade (TRG 
according to Mandard12, considered to be the gold standard) and tumour 
response (ypTN). The low-grade inflammation already present in colorectal 
cancer (CRC) tumours and their microenvironment13 is modulated during 
neoadjuvant chemoradiotherapy. This results in local oxygen radical production 
and increased microvascular permeability, both causing tissue damage by 
extensive leukocyte infiltration and oedema14. Peritumoural inflammation causes 
interference in tumour volume-assessment using PET-CT, hindering tumour 
response interpretation. Peritumoural inflammation can be assessed in the 
pathological specimen objectifying local immune cell influx and fibrosis. The 
local biological effects of nCRT caused by the presence or absence of the 
immune cell influx have not yet been evaluated. Assessing tumour inflammation 
could provide more information about a possible difference between responders 
and non-responders based on the patient's immune system abilities to respond 
adequately to the nCRT. Tumour inflammation and immune cell influx can be 
assessed investigating a semi-quantitative 4 point score, the INF-score. 
The aim of this current study is to assess values and value-variations of blood 
biomarkers and PET-CT parameters in relation to TRG, ypTN and INF in rectal 
cancer patients receiving nCRT. The ypTN will be evaluated for additional value 
to pCR prediction models9,15,16. The INF score will be assessed to investigate 
local biological effects caused by nCRT and immune cell influx. All parameters 
were assessed before nCRT started, during the nCRT period and during the 
waiting/recovery period. 
2. Materials and methods  
2.1 Patient population 
During the period July 2008 to july 2011, 116 patients with LARC were included 
in the combined PET-CT and blood biomarker analysis of MAASTRO Clinic, 
Atrium Medical Center Parkstad and Maastricht University Medical Center. 
The study was performed according to the Helsinki Declaration and was 
approved by the Medical Research Ethics Committee (MREC) of the Maastricht 
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University Medical Center and for local application by the MREC of the Atrium 
hospital. 
For this study, the following types of LARC were included: distal tumours with a 
T3- and/or N2 stage, mid- or upper rectal tumour with a circumferential resection 
margin prediction of <2 mm and T4 tumours 
Clinical TNM staging was performed by MRI. Patients underwent surgery 
8-10 weeks after finishing nCRT. In total 22 patients were excluded for various 
reasons: physical complaints (n=14), disease progression (n=4) and refusal of 
venipuncture (n=4). 
The remaining nCRT study population (n=94) was treated according to a 50.4 
Gy chemoradiotherapy protocol9. During nCRT peripheral blood samples (EDTA, 
heparin and serum) and PET-CT images were obtained on days 0, 7, 15 and 90. 
During the study, several patients dropped out at or between each study time 
point (t=15, n=86; t=90, n=67). Reasons for withdrawal were physical 
complaints, disease progression, blood sampling errors or technical laboratory 
problems. TRG and INF-scores could not be recovered for all patients; therefore 
the study populations for TRG (n=90) and INF (n=59) consist of subgroups of 
the total study population of 94 patients. Finally, an additional blood sampling on 
t=7 days of a subpopulation of patients was obtained to investigate variations 
within the first two treatment weeks. In this subgroup the known number of 
ypTN-statuses was n=34. The TRG status was recovered in n=33 patients and 
INF-score in n=21 patients. 
2.2  Blood analysis  
All blood samples were analysed within 8 hours after blood withdrawal. CEA was 
determined in serum on a Centaur (Siemens, Germany). CRP was tested in 
heparin by a particle-enhanced immunoturbidimetric assay on a Roche Cobas 
system (Roche Diagnostics GmbH, Mannheim, Germany). Leukocytes were 
determined on an automated hemocytometer system (Sysmex XE2100, Kobe 
Japan). 
2.2.1  Flowcytometrical analysis 
Peripheral EDTA-blood samples for flow cytometry were prepared and analysed 
as described in previous publications10,11. In short, peripheral blood monocytes 
were isolated from whole blood and relevant epitopes are labelled extra- and 
intracellularly. Using this technique, cell size and granularity, as well as intra- 
and extracellular epitope presence (e.g. CEA (CEA-IM)) can be investigated. 
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The fractions (%parent) of blood monocytes, activated macrophages and CEA-
IM were assessed. 
2.3  PET-CT measurements 
PET-CT measurements were obtained applying the same technical PET-CT 
protocols as published earlier9,16,17. Patients received an intravenous FDG-
injection with weight-dependent dose after 6 hours of fasting. Sixty minutes later 
PET-CT-scans were acquired. PET-CT-data was normalized for blood glucose 
levels obtained shortly before FDG-administration. Obtained PET-CT 
parameters were maximum standard-uptake value (SUVMax), mean standard 
uptake value (SUVMean) and Metabolic Tumour Volume (MTV) of the tumour. 
All values were obtained by an experienced PET-CT analyst. 
2.4  Histological specimen and tumour inflammation evaluation 
Tumour regression (TRG) and response (ypTN) were obtained by examining the 
pathology reports. If available, TRG according to Mandard was obtained besides 
ypTN. When TRG was absent, ypTN was used as primary outcome measure. In 
order to assess local tumour inflammatory response a non-validated semi-
quantitative 4 point scoring system was used. Immune cell infiltration (INF) was 
assessed by scoring immune cell infiltration and fibrosis in 4 categories 
according to histopathological evaluation: INF 0=no infiltration or fibrosis visible; 
INF 1=sparsely visible local reactive fibrosis; INF 2=evident fibrosis and some 
inflammatory cell(s)/deposits); and INF 3=finally widespread fibrosis and 
massive inflammatory cell influx. If descriptions were absent or incomplete, the 
INF-score was not determined. Standard pathology reports provided sufficient 
information in 62% of our study population. Finally, pooling of the results of the 
INF 0 and INF 1 groups into an INF Low group, along with pooling of the results 
of the INF 2 and INF 3 groups into an INF High group was performed. 
Regrouping enabled statistical analysis in equally large dichotomized groups. 
2.5  Patient group selections and endpoint selection 
Results are displayed by, and calculated in, patient groups based on the 
following endpoints: Pathological tumour response (ypTN; n=94), Tumor 
Regression Grade (TRG; n=90) and immune cell infiltration (INF; n=59). As a 
primary endpoint TRG was chosen because it is currently considered to be the 
gold standard; ypTN was a considered secondary endpoint. 
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2.6  Result presentation and statistical analysis reporting 
Paragraph 3.2 displays the results in tables and graphs with the aim of visually 
evaluating the changes during nCRT in the various patient groups. This 
approach enables identification of interesting variations over time in combination 
with statistical outcomes of all parameters that have been reported on in 
paragraph 3.3. 
2.7  Statistical analysis 
2.7.1 Univariate analysis 
Statistical analysis was performed in GraphPad Prism v 6.0 for Macintosh 
(GraphPad, La Jolla, CA, USA) and SPSS v 22.0 for Macintosh (IBM, Armonk, 
NY, USA). Statistical tests used were: ROC-curve analysis to assess AUC-
values of the calculated predicted probabilities, 95% confidence intervals and 
accompanying p-values. Confidence intervals with lower-boundaries of 0.500 
and above were considered significant18, reflecting in subsequent p-values equal 
to or below 0.05. Calculations of the AUC-values were made at the baseline 
time-point (t=0), and value-changes (or delta) within each time period, defined as 
t=0-7 days, t=7-15 days, t=0-15 days and t=15-90 days. 
2.7.2  Completing biomarker values for prediction model evaluation. 
Missing blood biomarker-values were completed using expectation-maximation 
imputation with a kNN imputation algorithm. This imputation method was only 
applied for investigating additional value to the existing prediction model, not in 
above described univariate analyses. Adding all parameters by Mathlab, release 
2010b (The Mathworks, Natick, MA) to prediction models was used to assess 
possible increase in predicting capacity for ypT0N0 (pCR). For baseline 
interpretation, a PET0 model was built of cT-stage, cN-stage, max diameter of 
tumour on PET-CT combined with the SUVmean at t=016. The established 
parameters of the existing PET15 prediction model, cT-stage, cN-stage and 
maximum diameter of the tumour on PET-CT were combined with ∆ SUVmean 
t=0-15 days17. For the PET90 model the combined parameters consisted of 
tumour length, SUVMax, ∆SUVMax 0-90 days16. A ROC-analysis with AUC 
calculation was performed after bootstrapping (n=1000) to approximate the true 
AUC as in previous studies9,16,17. 
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3.  Results  
3.1  Patient characteristics 
In Table 6.1 the characteristics of the total patient population and subpopulation 
at t=7 are shown. The age in both groups is comparable; the subgroup consists 
of slightly fewer men. In the subgroup, the cT3 and the cN1 stage are relatively 
more prevalent than in the total patient group. The subpopulation therefore 
consists of patients with more invasive tumours with less extensive nodal 
involvement. 
 
Table 6.1 Patient characteristics nCRT group. 
Patient characteristics Total population (n = 94) Subpopulation at t = 7 (n = 34) 
 n % n % 
Age     
   Median 65.9  67.6  
   Range 34.4-88.0  34.4-88.0  
Gender     
   Male 71 75.5 24 70.6 
   Female 23 24.5 10 29.4 
Clinical tumour stage (cT)     
   2 10 10.6   2   5.9 
   3 59 62.8 28 82.4 
   4 25 26.6   4 11.8 
Clinical nodal stage (cN)     
   0 17 18.1   8 23.5 
   1 36 38.3 15 44.1 
   2 41 43.6 11 32.4 
 
3.2  Blood biomarkers and PET-CT before, during and after nCRT 
Tables 6.2, 6.3, 6.4 and 6.5 show the actual means ± SD at each point in time 
per outcome measure in the TRG, ypTN and INF outcome group-comparisons 
respectively. On t=7 only a subgroup was investigated for blood biomarker 
values, no PET-values were obtained. Accompanying Figures 6.1A-C, 6.2A-C, 
6.3A-C and 6.4A-C visually demonstrate the variation in serum CEA, serum 
CRP and serum leucocytes. Figures 6.1D-F, 6.2D-F, 6.3D-F and 6.4D-F show 
the variation in the flow cytometrical measured fractions of monocytes, activated 
macrophages and CEA-IM. Figures 6.1G-I, 6.2G-I, 6.3G-I and 6.4G-I show 
SUVmean, SUVmax and MTV value variation. The subgroup analyses between 
t=0 and t=7, at t=7 and between t=7 and t=15 in all outcome measures show low 
patient numbers of below 10 patients and should be interpreted as such. The 
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discriminative power of all parameters or changes thereof are explored below in 
section 3.3. 
3.2.1  Tumour regression grade (TRG) 
The baseline CEA value in good responders is markedly lower than in bad 
responders. Measurements on t=7 show an interesting separation between good 
and bad responders in CEA, CRP and %parent Monocytes. This could be real, 
or a result of the selection effect of the subgroup selection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 A-I: Figure 1 shows the influence of neoadjuvant treatment on serum, flow cytometrical 
and PET-CT parameters considering TRG as the final outcome measure during the 
whole nCRT treatment period. 
3.2.2  Pathological response (ypTN) 
Patients were divided firstly by complete and incomplete pathological response, 
pCR (ypT0N0) and non-pCR (ypT1-4NallMall) respectively (Table 6.3 and 
Figure 6.2). Secondly they were divided by good and bad response, ypT0-2N0 
and ypT1-4NallMall (Table 6.4 and Figure 6.3). 
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3.2.2.1  Complete (ypT0N0) vs. incomplete response >ypT0N0 
Serum CEA shows a decrease during the 90 day period. CRP shows an initial 
decrease in the pCR group, while it increases in the non-pCR group. A decrease 
in leucocytes in non-pCR group between t=0 and t=90 is shown, the pCR group 
shows a steep decrease and a subsequent small increase. The fractions of 
activated macrophages and %CEA-IM in the pCR group show some different 
responses between pCR and non-pCR at day 7, although sample size is small. 
There is a difference in MTV between pCR and non-pCR groups from the start 
throughout the neoadjuvant treatment period. SUV-values decrease during 
treatment in both groups (Table 6.3 and Figure 6.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 A-I: Figure 6.2 shows the influence of neoadjuvant treatment on serum, flow 
cytometrical and PET-CT parameters considering pathological response (ypTN) as the 
final outcome measure; this first ypTN figure compares the pathological complete 
response group (pCR / ypT0N0) with the group of pathological incomplete response 
(non-pCR / > ypT0N0) during the whole nCRT treatment period.  
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3.2.2.2  Good (ypT0-2N0) vs. bad response (ypT3-4NallMall) 
CEA continues to show a decrease during 90 days and CRP again shows an 
increase and subsequent decrease during the first fifteen days in the bad 
response group. A decrease in leucocytes is shown in both groups between 
t=0-15 days, whereafter both groups seem to remain stable. The fraction of 
monocytes shows a more pronounced decrease in the bad response group than 
the good responders. The fraction of activated macrophages in the good 
response group shows a stronger increase during t=0-7 days than the bad 
response group, but the fraction of CEA-IM is almost equal in both groups. SUV-
values again decrease during treatment in both groups (Table 6.4 and Figure 
6.3). In general, the results resemble the outcomes of the complete responders 
vs the non-responders in paragraph 3.2.2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 A-I: Figure 6.3 shows the influence of neoadjuvant treatment on serum, flow 
cytometrical and PET-CT parameters considering pathological response (ypTN) as the 
outcome measure; this second ypTN figure compares the pathological good response 
group (ypT0-2N0) with the group of bad pathological response (ypT3-4NallMall) during 
the whole nCRT-treatment period.  
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3.2.3  Tumour inflammation and immune cell influx (INF) 
Patients were divided by high influx of immune cells and fibrosis (INF-High=INF 
2+3) vs low influx of immune cells and fibrosis (INF-Low=INF 0+1) respectively, 
both based on pathological specimen evaluation(Table 6.5 and Figure 6.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 A-I: Figure 6.4 shows the influence of neoadjuvant treatment on serum, flow 
cytometrical and PET-CT parameters considering influx of immune cells and fibrosis as 
outcome measure during the whole nCRT-treatment period. 
 
At t=0 CEA and CRP show higher baseline values in the INF-High group. CEA 
shows only little difference between both groups during t=0-90 days. CRP and 
Leucocytes both decrease between t=0-15 and t=0-7 respectively. Leucocytes 
increase slightly after t=15 for INF-Low but seem to remain stable for INF-High. 
The fraction of monocytes shows a bigger decrease in the INF-High group than 
the INF-Low group. The fraction of activated macrophages in both groups almost 
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show equal values and patterns. The fraction of CEA-IM baseline value in the 
INF-High group is higher; during neoadjuvant treatment both increase until t=7 
and start decreasing until t=90, where the INF-Low group decreases the most 
and the fastest. SUV-values decrease during treatment in both groups in similar 
patterns. The MTV-value of INF-High is at baseline higher than INF-Low and 
stays clear of the INF-Low line during the whole period. This final observation 
seems to be the most pronounced in this tumour inflammation assessment 
based on pathological immune cell influx and fibrosis. 
3.3  Predictive value (AUC) of blood biomarkers and PET-CT-
values on TRG, ypTN and INF outcomes 
In tables 6-9 the predictive values of the measured blood biomarkers and PET-
CT values have been calculated and expresses as AUC for the outcome 
measures TRG, ypTN and the biological effects of nCRT using INF. 
Measurements on t=7 have been additionally acquired in a subgroup, and show 
interesting variations during early neoadjuvant treatment. In CEA, CRP and the 
fraction of monocytes these variations are most pronounced (AUC-calculations 
for SUVmax, SUVmean and MTV were not available in this subgroup in the 
period t=0-7 days and t=7-15 days because no PET-CT was made on t=7). 
3.3.1 Tumour regression grade (TRG) 
Metabolic tumour volume (MTV) is a significant discriminator at t=0 for tumour 
regression (AUC=0.666, p=0.008). The change in serum CEA level between 0 
and 15 days of treatment has an AUC of 0.602. In the neoadjuvant treatment 
period t=0-7 days, CRP is significantly discriminative (AUC=0.816, p=0.002) for 
TRG 1-2; also leucocytes and the fraction of activated macrophages show AUC-
levels of 0.605 and 0.607 respectively. In the period t=7-15 days the fraction of 
monocytes is significantly discriminative (AUC=0.737, p=0.028). The number of 
patients is lower than at other time points (n=17). 
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Table 6.6 Calculated AUC-values of all parameters: AUC-values of the predicted probability for 
TRG1-2 as positive predicted outcome combined with the 95%CI and p-values are 
shown. 
 
ROC TRG 1-2 vs TRG 3-5                   
(AUC pred. prob.)   
treatment moment/period t=0 days t=0-15 days t=15-90 days 
parameters AUC 95% CI p AUC 95% CI p AUC 95% CI p 
serum CEA 0,656 0.542 - 0.769 0,011 0,602 0.471 - 0.733 0,120 0,602 0.452 - 0.751 0,188 
serum CRP 0,494 0.373 - 0.614 0,916 0,298 0.179 - 0.417 0,002 0,539 0.384 - 0.694 0,615 
serum Leucocytes 0,538 0.417 - 0.659 0,533 0,473 0.343 - 0.604 0,690 0,556 0.404 - 0.708 0,468 
Flow %parent Monocytes 0,490 0.368 - 0.613 0,874 0,560 0.430 - 0.690 0,364 0,624 0.473 - 0.774 0,112 
Flow %parent act. Mac. 0,442 0.320 - 0.564 0,347 0,518 0.388 - 0.648 0,786 0,512 0.358 - 0.666 0,876 
Flow %parent CEA-IM 0,531 0.410 - 0.652 0,613 0,524 0.394 - 0.655 0,716 0,475 0.317 - 0.634 0,755 
SUVMax 0,455 0.328 - 0.582 0,478 0,475 0.329 - 0.620 0,731 0,669 0.522 - 0.816 0,035 
SUVMean 0,464 0.335 - 0.594 0,573 0,487 0.338 - 0.636 0,863 0,706 0.524 - 0.887 0,059 
MTV 0,666 0.549 - 0.783 0,008 0,524 0.377 - 0.670 0,751 0,584 0.381 - 0.788 0,439 
ROC TRG 1-2 vs TRG 3-5                   
(AUC pred. prob.) subgroup-analysis    
treatment moment/period t=0-7 days t=7-15 days    
parameters AUC 95% CI p AUC 95% CI p    
serum CEA 0,504 0.291 - 0.717 0,970 0,487 0.269 - 0.706 0,906  
serum CRP 0,816 0.659 - 0.972 0,002 0,410 0.189 - 0.631 0,395 Table legend 
serum Leucocytes 0,605 0.393 - 0.817 0,321 0,550 0.341 - 0.759 0,635 value: AUC>0.6 
Flow %parent Monocytes 0,589 0.377 - 0.802 0,406 0,737 0.558 - 0.915 0,028 value: AUC>0.7 
Flow %parent act. Mac. 0,607 0.402 - 0.812 0,318 0,464 0.252 - 0.677 0,739 sign. discriminating 
Flow %parent CEA-IM 0,540 0.319 - 0.761 0,708 0,518 0.296 - 0.740 0,872 parameter if → 
SUVMax na na na na na na 95%CI [≥0.5 – any] 
SUVMean na na na na na na (equals p≤0.05) 
MTV na na na na na na  
 
3.3.2  Pathological response (ypTN) 
3.3.2.1  ypT0N0 vs. >ypT0N0 
MTV is the only significantly discriminative parameter at t=0 when using pCR as 
an outcome measure. CEA, leucocytes, SUVMax and SUVMean pose no 
significant discriminative potential although their AUC's range from 0.602-0.625. 
AUC-values at t=0-15 days and t=15-90 days are 0.623 and 0.631 respectively, 
showing metabolic tumour volume is continuous in its discriminative potential, 
although it is not significant during the whole neoadjuvant treatment period. 
Subgroup-analyses show only the fraction of CEA-IM at t=7-15 days as 
significantly discriminative (AUC=0.762, p=0.032). In the overall treatment period 
(t=0-15 days) and later time points this discriminative power is not reproduced. 
Significance may be erroneous due to n=8 but needs to be evaluated in a larger 
cohort to confirm. Other parameters in the subgroup-analysis show no significant 
discriminative power; only serum leucocytes (n=21 vs. n=13) at t=7-15 shows an 
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AUC of 0.659 and p-value of 0.184, which is in line with AUC values at t=0-7 
days and during t=0-15 days as well. 
 
Table 6.7 Calculated AUC-values of all parameters: AUC-values of the predicted probability for 
pCR as positive predicted outcome combined with the 95%CI and p-values are shown 
in the table above. 
ROC pCR (ypT0N0) vs. non-pCR (>ypT0N0)                   
(AUC pred. prob.)   
treatment moment/period t=0 days t=0-15 days t=15-90 days 
parameters AUC 95% CI p AUC 95% CI p AUC 95% CI p 
           
serum CEA 0,602 0.477 - 0.727 0,141 0,393 0.261 - 0.526 0,145 0,513 0.348 - 0.678 0,887 
serum CRP 0,607 0.484 - 0.729 0,123 0,438 0.309 - 0.567 0,397 0,596 0.452 - 0.739 0,306 
serum Leucocytes 0,557 0.428 - 0.686 0,406 0,603 0.465 - 0.740 0,169 0,587 0.421 - 0.752 0,354 
Flow %parent Monocytes 0,454 0.331 - 0.577 0,502 0,522 0.389 - 0.655 0,762 0,401 0.230 - 0.571 0,289 
Flow %parent act. Mac. 0,566 0.441 - 0.691 0,338 0,447 0.307 - 0.586 0,467 0,539 0.381 - 0.697 0,676 
Flow %parent CEA-IM 0,532 0.394 - 0.670 0,646 0,556 0.406 - 0.707 0,444 0,551 0.390 - 0.712 0,585 
SUVMax 0,625 0.483 - 0.767 0,089 0,628 0.473 - 0.783 0,141 0,507 0.339 - 0.676 0,938 
SUVMean 0,609 0.460 - 0.757 0,140 0,564 0.400 - 0.728 0,490 0,542 0.337 - 0.747 0,752 
MTV 0,750 0.638 - 0.862 0,001 0,623 0.477 - 0.768 0,186 0,631 0.417 - 0.845 0,320 
ROC pCR (ypT0N0) vs. non-pCR (>ypT0N0)                   
(AUC pred. prob.) subgroup-analysis    
treatment moment/period t=0-7 days t=7-15 days    
parameters AUC 95% CI p AUC 95% CI p    
serum CEA 0,603 0.378 - 0.827 0,389 0,414 0.211 - 0.617 0,473  
serum CRP 0,550 0.336 - 0.764 0,674 0,432 0.243 - 0.622 0,572 Table legend 
serum Leucocytes 0,633 0.428 - 0.837 0,267 0,659 0.469 - 0.849 0,184 value: AUC>0.6 
Flow %parent Monocytes 0,597 0.378 - 0.815 0,425 0,582 0.352 - 0.811 0,498 value: AUC>0.7 
Flow %parent act. Mac. 0,628 0.384 - 0.872 0,291 0,620 0.346 - 0.893 0,321 sign. discriminating 
Flow %parent CEA-IM 0,608 0.384 - 0.832 0,373 0,762 0.588 - 0.936 0,032 Parameter if → 
SUVMax na na na na na na 95%CI [≥0.5 – any] 
SUVMean na na na na na na (equals p≤0.05) 
MTV na na na na na na  
 
3.3.2.2  ypT0-2N0 vs. ypT3-4NallMall 
At t=0 days serum CEA (p=0.096), serum CRP (p=0.069) and MTV (p=0.005) 
show AUC levels between 0.6 and 0.7. During neoadjuvant treatment period 
t=0-15 days no AUC levels above 0.6 are present. During t=15-90 days interval 
only serum leucocytes, the fraction of CEA-IM and MTV show an AUC above 
0.6. Most discriminating parameters of the subgroup at t=0-7 days are the 
following: AUC values above 0.6 are shown for CEA, the fraction of activated 
macrophages and the fraction of CEA-IM. During t=7-15 days these are serum 
leucocytes (AUC=0.758, p=0.018), and the fraction of monocytes (AUC=0.600). 
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Table 6.8 Calculated AUC-values of all parameters: AUC-values of the predicted probability for 
ypT0-2N0 as the positive predicted outcome combined with the 95%CI and p-values are 
shown in the table above. 
ROC pCR+Good (ypT0-2N0) vs Bad (ypT3-4NallMall)                   
(AUC pred. prob.)   
treatment moment/period t=0 days t=0-15 days t=15-90 days 
parameters AUC 95% CI p AUC 95% CI p AUC 95% CI p 
serum CEA 0,600 0.485 - 0.714 0,096 0,566 0.438 - 0.694 0,311 0,504 0.342 - 0.666 0,959 
serum CRP 0,609 0.492 - 0.726 0,069 0,499 0.364 - 0.635 0,989 0,493 0.328 - 0.659 0,930 
serum Leucocytes 0,561 0.442 - 0.680 0,312 0,508 0.374 - 0.641 0,909 0,624 0.478 - 0.770 0,104 
Flow %parent Monocytes 0,475 0.349 - 0.601 0,685 0,484 0.350 - 0.617 0,804 0,485 0.325 - 0.644 0,841 
Flow %parent act. Mac. 0,536 0.414 - 0.659 0,554 0,423 0.294 - 0.553 0,245 0,485 0.330 - 0.639 0,841 
Flow %parent CEA-IM 0,585 0.468 - 0.702 0,165 0,543 0.416 - 0.670 0,522 0,644 0.491 - 0.797 0,067 
SUVMax 0,471 0.350 - 0.592 0,639 0,499 0.356 - 0.641 0,985 0,536 0.378 - 0.695 0,646 
SUVMean 0,495 0.374 - 0.616 0,935 0,520 0.377 - 0.664 0,783 0,557 0.345 - 0.769 0,583 
MTV 0,674 0.561 - 0.786 0,005 0,545 0.395 - 0.695 0,542 0,681 0.462 - 0.901 0,079 
ROC pCR+Good (ypT0-2N0) vs Bad (ypT3-4NallMall)          
(AUC pred. prob.) subgroup-analysis    
treatment moment/period t=0-7 days t=7-15 days    
parameters AUC 95% CI p AUC 95% CI p    
serum CEA 0,617 0.408 - 0.826 0,270 0,561 0.329 - 0.792 0,579 
serum CRP 0,577 0.354 - 0.800 0,446 0,556 0.331 - 0.781 0,606 Table legend 
serum Leucocytes 0,595 0.357 - 0.833 0,383 0,758 0.561 - 0.954 0,018 value: AUC>0.6 
Flow %parent Monocytes 0,533 0.291 - 0.774 0,775 0,600 0.373 - 0.827 0,364 value: AUC>0.7 
Flow %parent act. Mac. 0,630 0.427 - 0.833 0,253 0,495 0.282 - 0.709 0,967 sign. discriminating 
Flow %parent CEA-IM 0,670 0.471 - 0.869 0,135 0,521 0.294 - 0.748 0,854 Parameter if → 
SUVMax na na na na na na 95%CI [≥0.5 – any] 
SUVMean na na na na na na (equals p≤0.05) 
MTV na na na na na na  
 
3.3.3  Immune cell influx (INF) evaluation 
At t=0 days only MTV shows an AUC level between 0.6 and 0.7. At t=0-15 days 
MTV-values significantly discriminate (AUC=0.777, p=0.002) between INF-High 
and INF-Low and during the waiting/recovery period t=15-90 days the MTV 
shows a trend to significance (AUC=0.722, p=0.078). During the t=0-15 days 
interval CRP and SUVMax show AUC-levels above 0.6, only with CRP having a 
p-value of 0.183. Between t=15 and t=90 CRP, leucocytes, SUVMean show 
AUC-levels between 0.6 and 0.7. During t=0-7 days AUC values above 0.6 are 
shown for CEA, leucocytes, the fraction of monocytes (p=0.168) and the fraction 
of CEA-IM. CRP seems significantly discriminative with an AUC of 0.821 
(p=0.019) in predicting INF-High outcome. Although patient numbers at t=7 
(n=7) could result in an erroneous calculation of AUC and p-value, AUC values 
on t=7-15 days, t=0-15 days and t=15-90 days are above 0.6 as well. During 
t=7-15 days the AUC values of CEA, CRP and leucocytes are above 0.6 but 
show no significance (Table 6.9).   
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Table 6.9 Calculated AUC-values of all parameters: AUC-values of the predicted probability for 
INF-High as the positive predicted outcome combined with the 95%CI and p-values are 
shown in the table above. 
ROC INF High vs INF Low                   
(AUC pred. prob.)   
treatment moment/period t = 0 days t = 0 - 15 days t = 15 - 90 days 
parameters AUC 95% CI p AUC 95% CI p AUC 95% CI p 
serum CEA 0,502 0.349 - 0.655 0,981 0,597 0.442 - 0.752 0,221 0,387 0.209 - 0.564 0,230 
serum CRP 0,524 0.376 - 0.672 0,756 0,605 0.455 - 0.755 0,183 0,626 0.447 - 0.806 0,181 
serum Leucocytes 0,487 0.331 - 0.642 0,866 0,515 0.361 - 0.669 0,850 0,622 0.442 - 0.802 0,194 
Flow %parent Monocytes 0,507 0.355 - 0.659 0,930 0,537 0.381 - 0.692 0,649 0,557 0.369 - 0.746 0,544 
Flow %parent act. Mac. 0,415 0.259 - 0.571 0,283 0,489 0.333 - 0.645 0,891 0,578 0.389 - 0.768 0,408 
Flow %parent CEA-IM 0,578 0.423 - 0.733 0,320 0,540 0.381 - 0.699 0,620 0,528 0.338 - 0.719 0,767 
SUVMax 0,502 0.330 - 0.674 0,982 0,609 0.439 - 0.778 0,217 0,590 0.404 - 0.776 0,343 
SUVMean 0,515 0.341 - 0.689 0,865 0,515 0.336 - 0.693 0,870 0,627 0.399 - 0.855 0,313 
MTV 0,626 0.458 - 0 795 0,146 0,777 0.628 - 0.926 0,002 0,722 0.502 - 0.942 0,078 
ROC INF High vs INF Low             
(AUC pred. prob.) subgroup-analysis    
treatment moment/period t = 0 - 7 days t = 7 - 15 days    
parameters AUC 95% CI p AUC 95% CI p    
serum CEA 0,653 0.373 - 0.933 0,263 0,628 0.334 - 0.921 0,351  
serum CRP 0,821 0.631 - 1.000 0,019 0,617 0.321 - 0.914 0,391 Table legend 
serum Leucocytes 0,649 0.407 - 0.890 0,303 0,577 0.324 - 0.829 0,576 value: AUC>0.6 
Flow %parent Monocytes 0,689 0.431 - 0.946 0,168 0,531 0.275 - 0.786 0,823 value: AUC>0.7 
Flow %parent act. Mac. 0,474 0.210 - 0.739 0,852 0,510 0.253 - 0.768 0,941 sign. discriminating 
Flow %parent CEA-IM 0,612 0.305 - 0.919 0,412 0,643 0.352 - 0.934 0,310 Parameter if → 
SUVMax na na na na na na 95%CI [≥0.5 – any] 
SUVMean na na na na na na (equals p≤0.05) 
MTV na na na na na na    
 
3.4  Additional value to prediction models during nCRT 
Three prediction models, PET0, PET15 and PET90, were assessed for added 
value of the investigated biomarker parameters. All models predict pCR 
(ypT0N0) vs non-pCR as outcome measure. The addition of all biomarkers of 
t=0 to the PET0 model increases the mean AUC-value from 0.73 to 0.75. Adding 
∆biomarkers t=0-15 to the PET15 model showed a mean AUC-value of 0.94 
(95% CI 0.87-0.99). This is a significant increase in contrast to the AUC of 0.72 
of the PET-CT-values alone at t = 15 from previous studies16. The mean AUC of 
the PET90 model remained practically unchanged, showing an increase from 
0.75 to 0.76 when adding all biomarkers to the PET-values. 
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4.  Discussion  
This study evaluates parameters and parameter changes from different 
investigational modalities for their predictive capacity on outcome of nCRT in 
LARC patients. Several blood biomarkers and PET-CT parameters significantly 
discriminate in dichotomized outcome measures (such as TRG1-2 vs. higher, or 
ypT0N0 vs. higher) at multiple time points during nCRT. Adding the blood 
biomarkers to the existing prediction models strengthened their predictive value 
in predicting pCR during the first two weeks of nCRT prior to the 
waiting/recovery period. Thus, adding these markers to the PET15 model led to 
an increase of the AUC for the prediction of pCR to 0.94, well above the desired 
0.90. This could mean that changes between measured values during a 
treatment period could outperform the prediction capacity of stand-alone values 
measured at a fixed time point. The changes between time points seem to be 
better predictors than the values at a time-point themselves. 
Such predictive information could play a role in deciding which definitive 
treatment strategy would follow nCRT: any form of surgical resection, or close-
watching on the assumption of complete local disease control2,4. Thorough 
monitoring of such a patient every 3-6 months by clinical evaluation (such as 
digital rectal exam), blood analysis and imaging techniques (such as MRI, PET-
CT) remain warranted, just as currently applied protocols describe. In the current 
study the added predictive value of blood borne biomarkers for two different 
outcome measures were analysed: TRG, ypTN. The local biological effect of 
nCRT was investigated by immune cell influx evaluation. 
4.1  TRG outcome measure 
Together with MTV, serum CEA is an accurate discriminator for TRG 1-2 at t=0. 
The t=0 finding of CEA is concurrent with earlier findings by Buijsen et al.9, when 
predicting ypTN (pCR and ypT0-2N0) as an outcome measure. The similar 
results for ypTN and TRG in two different studies support the view that CEA at 
t=0 is a significant discriminator for tumour response and subsequent tumour 
regression. 
During the waiting/recovery period starting at day 15, continuing until day 90 
after the start of nCRT changes of serum CEA, the fraction of monocytes, 
SUVMax and SUVmean display predictive capacity. Their addition to established 
outcome prediction models increases pre-existent AUC-values. This may be 
clinically relevant as inclusion of (a combination of) these parameters could 
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change the choice for the type of surgery performed, e.g. an abdominal perineal 
resection (APR), low-anterior resection (LAR) or a TEM. Restaging by PET-CT 
prior to surgery revealing new SUVMax and SUVMean values correctly 
discriminates between TRG 1-2 stages and TRG3 and higher stages. However, 
performing a PET-CT evaluation at that point in time is beyond the decision 
moment on type and duration of treatment strategies. In contrast, monitoring at 
even smaller time intervals, and closer to the start of the nCRT yielded results 
potentially capable leading to adjustment of the nCRT strategy. Thus, data 
derived from the subgroup of patients that underwent additional sampling at 
day 7 post start of treatment suggest that changes of CRP and the fraction of 
monocytes over the period 0-7 days and the period 7-15 days are significantly 
predictive for TRG 1-2. As this observation was made in a small albeit randomly 
selected subset of patients it needs confirmation. 
4.2  pCR vs. non-pCR as outcome measure 
Determination of MTV with PET-CT at t=0 predicts pCR accurately in this study 
population. Repeated MTVs in subsequent measurements up until 90 days 
retain this predictive power, with AUC's ranging from 0.61 to 0.76. Monitoring 
MTV during the first two weeks could provide insight in the chance to reach 
pCR, although MTV did not show significant discriminative power in subsequent 
measurements. Subgroup analyses showed delta fraction of CEA-IM was 
significantly discriminative during the second treatment week. The levels of 
leucocytes show AUC's above 0.6 during the first and the second neoadjuvant 
treatment week and over the total initial two week period (t=0-15 days). Thus, 
determination of leucocyte numbers seems to be predictive for pCR during the 
first two weeks of nCRT. Evaluation of additional value to a treatment period 
prediction model is warranted. Such a model needs to be developed. 
The increase of the fraction of activated macrophages in the non-pCR group 
(graph 2E) almost appears to be delayed compared to its counterpart in the pCR 
group. The reaction-level in the non-pCR group is slightly lower and appears 
postponed to t=15. To interpret these results one could postulate that the pCR 
group is able to react to the combination of tumour, chemotherapy and 
radiotherapy earlier than the non-pCR group leading to a complete response 
within the timeframe of around 90 days. This difference in reaction time is 
present in ypT0-2N0 vs ypT3-4NallMall (graph 3E) as well, although bad 
response groups show a higher fraction of activated macrophage values at the 
later t=15 time point. Evaluating the fraction of activated macrophages in TRG 
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1-2 vs ≧TRG 3 (graph 1E) shows practically the same pattern as ypT0-2N0 vs. 
ypT3-4NallMall. Interpreting these results as a postponed or inadequate immune 
reaction in the non-pCR (≧TRG 3 and ypT3-4) outcome groups seems 
plausible. 
4.2.1  Good responders vs. Bad responders outcome 
As MTV remained a significant predictor for good response at t=0 (as in the pCR 
vs non-pCR bivariate analysis) it can inform clinicians early about a patient 
chances when nCRT is initiated. When a predictive value indicates a high 
chance for bad response, treatment could be intensified or performing surgery 
earlier could become an option to consider. CEA and CRP both show an AUC of 
above 0.6, with a trend to significance for CRP, indicating that both should be 
included in multi-parameter prediction models. Increasing patient numbers may 
further push these trends towards a pCR or non-pCR outcome. 
4.3  Immune cell influx evaluation by INF-score 
In 62% of our investigated patients an INF-score could be interpreted from 
standard pathology reports. This information-yield could easily be improved to 
85-90% or higher if further standardisation of reporting would be adopted. The 
simplicity of the score is one of its advantageous characteristics, leading to quick 
adoption. 
Assessing the number of monocytes, activated macrophages and CEA-
containing macrophages (CEA-IM) during nCRT of rectal cancer patients was 
hypothesised to be an effect-measurement of the biological ability of proper cell 
influx for anti-tumoural immune action around or inside the tumour. Lower blood 
levels would indicate increased influx. However, the results do not support this 
hypothesis. 
MTV shows the ability to discriminate between INF High and INF Low on all 
measured time points with an AUC above 0.6, even with significance during the 
period t=0-15 days and t=15-90 days. Monitoring MTV makes it possible to 
predict the influx of immune cells and fibrosis to a certain level already in the first 
two weeks of neoadjuvant treatment. This result may not only provide treatment 
alteration possibilities but more importantly, it may enable monitoring strategies. 
Baseline MTV-value is already predictive for the final INF-score, hence no 
neoadjuvant treatment was initiated at t=0. This could mean that a patients own 
immune system reaction to tumour presence or disease-load is reflected in the 
MTV-value. The highest (significant) AUC-value was calculated between t=0 and 
t=7 for serum CRP in the subgroup-analysis of the INF-score evaluation, 
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indicating CRP-level changes during early treatment may be predictive for 
immune cell influx. Further investigation, and subsequent validation of the INF-
score in larger patient cohorts is needed because of these interesting 
observations. 
4.4  Clinical value of (flow cytometrical) blood biomarkers 
Combining PET-values with the 6 measured blood biomarkers increased the 
pCR-prediction power of the PET15-model significantly to an AUC of 0.94. This 
means that when using the updated prediction model, one can predict ypT0N0-
outcome (pCR) with 94% certainty based on available clinical data, blood 
biomarkers and PET-CT-values focusing on the neoadjuvant treatment period 
t=0-15 days. This is a important improvement of previously generated prediction 
models. Patient numbers decrease after imputation (n decreases from 82 to 58 
for PET-15 model, for PET-90 model it decreases from 59 to 41). This means 
applying this model in the clinical setting would be premature and needs further 
investigation with larger cohorts, without the need for imputation techniques. 
Based on TRG results, validation of the following parameter-panel needs to be 
performed in a second study to predict. 
 
Time points Serum param.  Flow param. PET-CT param.  
t = 0 CEA CRP %p monocytes MTV  
t = 7 CEA CRP %p monocytes MTV  
t = 15 CEA CRP  MTV SUVMean 
t = 90 CEA    SUVMean 
Table 6.10 Parameters to validate for prediction capabilities in combination with PET-CT values 
based directed at TRG and ypTN outcomes. In a large cohort of rectal cancer patients 
these values should be collected and added to the PET0, PET15 and PET90 prediction 
models to validate their additional value to each of the prediction models. 
 
4.4.1  Translation to clinical setting 
Translation to the clinical setting would be a secondary goal. Thus, changing 
nCRT or surgical treatment choices could become based on reliable prediction 
outcomes once they have been validated. If treatment strategy adjustment could 
be accomplished without the need for imaging techniques patients would be 
relieved of additional radiation burden. When applying shared decision making, 
physicians and patients could profit from this enhanced prediction model in this 
process. An online prediction calculator could simplify applying the new model 
during outpatient consults. Applying the monitoring ability during the first 2 
weeks of treatment, a radiotherapist could at least predict with a 94% certainty if 
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the patient is a potential candidate for a wait-and-see policy or will need a 
resection. Whether the prediction-models could eventually lead to enhancing the 
nCRT-treatment or, in case of no remaining nCRT options, stopping nCRT and 
performing early surgery needs to be investigated. 
4.5 Conclusion 
pCR-response prediction during the first two weeks of chemoradiotherapy based 
on a combination of PET-CT-values and blood biomarkers is feasible as 
illustrated in the TRG and ypTN outcome measures. CEA and MTV at t=0 are 
significantly discriminative in TRG outcome prediction in patients during 
neoadjuvant treatment. In the ypTN outcome prediction only MTV reaches 
significance. Although TRG and ypTN show similar trends in pCR prediction, 
TRG is considered the gold standard and should therefore be used to validate 
response prediction models before clinical application. To gain insight in the 
biological effects of the nCRT during early neoadjuvant treatment, Further 
investigation on blood biomarker values is warranted. 
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1. General discussion 
This thesis reports on the development, cellular background, feasibility and early 
application of an experimental diagnostic assay detecting epitopes on tumour 
related material in the cytoplasm of monocytes/macrophages circulating in 
peripheral blood (epitope detection in macrophages (EDIM)). Although biological 
variation was found as the key interference factor, early application was shown 
to have additional value in monitoring neoadjuvant treatment in rectal cancer 
patients. This enables clinicians to initiate treatment evaluation during the early 
stages of neoadjuvant treatment and to alter treatment if needed. Refinement of 
the assay may lead to further additional value. The investigations in this project 
focussed on CRC as a research model. The principles could be valid in other 
tumours as well, because of their general applicability to immune cell research. 
2.  Cellular background  
Monocytes are known as the precursors of macrophages. Differentiation from 
one into the other can occur after intravascular activation by rolling and crawling 
over the intraluminal vascular wall, connecting to various receptors and 
subsequent extravasation1. Recruitment into tissue is initiated by chemotaxis, 
local cell-signalling, hypoxia and by gradients of all three2. Monocyte 
heterogeneity research shows three distinct subsets CD14++CD16- (classical), 
CD14+CD16++ (non-classical) and CD14++CD16+ (intermediate, including 
atypical macrophages and dendritic cells)3-5. Intermediate monocytes have been 
described to be more prevalent in primary CRC than in metastatic disease6. 
They could therefore be the most important population to investigate within the 
monocyte-macrophage system for more localised disease detection in CRC. The 
monocyte-macrophage system is highly versatile, it reacts in both a tissue 
and/or organ specific manner, as well as a situation specific manner. Monocytes 
and macrophages in breast (cancer) tissue7-10 have been shown to act differently 
than those in the intestinal tract to the presence of malignancy11,12. The 
difference between monocytes and macrophages could be less strict than 
described before13. Recent literature describes monocytes and macrophages 
more and more as parallel existing cell-types besides the known roles of 
predecessor and successor. Monocytes are known to extravasate, ingest 
pathogens, migrate to lymphoid organs via lymphatic vessels and differentiate 
into antigen presenting cells (dendritic cells or macrophages). Secondly they can 
migrate in the lymph nodes as monocytes/macrophages. Finally, monocytes can 
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be recruited directly from the blood into an inflamed lymph node via high 
endothelial venules14. Macrophage functions do not differ much from monocytes 
in the beginning. Macrophages are also known for their migratory and 
phagocytic capacities. The ability of macrophages to intravasate after substance 
uptake has been shown in murine models15. This phenomenon resembles the 
migratory ability of macrophage-tumour-cell hybrids. It could therefore be 
suggested that a continuum of myeloid derived (precursor) cells exists, almost a 
more general phagocyte, with a gradual change in surface markers during 
maturation6. These cells are able to act in an undifferentiated form16, differentiate 
into more specialised cell types with antigen-presenting or digestive functions 
after pathogen uptake14 and are even able to fuse with other (parts of) cells17-20. 
Based on both this continuum and the ability to return to the bloodstream, our 
studies hypothesised a blood-tissue circle in which monocytes and 
macrophages play a leading role in health, (chronic) inflammatory or malignant 
disease, such as CRC. The possible role monocytes and macrophages could 
play in (colorectal) cancer diagnostics have been described in chapter 1. 
2.1  The third monocyte subtype 
In our CRC-studies we focussed on intermediate monocytes (CD14++CD16+). 
At the start of our studies this third subtype, intermediate monocytes were still 
quit unknown and not generally used as a separate entity in monocyte 
heterogeneity studies. Therefore we always referred to the investigated 
population as CD14+CD16+ macrophages. In literature, the CD14++CD16+ 
subtype has recently been described as being positive for a range of markers, 
including CD64, CD115, CD163, CCR2 and CX3CR1. Also MHC class II was 
specifically high in intermediate monocytes21. Furthermore, we did not 
investigate other common monocyte and macrophage markers, such as CD11a, 
CDC11b, CD68 or HLA-DR, for their presence on the cells in our samples22 to 
stay as close as possible to the initial selected CD-marker palette. On the other 
hand we did perform flow cytometrical sorting which showed the CD14+CD16+ 
peripheral blood monocytes as irregular cells with large lobular cores, mimicking 
typical macrophage morphology. This finding has recently been confirmed by 
Mandl et al, characterising thawed human CD14++CD16+ bone marrow cells22. 
They found the CD14++CD16+ subset to be primarily enriched in human bone 
marrow and in lowest concentration in peripheral blood. Thus, other accessible 
sampling locations other than peripheral blood could provide a higher yield, 
considering these findings. In future studies these locations should be explored. 
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Further differentiation research could have brought us closer to answering the 
question of the monocyte-macrophage difference in this CRC model. On the 
other hand, it would have detached the performed research further from earlier 
promising results from our group in prostate cancer. Our primary goal was to 
reproduce those results in CRC, keeping most parameters equal to the prostate 
studies.  
2.2  Monocyte heterogeneity in murine and human research 
Many studies of monocyte heterogeneity are based on murine models. Mouse to 
human translation indeed has the advantage providing insight in functioning of 
the immune system without depending on human experiments. To confirm 
macrophage subtypes and functions found in mice, and which are present in 
human tumours, inter-species monocyte-subset and monocyte-marker mapping 
is needed. This mapping has been performed, but not all subsets have been 
shown to be equal3,23,24. For tumour-associated macrophages this mapping has 
been performed as well. Comparable macrophage populations exist, given that 
the individual TAM expression signatures derived from mice are represented in 
human tumour datasets and can even be predictive25. Newly developed 
fluorescence based mouse experiments show promising results, although the 
claimed results remain based on genetic murine models26. Animal experiments 
investigating tumour transplantation in immunocompetent animals should be 
interpreted cautiously. Reported outcomes are weakened by confounding 
factors, such as antigraft reactions (even in syngeneic contexts), as well as the 
skewed immune reactions in immunocompromised mice27. Therefore, research 
utilising human materials and complementary biomarkers should always be the 
preferred strategy, whenever feasible. 
2.3  Intracellular macrophage tumour marker presence 
In human lymphoid, CRC-tumour and CRC-tumour surrounding tissue the 
presence of CD14+CD16+ macrophages staining intracellularly positive for CEA, 
transketolase-like protein 1 (TKTL1)28-32, M3033,34 and CK34,35 was demonstrated 
using light microscopy (LM) (chapter 2). The reproducibility of the epitope 
detection in macrophages method (EDIM) has been assessed by investigating 
the latter four markers in the validation study (chapter 5). This chapter shows 
results about reproducibility of the EDIM-assay using multiple markers. These 
results illustrate monocyte/macrophage uptake versatility. Whichever non-self or 
degraded entity is encountered, it is ingested and digested and possibly 
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subsequently presented. Using electron microscopy (EM) we attempted to 
answer the question of where in the macrophage the tumour marker-specific 
epitope, connected to the tumour related material, would be situated. In some of 
the morphologically identified macrophages, tumour markers appeared to be on 
internalised villous cell-parts inside vesicles situated in the cytoplasm. These 
vesicles most likely represent lysosomes. Even though CEA was still detectable 
in some vesicles, not all vesicles showed tumour marker positivity, which is 
concurrent with the LM and flow cytometry results. This part of the project made 
clear that CEA was not actively presented on the cell-surface or excreted from 
the macrophages, but rather internalized and probably subsequently digested. 
This digestion process did not prohibit intracellular CEA detection. Furthermore, 
CEA was easily detected in the villous linings of CRC in almost all specimens 
(chapter 3). The study results show that morphologically identified macrophages 
were able to internalise tumour related material. It was not possible to 
immunochemically prove that the macrophages were positive for CD14 and/or 
CD16 in chemically fixed, resin embedded tissue samples prepared for 
microscopy (light- and electron microscope). Therefore there is the possibility 
that the identified cells were in fact another type of phagocyte, although 
morphology resembles that of macrophages. New attempts to successfully apply 
a double staining strategy for monocyte/macrophage identification and tumour 
marker presence should be pursued. 
3.  Development and feasibility of the technique  
3.1  Development of the peripheral blood macrophage assay 
Translation of the peripheral blood prostate cancer macrophage assay36-40 to 
CRC proved to be feasible using established tumour markers (chapter 4). CEA 
was investigated as the primary tumour marker, utilising earlier research by our 
group to select the most specific antibody directed against CEA41. Performing 
the assay with the buffy coat filtrate layer of EDTA whole blood using a CPT-
filtration tube (Becton Dickinson, California) sometimes introduced a monocyte 
yield problem. This yield appeared to be inconsistent between CPT-tubes. 
Increasing the total number of events counted by flow cytometer by raising the 
stopping gate event-number solved this. This solution subsequently introduced a 
low cell count problem in thin buffy coat layers in a minor part of the included 
patients. For the duration of the investigation this was accepted, enabling 
continuity of the same SOP during all experiments. However, some patients had 
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to be excluded due to low cell counts. This technical issue may have induced a 
selection bias, probably only affecting low-cell samples. Were patient numbers 
affected with low cell counts due to higher cell turnover for host-defence reaction 
regulation? Or did it affect patient numbers that have insufficient immune cell 
counts due to disease progression? Currently both questions have remained 
unanswered. In future research the low yield could be addressed by replacing 
the use of the filtration tube in the SOP by performing a red blood cell lysis in the 
whole blood sample42. Increasing the monocyte yield has been described in 
other studies investigating the CD14/CD16-monocyte population31,43. Yield 
improvement was attained successfully without the disturbance of red blood cell 
clotting, utilising the red blood cell lysis technique. 
3.2  Pilot study 
By combining the experimental assay with routine serum c-reactive protein 
(CRP) measurements healthy individuals could be distinguished from patients 
with chronic inflammatory or malignant bowel diseases (chapter 4). Based on 
AJCC staging for CRC it was possible to distinguish between AJCC I to AJCC IV 
stages. In addition to CEA, also M30 and CK were also detectable in varying 
numbers of macrophages in each patient. In contrast to CEA, M30 and CK were 
not able to significantly distinguish AJCC stage I to IV groups (unpublished 
data). The consecutively included CRC patients were diagnosed at our 
outpatient clinic without any form of prior selection. The co-morbidity level of 
patients in our region is known to be higher than on average in the Netherlands, 
and may prove to be higher in relation to other western countries as well. 
Therefore a control study in another region or country should be performed 
before new clinical studies (in either follow-up or screening setting) should be 
started. In diagnostic tool development this is considered part of standardised 
protocol. In the pilot study, healthy hospital personnel were included from a 
similar age range. The included number of benign disease cases was relatively 
low in this pilot study. This may have led to overestimation of the difference in 
the fraction of monocytes and CEA-IM between benign and malignant disease 
cases. In a new control study a larger cohort of benign disease cases should be 
investigated to rule out possible influences induced by the small number of 
benign disease patients. 
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3.3  Validation of diagnostic test 
In diagnostic test evaluation, not only patient controls need to be investigated, 
but biomarker control application as well. In the pilot study investigating the 
EDIM-method, isotype controls were applied to correct for background signals. 
Sometimes strange cell population shifts occurred during the pilot inclusion 
period, leading to exclusion of certain patients because of outcome interpretation 
issues. Investigating a possible solution for the isotype control problems led to 
the introduction of a modified fluorescence-minus-one (mFMO) control. Applying 
this type of control resolved the issue of the shifting cell populations, but it 
changed the pilot-SOP. During a transition period, double controls (isotype 
alongside mFMO) were used in the studies. No explanation was found for the 
cell population shifts. For that reason the mFMO was permanently introduced as 
the primary control. According to literature an FMO is the preferred control in 
these types of multi parameter flow cytometrical tests44. However, the difference 
with the pilot study remains. The mFMO creates the possibility for undesired 
interpretation differences, which thus remain undetected after permanent mFMO 
application. During the validation period the gating strategy was slightly altered 
as well, which was recently proven to actually be more competent to investigate 
the earlier mentioned intermediate monocytes21,45. The focus on this subtype 
alone was not all that was changed. Considering larger and more complex 
CD14++CD16+ cells as the cell-type of interest, height and width of the forward 
scatter (FSC)-signal were investigated (Figure 7.1A-C) along the CD14 and 
CD16 positivity to separate debris from intact cells. The characteristic 
maturation/activation curving of the "CD14CD16-population-continuum" showed 
the larger and more irregular cells to be just on the outside of the corner of the 
curve (Figure 7.1B), mostly at the maximum of CD14 and CD16 positivity 
(unpublished results). These cells being doublet cells or aggregates would not 
have positioned them exactly on the edge of the maturation curve. In CRC 
patients the population is interesting, as it was described in literature that the 
intermediate monocyte subtype is considered a more sensitive diagnostic 
indicator of CRC compared to other subtypes6. 
 
By performing different relevant reproducibility tests multiple times the 
macrophage assay has been proven technically reproducible. Biological 
variation has been found as the main interference factor (chapter 5) in healthy 
control subjects. The (activated) monocyte population is varying over time, which 
could be a reason to establish a normal range for each patient. If fluctuation 
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remains within this range, no further action is needed. The problem with this 
approach is that a normal range would have to be established in healthy 
conditions for each individual. That would account for the population as a whole. 
In current tumour marker research and quality control studies another approach 
is applied. A change of more than 25% of a test result of an established serum 
tumour marker occurring in two subsequent measurements is considered 
clinically relevant (25% twice in a row approach)46-48. Further follow-up of the 
patients included in our research population need to confirm the applicability of 
this rule to the new assay. The biological variability issue could be solved 
utilising this approach. The follow-up period of the investigated population is 
currently over two years postoperatively, enabling the analysis of these results in 
relation to the mentioned "25% twice in a row" approach. 
4.  Early clinical application in rectal cancer patients  
During nCRT a substantial cell shedding effect is hypothesised, not only in the 
rectal tumour, but in the patient as a whole. All body cells receive the same 
chemotherapy dosage and locally the tumour area receives frequent 
radiotherapy. Ingestion by macrophages of shedded (parts of) tumour cells and 
tumour related material should result in detectability by the EDIM-test. Blood 
levels of shedded material are hypothesised to be high in this setting, and may 
be distinguished more easily from a continuous background signal and 
persistent biological variability. Therefore, the population of rectal cancer 
patients during nCRT was chosen for early clinical application of the EDIM-test. 
 
4.1  Choice of patient population 
Loco-regional control is the main goal of pre-surgical radiochemotherapy in 
rectal cancer patients. The benefit of decreasing tumour size and destruction of 
metastasis in regional lymph nodes enables limited resections49 and reduces 
(metastatic) recurrence respectively. The pre-treatment period of rectal cancer 
patients is intriguing because of malignant cell development combined with 
counter-events induced by radiochemotherapy. Inflammation, DNA-damage and 
cell-decay50 are only some of the effects of the combination of rectal cancer and 
neoadjuvant treatment51,52. Not every patient benefits from neoadjuvant 
treatment. Recent publications report that approximately 50% of the patients 
respond to neoadjuvant chemoradiotherapy. Of that group only 20-25% shows 
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complete pathological response53. The last category warrants a wait-and-see 
policy54-56. The non-responders should become candidates for (experimental) 
alternative neoadjuvant treatment strategies. If no other options remain, early 
surgery could be an option; otherwise palliative treatment should be offered. 
Distinguishing patients before and during radiochemotherapy, based on 
pretreatment values and response measurements during early treatment, was 
the goal of our research (chapter 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 Identification of large cells applying a back-gating strategy using forward scatter height 
and width properties (A). In the hierarchy (C) is displayed that this intermediate 
monocyte population comes forth from all events and is mostly displayed on the corner 
of the CD14++CD16+ activation/maturation curve (B) inside the activated macrophages 
selection area (unpublished results). In the performed CEA-IM experiments this 
localisation was not always as explicit as in this example. 
 
 General discussion 
     145 
7 
Predicting a patient's benefit to radiochemotherapy should be the main 
investigative outcome measure in this area of research. Investigating the 
possibility to monitor the response and maybe even evaluating the methods of 
the response assessment could be another goal of this type of research. 
Established surveillance protocols are considered safe and proposing changes 
based on blood biomarker outcomes may not be accepted directly. This should 
not stop innovation in the research-setting; the rectal cancer wait-and-see policy 
for complete responders after neoadjuvant chemoradiotherapy was also 
considered controversial at first54,56-60. 
 
4.2  Response prediction 
Response prediction to neoadjuvant chemoradiotherapy is not generally 
practiced61,62. Only a select few groups are showing experimental results. These 
results suggest mainstream application is possible63-65, although they are not 
always concurrent66. Measurement of response without adding an extra risk 
factor (or patient burden), such as additional radiation, would be preferable. 
PET-CT-scans deliver large amounts of additional radiation; MRI on the other 
hand does not57. Both entities have shown monitoring capabilities, with the best 
results currently for FDG-PET-CT67,68. Major drawbacks of these techniques are 
that they are expensive, in addition to patient discomfort during these scans that 
take up to 45 minutes. The use of blood biomarker assay(s) could fill in a gap. 
The challenge is to find a (panel of) biomarker(s) that differentiates enough to 
predict response before or in early radiochemotherapy phases. Up until now, no 
biomarker or biomarker panel has proven to have enough predictive power by 
itself69,70 Additional imaging modalities are able to boost the predictive capacity 
(AUC's) to acceptable levels71. The occurrence of response is defined 
pathologically as decrease in tumour size, no (vital) remaining tumour cells (or 
tumour cell budding72) and no lymph nodes with vital tumour tissue. Recently 
added were local fibrosis and influx of immune cells70,73,74. Combining PET-CT 
with serum (tumour) markers (75) as well as inflammatory parameters was 
hypothesised to be able to reflect the local and systemic reactions of the patient 
on radiochemotherapy. Chapter 6 reports on the results of a nine-parameter 
analysis, combining serum biomarkers with the experimental monocyte/ 
macrophage assay and FDG PET-CT results. Focussing on TRG and ypTN 
response assessment, it was shown that serum CEA and metabolic tumour 
volume can be used as predictors at the start of radiochemotherapy. Adding a 
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monocyte-fraction analysis boosted the predictive capacity of the prediction 
models during the first two weeks of radiochemotherapy.  
4.2.1  Immune system applicability in response prediction 
Whether the immune system could be addressed as a possible predictive factor 
is debatable. Bone marrow depression is a known side effect in patients 
receiving radiochemotherapy51. This effect was also reflected in lower monocyte-
levels in rectal cancer patients in our studies (unpublished data), although the 
activated monocyte-population within the whole monocyte population did 
increase during the radiochemotherapy. The mentioned biomarkers were not 
predictive enough by themselves, and still needed the combined analysis with 
FDG PET-CT. However, the predictive value of earlier prediction models was 
increased substantially though (chapter 6). Further biomarker research may 
enable a blood biomarker-panel composition sufficiently predictive to indicate 
whether a scan is needed to objectify the response or even to refrain from 
scanning. Once validation has been performed in multiple patient groups, the 
application of a biomarker panel could lead to a decrease of the additional 
radiation burden for neoadjuvant treated rectal cancer patients.  
5.  Future developments, challenges and 
recommendations  
5.1  The monocyte or macrophage continuum 
Investigating other common monocyte and macrophage markers, such as 
CD11a, CD11b, CD64, CD68, CX3CR1, TLR-2, TLR-4 or HLA-DR, should be 
used to elaborate on the roles of specific mononuclear cell and monocyte 
subtypes in future investigations76,77. Identifying these in relation to macrophage 
marker presence could inform about marker overlap in certain situations, 
enabling monocyte, macrophage or subtype identification. Monocyte and 
macrophage synthesised products and behavioural evaluation could provide 
insight in identification as well, such as different chemokines and phagocytic 
activity in specific circumstances respectively. 
5.2  Closing the loop 
During the prostate cancer pilot the question arose whether monocytes could 
finally return to the bloodstream after performing phagocytic tasks, presumably 
after differentiating into macrophages40. Apart from this feature, also the 
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phagocyte's ability to concentrate internalised tumour related material was 
investigated in the CRC-pilot78. The concentration hypothesis stated that 
internalisation enhanced the possibility to detect even lower levels of specific 
internalised materials. The travelling route of monocytes into the tissue and 
towards lymph nodes has been described and visualised in literature. The ability 
to return to the blood stream has not been properly investigated yet. One of the 
hypothesised routes is via the lymph nodes, through the collecting cavity, the 
cisterna chyli (or receptaculum chyli). The cells would then continue into the 
thoracic duct and right lymphatic duct and finally enter the superior vena cava 
via both subclavian veins. Puncture of the cisterna chyli would allow for 
investigating whether macrophages containing tumour related material are 
present. In cadaver studies the cisterna chyli could be accessed. Our group is 
confident that these cells will be present and detectable. Further research 
investigating the concentration of macrophages in the thoracic duct and the 
superior vena cava would be logical steps. 
Secondly, through puncture of the portal vein during colorectal surgery the 
presence of macrophages in portal vein blood may be determined as it is the 
outflow from the colorectal tumour-site. In combination with central venous and 
peripheral venous puncture this would provide information about which location 
contains the highest yield of tumor-marker containing macrophages. A possible 
first-pass effect of the liver is hypothesised, where macrophages containing 
tumour-related material could extravasate. The concentration of macrophages 
containing tumour-related material is hypothesised to decline gradually. It is 
thought to be the highest in portal vein blood, then in caval blood and finally the 
lowest in peripheral blood. Ethical approval for performing these studies has 
been applied for. 
Finally, a direct route has been described from the circulation towards lymph 
nodes using high endothelial venules. Monocytes and macrophages use that 
route for quick access to lymph nodes in case of infection or other intrusion. This 
route could be used in the opposite direction as well, as it has been shown that 
monocytes are able to move upstream in blood vessels during regular patrolling 
actions1. Performing GFP-labelling of human monocytes in vivo has not been 
done yet. Experimental in vivo mouse models and in vitro experiments are 
currently used to investigate the feasibility of fluorescent protein labelling in 
humans79. 
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5.3  Tumour environment research 
We investigated the presence of tumour-related material in macrophages in 
breast cancer and in regular breast cysts. Surprisingly enough the non-
malignant cyst-wall contained the highest number of macrophages containing 
tumour-related material (unpublished results). This is concordant with our 
observations in lymphnodes of CRC-patients. Even though not all lymph nodes 
had metastatic tumour cells, all lymph nodes displayed a number of 
macrophages containing tumour-related material. One could hypothesise that 
macrophages, known to ingest everything on their path, could become  
"acquired" or "overtaken" at a certain point by a malignant induction. This could 
be caused by ingested tumour related material, for instance a strand of DNA. 
Parts of DNA can be incorporated into the macrophages DNA and explain 
alternate macrophage behaviour. Lymph node metastasis based on hybrid 
presence has not been described before. If macrophages in lymph nodes make 
contact with tumour cells travelling along a lymphatic route, a hybrid cell could 
evolve from that contact after fusion. The ability of (hybrid) macrophages to 
enable hematogenous metastasis by creating the optimal environment for 
entrance into the blood stream80-82 may apply to (hybrid or tumour) cell passage 
through the lymph node as well. This would enable further lymphatic spreading. 
The existence of dormant hybrid cells may be an explanation for late local 
recurrence in breast cancer, sometimes after years of disease free survival83. 
These hybrids would not be attacked by a patiënt's own immune system, 
because they are recognised as "self". If these hybrids exist in this context, the 
reason for awaking from dormancy would be the next question. It could be 
related to accumulation of certain genetic and epigenetic traits, or a need for a 
certain level of specific (combined) stimulus from the stromal surrounding before 
metastasis. 
5.4  Macrophage-tumour cell fusion: investigating hybrids 
Hybrid cells and or macrophages orchestrate the transformation of the stromal 
environment by means of cytokines, matrix metalloproteinases (MMP's) and 
chemokines. It is thought that the macrophages exhibit a faulty M2-activation 
status, leading to tissue-regenerative actions. The negative effects of this altered 
functionality and its by-products induce environmental effects. In the beginning 
the immune system may be able to correct (stromal) abnormalities. When the 
number of abnormal cells, their inherent functioning and products increase, 
recuperation is less likely to occur. This results in crossing a point of no return 
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and disease will eventually progress. During our research it was discovered that 
comparing monocyte fractions between AJCC stages I-IV in CRC patients 
resulted in a bell-shaped (Gaussian) graph. This implies that along the TNM-
stage development the immune system is initially activated, but activity is 
decreasing and eventually malfunctioning in activity during the later phases 
(unpublished results). Research focusing on the early changes during tumour 
and hybrid development has shown a unified way for tumour and metastases 
development17,20. 
Tumour budding might be equal to tumour cells migrating from the primary 
tumour site. On the other hand the tumour cells at the edge of the tumour could 
also be migrating around in the vicinity of the tumour. This resembles paving a 
road for other tumour cells or hybrids willing to migrate, or stimulating 
angiogenesis. All together these observations combine interestingly. In 
colorectal cancer the following question arises: If the tumour budding represents 
(a form of) metastasis, could these "buds" be hybrid tumour-macrophage cells 
themselves? This hypothesis has not been postulated yet, although the 
diagnostic differentiation problem between budding carcinoma cells and 
macrophages preceding the invasive front has been described84. This finding 
supports this hypothesis. Research aimed at retrieving the identity or origin of 
the budding tumour cells needs to be initiated. Identification by an array of 
hybrid-specific markers would be an possibility, if only the specific markers could 
be identified first. Genetic profiling of these cells could therefore be an option, 
focussing on possible genetic markers. 
5.5 Clinical recommendations 
In oncology it is common to evaluate a patients situation by TNM staging based 
on tumour growth, size and invasion, nodular involvement and metastasis. If a 
goal is to preclude the situation that tumour growth spins out of control, attention 
to the patients immune system would be appropriate, especially considering the 
information in this thesis and recent literature. It seems that tumourigenesis 
always starts with immune system errors or influenced immune cells85,86. A 
patiënt's defence degenerates, and even worse, it evolves into a part of the 
offense (at least locally). If it would be possible to measure a patiënt's immuno-
competence, this could enable monitoring of the ability to conduct adequate 
immune responses. Such a test would should be organ-specific, because (parts 
of) the immune system functions are differently in different organs. A multi-array 
assay would therefore be most appropriate. 
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6.  Concluding remarks  
Our research, described in this thesis, has been conducted in the area of cancer 
immunology. Combined efforts between the departments of General Surgery, 
Clinical Pathology and Clinical Chemistry and Haematology have led to 
successful projects delivering potential useful diagnostic tools. Further research 
will investigate the position of the diagnostic tools in relation to existing 
modalities, the width of the concept to other types of immunological 
disturbances, and will need to answer marked questions from previous 
paragraphs. 
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1.  Diagnosing cancer (of the large bowel)  
1.1  Colorectal cancer 
Tumours are composed of cellular growth that is not properly controlled by the 
body. In general, if a tumour grows it can develop malignant components which 
are potentially hazardous to the human body, eventually resulting in progression 
and finally in death. This thesis is focussing on cancer of the large bowel. The 
large bowel (the colon) consists of six parts, the cecum, the ascending colon, the 
transverse colon, the descending colon, the sigmoid colon and the rectal part, 
often called the rectum. Cancer of the large bowel or colorectal cancer (CRC) is 
a disease frequently diagnosed. In the total population of adults CRC is third 
most appearing form of cancer worldwide with over 12.000 new cases of CRC 
diagnosed in the Netherlands in 2012. CRC can develop as a hereditary or non-
hereditary form, the latter is called sporadic CRC. Age is the number one risk 
factor for developing sporadic CRC, over 90% of all patients are over 50 years 
old. In medicine we are used to perform colonoscopies to inspect the inside of 
the colon and rectum, and perform biopsies of visually aberrant tissue during the 
procedure (Figure 8.1). These tissue samples can be investigated by a 
pathologist, resulting in an assessment of the presence of malignant cells. If 
CRC is diagnosed a patient will follow a predefined trajectory of investigations 
based on the location and the extent of the tumour. These results are discussed 
in a multidisciplinary team and a treatment plan, mostly including surgery, is 
started in accordance with the patient. After surgery a patient is put under 
surveillance according to CRC treatment guidelines. One of the parts of 
surveillance is based on a blood investigation, determining the levels of the 
tumour marker carcinoembryonic antigen (CEA). Since 1965 CEA is known to 
be present in large amounts in CRC-tissue. It has been investigated and 
clinically applied in CRC diagnostics and clinical management of CRC ever 
since. Currently it is only applied in the follow-up of patients after CRC surgery. 
CEA is also present in the healthy lining of the large bowel and other specific 
tissues in the body, but in much lower concentrations. This would allow for 
higher levels as being considered as disease-related. 
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Figure 8.1 Colonoscopy: a flexible tube with a camera is introduced through the anus into the 
rectum, sigmoid, descending colon, transverse colon and finally through the ascending 
colon into the cecum. It is possible to take tissue samples of suspect lesions and to ink 
those lesions for future surgical resection procedures. 
1.2  CRC development 
Sporadic CRC starts developing from basal cellular changes in the colon wall, 
which occur during cell division. Some are genetically and some are 
environmentally initiated. The stages of development of CRC can be seen in 
Figure 8.2.  
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Figure 8.2 The developmental stages of colorectal cancer in the colon wall. 
 
CRC can have a polyp like phenotype and grow larger and larger, or CRC starts 
as a flat lesion and progress towards further invading the colon wall. A mixture of 
both paths is also possible, when a cancerous component in the polyp head 
invades the colon wall through the foot of the polyp. Two examples are shown in 
Figure 8.3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3 On the left side a colonic polyp and on the right side semi-circular colorectal cancer is 
shown. 
  
162 
S 
Curative treatment for CRC becomes more easily achievable when the 
diagnosis has been made in an early stage. Then it is statistically probable that 
no local progression or spreading throughout the body has occurred 
(metastasis). To diagnose CRC, a patient should present him- or herself with a 
recognisable pattern of complaints. Very often complaints are vague and do not 
immediately lead to the needed diagnosis. Proper diagnostic tools, such as 
imaging tools are often only applicable in advanced tumour stages. Investigating 
the presence of occult blood in the stool (iFOBT) can give an indication of the 
presence of possible tumoural development. After a positive result, a 
colonoscopy is always needed to confirm the diagnosis. A CRC-blood-test is not 
(yet) available for diagnosis, although it would potentially fill in a gap in CRC-
diagnostics.  
The changes in the bowel wall during CRC development can be initiated by 
inflammation and subsequent mutation. Faulty cell repairs to the inflamed area 
leading to DNA damage can cause this. This DNA damage can result in mutated 
cells with a possible malignant nature. Investigating this inflammatory process 
and the cells that cause it, can give information about how the body is resolving 
problems in this inflamed area.  
2.  Macrophages  
To determine whether the earlier mentioned inflammation in the vicinity of 
tumour development, when a tumour progresses and finally during treatment of 
cancer could be helpful in diagnostic testing, we investigated a specific type of 
immune cells. These cells are called macrophages, and they are a subtype of all 
clean-up cells or (as these are also called) phagocytes. In "phagocyte" "phagos" 
means "to eat" and "cyte" means "cell". In "macrophage" "macros" means 
"large", combining both names ends up in "large eating cell", which indeed is 
one of its primary functions and describes the macrophage looks (their 
morphology).  
Macrophages develop from other immune cells, called monocytes. These cells 
are produced in the bone marrow inside all long bones in the body. Monocytes 
and macrophages can be found in all persons, not only if you are ill. In your 
blood the monocytes swarm around and wherever needed they are able to go 
into tissue after receiving specific signals to do so. After they move into the 
tissue, these monocytes are able to develop macrophage looks and functions. 
Macrophages normally protect us from the outside world by eliminating invaders 
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and instructing other immune cells how to attack these invaders, but they also 
attack tumour cells. Further, they have a function in wound healing, creation of 
blood vessels, influencing other (immune) cells and they produce various kinds 
of helpful substances to be used in these processes.  
2.1 Macrophages in (colorectal) cancer 
Macrophages are known to not only reside in the vicinity of a tumour, but also 
inside a tumour. The direct vicinity of the tumour is called the stromal 
environment. In both localisations, the cancer cells can influence the functions of 
the macrophage. Cancer cells are able to change the macrophages actions 
toward tumour promoting actions rather than actions resulting in tumour 
elimination. This means tumour cells are assisted in performing tumour 
progression tasks, for example alterations to the stromal environment so tumour 
cells are able to more easily move around. Also other tasks are known such as 
blood vessel formation to aid tumour growth and facilitating the entrance to the 
blood stream of cancer cells enabling subsequent metastasis throughout the 
body. Therefore the acquisition of macrophages by tumour environments can 
result in adverse actions of these cells, leading to disease progression rather 
than disease inhibition or even elimination. Macrophages do not act the same in 
(the vicinity) of all solid tumours. In breast cancer they are associated with poor 
prognosis, and in CRC their roles are not clear yet. Some researchers state that 
macrophages pose a risk in disease progression; others have found the 
macrophages able to deliver an anti-tumoural response. The distinction in the 
role of the macrophage in CRC has not yet been clarified. Maybe both roles 
exist depending on the influences they encounter. To investigate the presence of 
CEA in macrophages in CRC (related) tissue two studies were conducted. The 
first study evaluated the presence of CEA inside the macrophages in CRC tissue 
and lymph nodes. This was done by the use of a light microscope and applying 
substances that can highlight the presence of CEA in (the macrophages in) 
these tissues. It was found that CRC tissue contained CD68 positive cells 
(macrophages) being positive for CEA and that these macrophages were able to 
migrate into blood vessel walls (Figure 8.4 and chapter 2). Also lymph nodes 
were found to contain CEA-containing macrophages (Figure 8.5 and chapter 2).  
  
164 
S 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.4 a. CD68 stain of a blood vessel (outlined) next to tumor tissue; b. CEA stain of the same 
blood vessel. Intramural macrophages are present; two macrophages are positive in the 
CEA stain (arrowheads, circles). CEA reactivity is also visible at the luminal borders of 
this vessel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.5 a. CD68 stain of a lymph node with widespread macrophage distribution; b. 
corresponding CEA stain. CEA-containing macrophages can be seen along the lining of 
and are limited to the medullary sinuses. Granular staining is visible in a number of 
macrophages (example at arrow). 
 
The second study was used to find out the following: Are these macrophages 
ingesting and digesting tumour tissue with CEA? Or are they ingesting tumour 
tissue and subsequently produce and present a tumour-specific marker (in this 
case CEA) on the macrophage-surface to signal other immune cells? As was 
found out, the macrophages did ingest the tumour-tissue including the CEA and 
that it was possible to put a staining on the ingested CEA. Using electron 
A B
A B
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microscopy pictures were taken of macrophages containing tumour tissue with 
CEA present in digesting chambers called lysosomes (Figure 8.6 and chapter 3) 
by applying a CEA-antibody combined with a gold particle staining. This means 
that indeed macrophages ingest tumour-related material containing CEA. 
Further it means that maybe these macrophages could be detectable when 
investigating the blood of CRC-patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.6 Electron-microscopy photograph showing a phagocyte (possibly a macrophage) having 
ingested a cell-core (lower right insert in detail) and parts of the villous membrane of a 
cancer cell (upper left insert). The numbers 1, 2 and 3 resemble a villous part, a gold 
particle and a vacuole membrane respectively. Number 4 resembles part of the 
endoplasmic reticulum used for transport throughout the cell.  
 
2.2 Utilising macrophages in diagnosis of CRC 
Earlier research on prostate cancer diagnostics utilising prostate specific antigen 
(PSA, a tumour marker) detection in macrophages was successful in a pilot 
setting. Pursuing the same result with the colorectal cancer tumour marker CEA 
led to the development of a new diagnostic test for CRC. The new test uses a 
technique called flow cytometry. This technique is able to count cells from a test 
tube and detect specific cell characteristics (Figure 8.7).  
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Figure 8.7 Simplified schematic of a flow cytometer. From the left side cells are taken from the test 
tube and inserted in a fluidics stream on the right side, ensuring the cells pass the laser 
one by one for cell counting and characteristics determination by the detectors. 
 
These characteristics can be cell size, cell complexity and cell surface markers 
by which a cell can be identified and intracellular markers telling us what is 
inside the cell (Figure 8.8).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.8 Flow cytometry is able to distinguish cell size and cell complexity by laser excitation and 
measuring the light that is reflected or passed by the cell. These are called side scatter 
and forward scatter respectively, and both can be measured by detectors in the flow 
cytometer. 
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The cells we wanted to count were marked with specific antibodies with 
fluorochromes on them. Antibodies are substances that connect to specific 
connectors on the cell surface, called epitopes (antibodies directed against 
CD14 and CD16 in case of activated macrophages). Fluorochromes are 
substances that send out a specific colour (thus a specific frequency) of light 
once a laser has hit them. Allophycocyanin (APC) and Fluorescein 
isothiocyanate (FITC) were used for this purpose. By adding these 
fluorochromes to the antibodies we were able to identify the cells (activated 
macrophages) that could contain tumour marker epitopes we wanted to detect, 
by means of cell size, cell complexity and emitted light based on the presence of 
cell surface markers (Figure 8.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.9 On the left side monocytes and macrophages are shown being positive for CD14 and 
CD14CD16 respectively. On the right side the identification of monocytes and 
macrophages is done by antibodies directed against CD14 and CD16 in combination 
with fluorochromes (APC and FITC).  
 
After identification, the activated macrophages were treated with a substance to 
enable intracellular addition of antibodies directed against CEA and a 
fluorochrome. We used antibodies directed against CEA in combination with a 
third colour, phycoerythrin (PE). This enabled us to count the activated 
macrophages that contained CEA-positive tumour-related material (Figure 8.10). 
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Figure 8.10 In the left figure the intracellular staining using a biotinylated antibody directed against 
CEA is shown after permeabilising the cell membrane. The right figure shows the 
addition of the PE-fluorochrome to the intracellular attached antibody directed against 
CEA. 
 
 
This new macrophage-test was investigated in a small group of CRC patients, in 
benign (= non-malignant) inflammatory colon disease patients and in healthy 
individuals. The results showed the ability to distinguish the healthy individuals 
from the patients in general by the new test. When combining the new test with 
existing inflammation tests it was possible to distinguish the cancer patients from 
the benign inflammatory patients as well (Figure 8.11 and chapter 4). 
 
Large cells with multi-lobulated nuclei being positive for CEA were photographed 
by investigating the used flow cytometric analysis samples prepared from 
peripheral blood utilising light microscopy (cytospin analysis) (Figure 8.12). 
These findings confirm the earlier photographed tissue macrophages findings 
and thereby confirm the hypothesis of macrophages with internalized CEA in 
colorectal cancer patients. 
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Figure 8.11 Results of the pilot study, revealing the possibility to distinguish healthy controls from 
benign inflammatory disease patients (BI) and CRC patients in AJCC-stage I-IV. 
Combining the macrophage assay with CRP measurements enabled to distinguish even 
early stages of cancer from the BI-group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.12 CEA in activated macrophages: The bluish colour is a core staining and the brownish 
colour is the staining for CEA. The CEA-staining shows a granular texture, as if the CEA 
remains in small pockets inside the cell. 
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2.3  Validation of the new macrophage assay 
Such a result is exciting in the beginning, but should also lead to the question if 
the test results are outcomes you can trust. To investigate this question, a series 
of tests was conducted to confirm the so-called reproducibility of this new CRC 
assay. Reproducibility for instance means that measuring a test tube twice, it 
should give the same result within a small range. Or if a test tube is measured 
on two different analysers, the result is the same. We also investigated the 
variations of monocytes and activated macrophages in healthy persons, during 
one month and one year (Figure 8.13). We found that the numbers of these cells 
do vary over time, also in healthy persons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.13 Variation of CEA-containing macrophages in 6 healthy person during one month and 
one year. The dotted red line shows a mean value of the six persons over this whole 
period. 
 
As a result of the validation trajectory, it was found that the test was technically 
reproducible, but that a biological variability occurred, meaning that the patient 
himself causes this type of variability. This biological variability was the main 
source of interference with the diagnostic capabilities of the new macrophage-
assay (chapter 5). Therefore it was decided that the macrophage test should 
only be applied if another way of interpreting would be found reproducible. 
Another way of interpreting is currently under investigation. A change of the 
measured value of 25% or higher twice in a row is a new way to evaluate the 
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outcomes. This interpretation option is an established way of interpreting other 
(serum) tumour markers. We have also investigated the macrophage test 
performance in alternative clinical situations. 
Such alternative situations include monitoring radiochemotherapy treatment or 
disease progression during the follow-up period after surgery. We have 
investigated the treatment monitoring ability (paragraph 2.4 and chapter 6). 
Currently we are still performing disease monitoring during follow-up.  
2.4  Monitoring the effect of radiochemotherapy in 
rectal cancer 
One of the other possible applications was thought to be monitoring of 
neoadjuvant treatment (pre-treatment or nCRT) effects (response prediction). In 
rectal cancer it is common practice to perform nCRT before surgery. nCRT is 
directed at the reduction of tumour size and destroying lymph node metastasis. 
nCRT can possibly lead to downsizing the intended resection or even result in a 
wait and see policy when the tumour vanishes. This means a patient can benefit 
from predicting the response because it potentially has effect on the remaining 
treatment. If the prediction is that a patient would not respond at all to the regular 
nCRT, an alternative treatment could be chosen including even earlier surgery. 
nCRT consists of radiotherapy in combination with chemotherapy. During the 
period of nCRT it was thought that the rectal tumours could be shedding tumour 
material, and that this material could be cleaned up by macrophages. To 
determine an additional value in predicting the effect of nCRT in rectal cancer, a 
group of rectal cancer patients before, during and after nCRT was investigated. 
Blood-analysis of blood drawn from rectal cancer patients during the nCRT 
period was performed, and PET-CT-scans of the patients were made at the 
same time. It was possible to see changes during the nCRT in many 
parameters, and some of them had promising predictive values. Adding the 
results of all measurements to existing response prediction models led to an 
increase of predictive capacity from 72% to 94% accuracy in the first two weeks 
of nCRT. This means that early during the nCRT, the treatment-team can predict 
with 94% certainty if the proposed treatment will have the desired effect by 
including the new markers. 
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2.5 Conclusion 
In conclusion, this PhD trajectory has focused on investigating the principle of 
using macrophages in a diagnostic setting in human tissue and blood, the 
development of a macrophage assay and the early clinical application of the 
macrophage assay in monitoring neoadjuvant treatment of rectal cancer 
patients. The assay has potential to add to the predictive capacity of response 
prediction models and is currently under investigation for additional value in the 
follow-up setting after colorectal surgery. 
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1. Het stellen van de diagnose (darm)kanker  
1.1  Darmkanker 
Tumoren zijn opgebouwd uit cellen die een ongecontroleerde groei hebben 
doorgemaakt, waarbij het lichaam niet adequaat heeft ingegrepen. In het 
algemeen is het zo dat, wanneer een tumor groeit, er kwaadaardige 
componenten in kunnen ontstaan welke in potentie bedreigend zijn voor het 
menselijk lichaam, resulterend in ziekteprogressie en uiteindelijk de dood. Dit 
proefschrift focust zich op dikke darmkanker. De dikke darm (het colon) bestaat 
uit zes delen: het coecum, het ascenderende (opstijgende) colon, het transverse 
(overstekend) colon, het descenderende (afdalende) colon, het sigmoidale colon 
en het rectale colon, meestal het rectum genoemd. Dikke darmkanker oftewel 
colorectaal carcinoom (CRC) is een frequent gediagnosticeerde ziekte. In de 
totale populatie van volwassenen wereldwijd is CRC de derde meest 
voorkomende vorm van kanker waarvan in Nederland in 2012 meer dan 12000 
nieuwe gevallen werden gediagnosticeerd. Er bestaan twee vormen van CRC: 
een erfelijke en een niet-erfelijke vorm. De laatste vorm word ook wel het 
sporadisch CRC genoemd. Leeftijd is de grootste risicofactor voor het 
ontwikkelen van sporadisch CRC; meer dan 90% van de patiënten is boven de 
50 jaar oud. In de medische wereld zijn we gewend om colonoscopieën uit te 
voeren om de binnenzijde van de dikke darm en het rectum te inspecteren, 
zodat de mogelijkheid ontstaat om een weefselhapje, een zogenaamde biopsie, 
van afwijkend ogend weefsel te kunnen nemen (figuur 1). Deze weefselhapjes 
kunnen vervolgens door een patholoog onderzocht worden, wat een analyse 
naar de aanwezigheid van kwaadaardige (maligne) cellen betekent. Als de 
diagnose CRC bij een patiënt gesteld wordt, dan zal de patiënt een 
voorgedefinieerd zorgpad bewandelen waarin specifieke onderzoeken worden 
uitgevoerd om de locatie en de uitgebreidheid van de tumor te bepalen. Deze 
resultaten worden multidisciplinair besproken en er wordt, na overleg met de 
patiënt, een behandelplan gestart, waarin een chirurgische behandeling meestal 
een plaats krijgt. Na afloop van de chirurgische interventie wordt de patiënt 
vervolgd in de tijd, de zogenaamde follow-up, conform de CRC behandel-
richtlijnen. Een van de onderdelen van de follow-up is het bepalen van de bloed 
serum analyse van de tumormarker carcinoembryonic antigen, oftewel het CEA. 
Sinds 1965 is het bekend dat het CEA in hoge concentratie aanwezig is in CRC-
weefsel. Het CEA is sindsdien uitgebreid onderzocht en klinisch toegepast in het 
kader van CRC diagnostiek en behandeling van patiënten. Tegenwoordig wordt 
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het CEA alleen nog maar toegepast in de follow-up van patiënten na CRC 
chirurgie. CEA is ook aanwezig in de gezonde dikke darmwand en andere 
specifieke weefsels in het lichaam, echter de concentratie ervan is lager. Dit 
geeft de optie om hogere concentraties te relateren aan de aanwezigheid van 
ziekte. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.1 Colonoscopie: een flexibele buis met camera wordt via de anus geïntroduceerd in het 
rectum, door het sigmoïd, het descenderende, transverse en uiteindelijk via het 
ascenderende colon tot in het coecum. Het is mogelijk om weefselhapjes te nemen van 
verdachte laesies en om deze locaties met Oost-Indische inkt te markeren voor latere 
chirurgische uitname procedures. 
1.2  CRC ontwikkeling 
Sporadisch CRC begint haar ontwikkeling vanuit basale celveranderingen 
tijdens de celdeling in de darmwand. Sommige celveranderingen zijn genetisch 
bepaald en anderen zijn ontstaan onder invloed van omgevingsfactoren. De 
verschillende stadia van CRC zijn in figuur 2 in beeld gebracht. 
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Figure 9.2 De verschillende ontwikkelstadia van CRC in de wand van de dikke darm. 
 
CRC kan een poliep-achtig uiterlijk hebben, welke steeds groter blijft groeien. 
Ook kan CRC als een zogenaamde vlakke afwijking beginnen welke zich steeds 
verder ontwikkelt door ingroei in de darmwand. Een gemengd beeld is ook 
mogelijk, waarbij een kwaadaardige component in een poliepknop in de 
darmwand invadeert door de poliepvoet. De eerste twee voorbeelden zijn 
getoond in Figuur 9.3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.3 Aan de linkerzijde is een dikke darm poliep en rechts is een semi-circulaire verschijning 
van CRC gefotografeerd. 
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Totale genezing van CRC wordt meer haalbaar indien de diagnose vroeg 
gesteld kan worden. Dan is het statistisch haalbaar om lokale doorgroei of 
uitzaaiingen voor te zijn. Een herkenbaar patroon van klachten draagt bij aan het 
stellen van de diagnose CRC bij een patiënt. Vaak zijn de klachten aspecifiek en 
leiden deze niet tot de benodigde diagnose. Adequate diagnostische methoden, 
zoals bijvoorbeeld beeldvorming, zijn pas toepasbaar in de meer gevorderde 
tumor stadia. Het onderzoek naar de aanwezigheid van occult (=onzichtbaar) 
bloed in de ontlasting (iFOBT) kan een indicatie geven van de aanwezigheid van 
een mogelijke tumorale ontaarding in de dikke darm. Bij een positief resultaat 
dient er altijd een colonoscopie te volgen om de diagnose te verifiëren. Een 
CRC-bloed test is momenteel (nog) niet beschikbaar maar zou potentieel een 
leemte kunnen vullen in de CRC-diagnostiek.  
De veranderingen in de dikke darmwand gedurende het ontstaan van CRC 
kunnen het gevolg zijn van lokale ontsteking, ook wel inflammatie genoemd. 
Inadequate reparatie van de aangedane darmwand na de lokale inflammatie kan 
leiden tot DNA-schade. Deze DNA-schade kan resulteren in kwaadaardig 
gemuteerde cellen. Het onderzoeken van het inflammatoire proces en de 
bijbehorende inflammatoire cellen kunnen informatie geven over hoe het 
lichaam problemen oplost in ontstoken gebieden. 
2.  Macrofagen  
Om te bepalen of de genoemde inflammatoire cellen van toegevoegde waarde 
kunnen zijn in de in ontwikkeling zijnde tumoromgeving, gedurende tumor-
progressie en ook in tumordiagnostiek van toegevoegde waarde kunnen zijn, 
onderzochten we een specifiek type immuuncellen. Deze cellen worden 
macrofagen genoemd, en ze zijn een subtype van alle opruimcellen, ook wel 
fagocyten genoemd. In "fagocyt" betekent "fagos" "eten" en "cyt" betekent "cel". 
In "macrofaag" betekent "macro" "groot", en gecombineerd leidt dat tot "grote 
eetcel", wat inderdaad een van de primaire functies is en ook het uiterlijk (de 
morfologie) van de macrofaag beschrijft. 
Macrofagen ontwikkelen zich vanuit andere immuuncellen, de zogenaamde 
monocyten. Deze cellen ontstaan in het beenmerg wat aanwezig is in alle lange 
pijpbeenderen in het lichaam. Monocyten en macrofagen zijn in alle mensen 
aanwezig, ook in gezonde toestand. Monocyten zwermen rond in de bloedbaan 
en waar nodig zijn ze in staat het weefsel binnen te dringen indien specifieke 
signalen daarvoor aanwezig zijn. 
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Na het binnendringen in het weefsel zijn de monocyten in staat het uiterlijk en de 
functionaliteit van macrofagen aan te nemen. Macrofagen beschermen ons 
normaliter voor de buitenwereld door directe eliminatie van binnendringende 
ziektekiemen en het dirigeren van ander immuuncellen in het aanvallen van de 
binnendringers, maar ze vallen ook tumorcellen aan. Verder hebben ze een rol 
in wondheling, de aanleg van bloedvaten, het beïnvloeden van andere 
(immuun)cellen en produceren ze vele relevante stoffen die benodigd zijn voor 
de uitvoer van voornoemde taken. 
2.1 Macrofagen in (colorectaal) carcinoom 
Van macrofagen is bekend dat ze zich niet alleen in de nabijheid van een tumor 
ophouden, maar ook aanwezig zijn binnen in een tumor. De directe omgeving 
van een tumor wordt ook wel het stromale weefsel genoemd. In beide 
lokalisaties kunnen de functies van macrofagen beïnvloed worden door de 
kankercellen. Kankercellen zijn in staat de macrofagenfuncties richting tumorcel 
progressie te sturen in plaats van tumorcel eliminatie. Dit betekent dat 
tumorcellen geholpen worden in de taak van tumor progressie, bijvoorbeeld door 
het stromale weefsel dusdanig te veranderen van samenstelling dat tumorcellen 
er gemakkelijk doorheen kunnen bewegen. Ook andere taken worden 
beïnvloed, zoals bloedvatformatie ten behoeve van tumorgroei en het faciliteren 
van toegang tot de bloedbaan voor de kankercellen; deze aanpassingen maken 
de vorming van uitzaaiingen (metastasering) mogelijk.  
Het aantrekken van macrofagen richting tumor omgevingen kan daarom leiden 
tot tegengestelde acties van deze cellen, wat vervolgens leidt tot ziekte-
progressie in plaats van het inhiberen of elimineren van de ziekte. Macrofagen 
gedragen zich niet hetzelfde in (de omgeving van) alle vaste (solide) tumoren. In 
borstkanker worden ze geassocieerd met een slechtere prognose, maar in CRC 
zijn hun rollen nog niet geheel duidelijk. Sommige onderzoekers stellen dat 
macrofagen een risico vormen op ziekte progressie, anderen hebben gesteld dat 
macrofagen in staat zijn om een antitumorale reactie te leveren. 
Het onderscheid in de verschillende rollen van de macrofaag in CRC is nog niet 
gemaakt. Misschien bestaan beide rollen simultaan afhankelijk van de stimuli 
waaraan ze bloot gesteld worden. Om de aanwezigheid van CEA in macrofagen 
in CRC (geassocieerd) weefsel te onderzoeken werden twee studies uitgevoerd. 
De eerste studie evalueerde de aanwezigheid van CEA in macrofagen en 
lymfeknopen. Dit werd gedaan middels het toevoegen van substanties die CEA 
in (macrofagen in) het weefsel konden aantonen, gebruikmakende van 
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lichtmicroscopie. Er werden CD68 positieve cellen (macrofagen) in het CRC 
weefsel gevonden, die ook positief waren voor CEA. Tevens bleek dat deze 
macrofagen in staat waren om in de wand van bloedvaten te migreren (Figuur 
9.4 en hoofdstuk 2). Er werden ook lymfeknopen gevonden die positief waren 
voor CEA-bevattende macrofagen (Figuur 9.5 en hoofdstuk 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.4 a. CD68 kleuring van een bloedvat (omlijnd) liggend in tumorweefsel. b. CEA kleuring 
van het zelfde bloedvat, in de wand van het bloedvat (intramuraal) zijn 2 macrofagen 
aanwezig die CEA-positief zijn (omcirkeld met pijlhoofdjes erbij). CEA reactiviteit is ook 
zichtbaar aan de binnenzijde (luminale zijde) van het bloedvat. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.5 a. CD68 kleuring van een lymfeklier met uitgebreide macrofagen distributie; b.. 
bijbehorende CEA-kleuring. CEA-bevattende macrofagen kunnen herkend worden 
langs de belijning van en zijn beperkt tot de medullaire sinussen van de lymfeklier. 
Granulaire kleuring is herkenbaar in meerdere macrofagen (zie pijlhoofd). 
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De tweede studie werd uitgevoerd om de volgende vraag te beantwoorden: 
nemen macrofagen tumorweefsel met CEA op en verteren ze dat? Of nemen ze 
tumorweefsel op en produceren en presenteren ze vervolgens een tumor-
specifieke marker (in dit geval CEA) op het macrofagen oppervlak met als doel 
om andere immuuncellen te informeren? De studie wees uit dat macrofagen 
inderdaad tumorweefsel inclusief CEA opnamen en dit verteerden, en dat het 
mogelijk was om het opgenomen CEA aan te kleuren. Door middel van 
elektronen microscopie werden foto's gemaakt van macrofagen die 
tumorweefsel inclusief CEA hadden opgenomen in speciale verteringskamers, 
zogenaamde lysosomen (Figuur 9.6 en hoofdstuk 3), door het toepassen van 
CEA-antilichamen in combinatie met een goud-bolletjes kleuring. Dit betekent 
dat macrofagen inderdaad CEA-bevattend tumor-gerelateerd materiaal 
opnemen. Verder betekend dit dat deze macrofagen misschien aantoonbaar zijn 
in het bloed van patiënten met colorectaal carcinoom. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.6 Elektronenmicroscopie foto waarin een fagocyt zichtbaar is, (mogelijk een macrofaag) 
na het opnemen van een celkern (inzet rechtsonder in detail) en delen van het villeuze 
membraan van een kankercel (inzet linksboven). De nummers 1, 2 en 3 staan voor een 
villeus membraandeel, een goudbolletje en een membraan van een vacuole). Nummer 
4 geeft een deel van het endoplasmatisch reticulum weer, bedoeld voor transport door 
de cel.  
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2.2  De toepassing van macrofagen in de diagnostisering van CRC 
Eerder experimenteel onderzoek gericht op prostaat kanker diagnostiek waarbij 
gekeken werd naar het detecteren van prostaat specifiek antigen (PSA, een 
tumormarker) in macrofagen bleek succesvol. Het nastreven van hetzelfde 
resultaat bij CRC met de tumormarker CEA leidde tot de ontwikkeling van een 
nieuwe diagnostische test voor CRC. De nieuwe test maakt gebruik van een 
techniek welke flowcytometrie genoemd wordt. Deze techniek is in staat cellen 
te tellen in een testbuisje en detecteert specifieke cel karakteristieken. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.7 Een versimpeld schema van een flowcytometer. Vanaf de testbuis links in het schema 
worden cellen opgezogen en in een vloeistofstroom geïnjecteerd aan de rechterzijde 
van het schema, wat ervoor zorgt dat de cellen één voor één een laser passeren om de 
cellen te tellen en de cel-karakteristieken te bepalen doormiddel van detectoren die het 
laserlicht opvangen. 
 
Deze karakteristieken kunnen celgrootte, cel-complexiteit, cel-oppervlakte 
markers ter identificatie van de cellen, en intracellulaire markers welke de 
inhoud van de cel beschrijven inhouden.   
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Figure 8.8 Flowcytometrie is in staat celgrootte en cel-complexiteit te onderscheiden doormiddel 
van het meten van het laserlicht wat gereflecteerd en doorgelaten wordt . Deze 
parameters worden respectievelijk Side scatter oftewel "zijwaartse strooiing" en Forward 
scatter oftewel "voorwaartse strooiing' genoemd; beide kunnen gemeten worden door 
de detectoren in de flowcytometer. 
 
De cellen welke geteld dienden te worden werden gemarkeerd met specifieke 
antilichamen met fluorochromen. Antistoffen zijn stoffen welke kunnen 
aangrijpen op specifieke aangrijpingspunten op het celoppervlak, ook wel 
epitopen genoemd (anti-CD14 en anti-CD16 in het geval van geactiveerde 
macrofagen). Fluorochromen zijn stoffen die in staat zijn een specifieke kleur 
(een specifieke frequentie) licht uit te zenden na aanstralen middels de laser. 
Allophycocyanin (APC) en Fluorescein isothiocyanate (FITC) werden gebruikt 
voor dit doeleinde. Het toevoegen van deze fluorochromen aan de antilichamen 
stelde ons in staat de cellen (in dit geval de geactiveerde macrofagen) welke 
tumormerkstoffen zouden kunnen bevatten, te identificeren, doormiddel van de 
celgrootte, de cel-complexiteit en het uitgezonden licht op basis van de 
oppervlaktemarkers (Figuur 9.9). 
Na identificatie werden de geactiveerde macrofagen behandeld met een 
substantie die intracellulaire kleuring met een antilichaam tegen CEA mogelijk 
maakte, waarna tevens de toevoeging van een fluorochroom mogelijk was. Er is 
gebruik gemaakt van een antilichaam tegen CEA in combinatie met een derde 
kleur, phycoerythrin (PE). Deze stap maakte het mogelijk om de geactiveerde 
macrofagen te tellen die CEA-positief tumorgerelateerd materiaal bevatten 
(Figuur 9.10). 
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Figure 9.9 Aan de linkerzijde worden monocyten en macrofagen getoond welke respectievelijk 
positief zijn voor CD14 en CD14CD16. Aan de rechterzijde wordt de identificatie 
getoond van monocyten en macrofagen op basis van antilichamen gericht tegen CD14 
en CD16 in combinatie met fluorochromen (APC en FITC). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.10 In het linker figuur wordt de intracellulaire kleuring getoond middels gebiotynileerd 
antilichaam gericht tegen CEA na het doorgankelijk maken van het celmembraan. Het 
rechter figuur toont de toevoeging van het PE-fluorochroom aan het intracellulair 
gekoppelde antilichaam tegen CEA. 
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Deze nieuwe macrofagen-test werd onderzocht in een kleine groep CRC-
patiënten, bij patiënten met goedaardige (benigne) darmaandoeningen en bij 
gezonde individuen. De resultaten lieten de mogelijkheid zien om de gezonde 
individuen te onderscheiden van de totale patiëntengroep. Na combinatie van de 
nieuwe macrofagen test met een bestaande inflammatietest bleek het mogelijk 
om de kankerpatiënten te onderscheiden van de patiënten met benigne 
inflammatoire darmziekte (Figuur 9.11 en hoofdstuk 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.11 De resultaten van de proefstudie, welke laat zien dat er onderscheid gemaakt kan 
worden tussen de gezonde individuen, benigne darmziekte patienten (BI) en de CRC 
patienten in de stadia I-IV. Na het combineren van de macrofagen-test met CRP 
metingen blijkt het mogelijk om ook de vroege CRC-stadia te onderscheiden van de BI-
groep. 
 
Uit flowcytometrische analyse buisjes, die vanuit perifeer afgenomen bloed 
waren opgewerkt, werden grote cellen met meerlobbige kernen geëxtraheerd, 
welke positief bleken voor CEA. Middels lichtmicroscopie (cytospin-analyse) 
konden deze cellen gefotografeerd worden (Figuur 9.12). Deze bevindingen 
bevestigen het beeld van de eerder gefotografeerde weefsel macrofagen en 
daardoor wordt de hypothese van macrofagen met geïnternaliseerd CEA 
bevestigd. 
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Figure 9.12 CEA in geactiveerde macrofagen: De blauwachtige kleur is een kernkleuring en de 
bruinachtige kleur is de CEA kleuring. De CEA-kleuring laat een korrelige (granulaire) 
textuur zien, alsof het CEA zich in kleine holtes in de cel bevindt. 
 
2.3  Validatie van de nieuwe macrofagen test 
Een resultaat zoals hierboven beschreven leidt tot enthousiasme, maar dient 
ook te leiden tot de vraag of de uitkomsten betrouwbaar zijn. Om deze vraag te 
beantwoorden werd een serie testen uitgevoerd om de zogenaamde 
reproduceerbaarheid te onderzoeken. Reproduceerbaarheid betekent bijvoor-
beeld dat het twee keer meten van één enkele analysebuis een gelijk resultaat 
geeft binnen bepaalde minimale marges. Tevens dient het zo te zijn dat 
wanneer één analysebuisje op twee verschillende analyseapparaten gemeten 
wordt de uitkomsten overeenkomen. De variatie van monocyten en geactiveerde 
macrofagen bij gezonde proefpersonen werd gemeten gedurende één maand 
en één jaar (Figuur 9.9). We concludeerden dat de aantallen van de 
voornoemde cellen varieerden in de tijd, ook in gezonde proefpersonen. 
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Figure 9.13 Variatie van de CEA-bevattende macrofagen in zes gezonde proefpersonen gedurende 
één maand en gedurende één jaar. De rode stippellijn laat de gemiddelde waarde van 
de zes gezonde proefpersonen over de hele periode van één jaar zien. 
 
Het validatietraject resulteerde in de conclusie dat de macrofagentest technisch 
reproduceerbaar was, maar dat biologische variatie optrad, wat betekent dat de 
patiënt zelf de variatie veroorzaakt. Deze biologische variatie bleek de grootste 
bron van verstoring te zijn ten opzichte van de diagnostische capaciteiten van de 
nieuwe macrofagen test (hoofdstuk 5). Zodoende werd besloten dat de 
macrofagen test alleen toegepast kon worden indien een andere wijze van 
interpretatie als reproduceerbaar aangeduid kon worden. Een andere 
interpretatiewijze wordt momenteel onderzocht; dit betreft de verandering van de 
parameters van 25% of meer op twee opeenvolgende momenten. Deze wijze 
van interpretatie is een geaccepteerde wijze van andere (serum) tumormarkers. 
Daarnaast hebben we de toepasbaarheid van de macrofagentest in andere 
klinische situaties onderzocht. Het monitoren van radiochemotherapie of 
ziekteprogressie gedurende de follow-up periode na chirurgie zijn hier 
voorbeelden van. De mogelijkheid tot monitoring van radiochemotherapie bij 
rectumcarcinoom patiënten is onderzocht (paragraaf 2.4 en hoofdstuk 6). 
Momenteel wordt de monitoring van ziekteprogressie na afloop van chirurgie 
nog uitgevoerd. 
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2.4  Monitoring van het effect van radiochemotherapie bij 
rectumcarcinoom 
Een van de andere mogelijke applicaties werd gezien in de monitoring van de 
effecten (response predictie) van voorbehandeling middels radiochemotherapie 
(neoadjuvante therapie of nCRT). Bij patiënten met rectum carcinoom is het 
geven van nCRT een gebruikelijke wijze van voorbehandelen. nCRT is gericht 
op het reduceren van de grootte van de tumor en het destrueren van lymfeklier 
metastasen. nCRT kan in potentie leiden tot verkleinen van de voorgenomen 
chirurgische resectie-gebied, en kan zelfs leiden tot een afwacht-en-monitor 
beleid indien de tumor als gevolg van de nCRT verdwijnt. Dit betekent dat een 
patiënt voordeel kan hebben van het voorspellen van de reactie op de nCRT 
omdat het mogelijk effect kan hebben op de daaropvolgende behandeling. 
Indien de voorspelling laat zien dat de kans groot is dat de patiënt in het geheel 
niet zal reageren op de reguliere nCRT, er dan gekozen kan worden voor een 
alternatieve voorbehandeling, of zelfs voor direct uitvoeren van een chirurgische 
behandeling. nCRT bestaat uit een combinatie van bestraling (radiotherapie) en 
chemotherapie. Een gedachtegang was dat er door de tumor in het rectum 
tumorgerelateerd materiaal losgelaten wordt gedurende de periode van nCRT, 
en dat dit materiaal opgeruimd kan worden door macrofagen. Om de eventuele 
additionele waarde van macrofagen in het voorspellen van het effect van nCRT 
te bepalen, werd een groep rectumcarcinoom patiënten voorafgaand, gedurende 
en na afloop van nCRT onderzocht. Bloedanalyse bij rectum carcinoom 
patiënten gedurende de nCRT-periode werd uitgevoerd en PET-CT-scans 
werden gelijktijdig gemaakt. 
Het bleek mogelijk om veranderingen te meten in meerdere parameters 
gedurende nCRT, en sommigen van hen hadden voorspellende waarde. Het 
toevoegen van alle metingen aan reeds bestaande respons predictie modellen 
bleek te leiden tot een toename van de predictieve capaciteit van 72% naar 94% 
accuraatheid in de eerste twee weken van de nCRT. Dit betekent dat vroeg in 
de nCRT-periode het behandelteam met 94% zekerheid kan voorspellen of de 
gestarte voorbehandeling het beoogde effect zal hebben door het toevoegen 
van de nieuwe markers. 
2.5 Conclusie 
Concluderend, in dit promotietraject is gefocust op het onderzoeken van het 
principe van het gebruik van macrofagen in diagnostische setting in humaan 
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weefsel en bloed, de ontwikkeling van een macrofagentest en de vroege 
toepassing ervan gedurende het monitoren van nCRT bij rectumcarcinoom 
patiënten. De test heeft de potentie om de predictieve waarde van 
predictiemodellen te verhogen en wordt momenteel onderzocht op additionele 
waarde in de follow-up periode na colorectale chirurgie. 
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1.  Relevance  
Cancer is death cause number one in developed countries. Worldwide 12.4 
million new cases of cancer occurred in 2008, of which more than 50% is 
diagnosed in the developing countries1. In the US alone an estimate of 1.7 
million new cancer patients is predicted for 20142. The incidence in the 
Netherlands was 100.000 in 2011, and the incidence increased with 1.1 percent 
for men and 1.7 percent for women in the period from 2001 to 2011. The total 
costs generated by cancer care in the Netherlands in 2011 was 4.8 billion Euro, 
of which almost 73% accounts for hospital care3. Besides the patient and family 
burden, the costs of cancer diagnostics and cancer treatment, also the economic 
impact of cancer is substantial. The worldwide economic impact of premature 
death and disability caused by cancer was 895 billion dollars in 2008. This 
analysis was made without taking the actual medical costs into account. 
Effectively this is 1.5 percent of the world's gross domestic product (GDP). The 
three cancer types causing the most economic impact globally per year were 
lung cancer, colorectal cancer and breast cancer, with the amounts of 188, 99 
and 88 billion dollars respectively. Nations with smaller economies are less 
capable to allocate the needed financial funds to cancer diagnostic and 
treatment programs1.  
1.1  Diagnostic relevance 
All above mentioned  facts underline the need for reliable cancer diagnostics, 
preferably low cost types. Reliable cancer diagnostics, in all settings, can aid in 
early cancer detection, in primary as well as secondary setting. Earlier detection 
could enable less invasive treatment options in both primary and secondary 
disease. Hereby improvement of quality of life for patients during and after the 
initial cancer detection phase is possible. This results in lower impact on patient, 
family and the global economy. Cancer treatment can only become more patient 
friendly and cost-efficient if cancer diagnostics are optimised first. Therefore 
population based screening has become an option for certain forms of cancer. 
Population based screening is known to reduce mortality for breast cancer, 
colorectal cancer, cervix cancer and lung cancer2. In the Netherlands the first 
results of a population-based screening-trial for colorectal cancer (CRC) have 
been reported with promising results. In 2014 almost 130.000 persons over 50 
years of age were asked to perform an iFOBT test at home and over 15.000 
persons tested positive. A colonoscopy was performed in over 10.000 persons 
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up until now. In 40 percent of this population CRC or advanced colorectal 
adenoma (AAD) was diagnosed. These results illustrate possible benefits of a 
population based screening for CRC. Risks of false positive results and 
complications in iFOBT and colonoscopy screening respectively are under 
investigation in this trial as well. The false positive rate (no CRC or AAD) of 
iFOBT in these first results was 58.9 percent as was confirmed by colonoscopy. 
In 31.9 percent of the persons with a positive iFOBT test not even low grade 
adenomas were found during colonoscopy. Colonoscopy has risks as well, such 
as bleeding and perforation (1.34 percent and 0.07% respectively). These 
problems are serious adverse events in an asymptomatic screening population4. 
If parts of the diagnostic trajectory could be optimised further, for example by 
exchanging one of the screening tools, a more reliable or less invasive 
screening protocol could be applied. This thesis elaborates on the investigation 
of epitope detection in macrophages (EDIM) as a candidate for screening 
purposes. The pilot study (chapter 4) in a randomly selected CRC-patient 
population showed a sensitivity and specificity of 100.0 percent and 83.3 percent 
respectively, using a cut-off point of 4.25 percent of CEA- in macrophages (CEA-
IM). In the validation study (chapter 5) it was shown the biological variability 
within a person leads to a range of normalcy values, which precludes single-
sample analyses per person. Multiple analyses in a healthy person are needed 
to establish a range of normal values for this person. Aberrant values from that 
range would indicate presence of disease. 
1.2 Follow-up relevance 
In postoperative surveillance after colorectal surgery the carcinoembryonic 
antigen (CEA) serum test is combined with periodic ultrasound or CT-scan and 
colonoscopy. This surveillance protocol (including possible variations) have 
been captured in worldwide CRC follow-up guidelines5,6. The addition of the 
EDIM-method to the follow-up setting is currently under investigation. If an 
additional value could be found and it would outperform the diagnostic capacity 
of currently implemented follow-up strategies, then a possible change in the 
established protocols could become warranted. Additional costs would not 
outweigh the ability to detect recurrence earlier, to treat patients earlier with less 
invasive techniques. 
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1.3 Monitoring relevance 
Monitoring response to neoadjuvant treatment in rectal cancer patients could 
enable identification of responders and non-responders before or early during 
neoadjuvant therapy7. In combination with blood biomarkers this additional value 
was reported in a prediction model utilised before neoadjuvant treatment8. In our 
studies it was shown that the added value could be increased even further (AUC 
0.94), by adding monocyte and macrophage analyses in combination with other 
serum markers and PET-CT values to a prediction model during the first two 
weeks of neoadjuvant treatment. When evaluating these outcomes upfront in all 
rectal cancer patients, the patients benefitting from neoadjuvant treatment could 
be identified. The patients who would not benefit could be treated according to 
other protocols or specific patients could refrain from therapy at all. These 
emerging options would lead to personalised medicine, that could lead to better 
quality of life for rectal cancer patients, and more appropriate spending of 
resources. 
2.  Target groups, activities and products  
The medical specialities who could utilise the outcomes of this thesis arethe 
gastroenterologists and surgeons treating CRC patients. Immunologists could 
utilise the outcomes to further investigate the role of macrophages and 
monocytes in immunocompetence in cancer in general and specifically in CRC. 
When proven useful, development of an immuno-competence assay for cancer 
patients could be the next step. Oncologists could incorporate immunological 
assays (such as the EDIM-assay) in cancer follow-up settings for disease 
monitoring purposes. Finally, Radiotherapists could first investigate and at a 
later time point include monocyte and macrophage measurements, utilising the 
EDIM method, in treatment monitoring settings. National and global funding 
organisations should recognise the potential of immunological cancer research 
and expand their funding capacity towards this part of medical research. 
Participation of other (UM-) parties in further development of this assay could 
accelerate the development and broaden the applicability in medicine. 
3.  Innovation  
The EDIM-method is a completely new way of utilising cells of the immune 
system, such as monocytes and macrophages, for diagnostic, follow-up and 
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monitoring purposes. In prostate cancer this method was first described for 
diagnostic purposes by Herwig et al.9-12 and confirmed by Leers et al. in 200813. 
The basic question of the actual localisation of tumour markers in macrophages 
was investigated by our group using the colorectal cancer model. Utilising light 
and electron microscopy the localisation of the antibody against CEA inside the 
monocytes and macrophages was visualised and confirmed14,15. In a pilot setting 
this innovative method was applied in a CRC diagnostic setting showing 
distinguishing capabilities between healthy and CRC patients. Addition of CRP 
allowed distinguishing CRC patients from benign inflammatory diseases of the 
colon16. Validation of such an assay is innovative. All parts of the validation 
process must be conceived, tested and applied. This process has been 
performed and reported by our group17. The potential of applying the assay in 
CRC follow-up (research in progress) and in monitoring rectal cancer (paper 
submitted) has been and is currently being explored by our research group. The 
value of the EDIM-method in comparison to established diagnostic tools and 
other experimental methods in cancer diagnostics needs further evaluation. 
4.  Planning and realisation  
Studies as described above are currently performed or have been performed 
with the results being published soon.  
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Dankwoord  
Allereerst Maarten, mijn promotor. We waren al wat jaren onderweg toen we 
vanuit Heerlen bij je aanklopten om als promotor te fungeren. Het op de rijdende 
trein springen heb je als de beste gedaan, dank daarvoor. Wat hebben we in de 
afgelopen jaren veel aan tafel gezeten samen, eerst echt als promotor en 
promovendus, maar in de afgelopen jaren is het overleg voor mij echt gegroeid 
tot een vriendschappelijk overleg, wat ik zeer waardeer en waar we ook de 
wereld, het ziekenhuis en ons leven bespreken. Je wijsheid en “alles al gezien” 
hebbende heeft me meermaals behoedt voor enthousiaste acties die op niets 
zouden uitlopen, zowel in positieve als negatieve zin. Je hebt me naast veel 
input ook geleerd beter te schrijven, al hadden we allebei een andere methode, 
we kwamen samen uiteindelijk tot een pracht manuscript. Maarten bedankt en ik 
hoop dat we nog vaak samen mogen bomen. 
 
Dan de copromotoren, ik heb er drie en daar ben ik trots op.  
Laat ik beginnen met Marius, onze vriendelijke bebaarde patholoog in het team. 
Inspirerend als je bent op onderzoeks- en leidinggevend gebied, zo heb ik ook 
met je gediscussieerd, ben ik het met je eens geweest, maar ook even zo vaak 
oneens. Je onorthodoxe wijze van onderzoek doen, bespreken en schrijven 
hebben me wel eens op de kast gejaagd, maar daar hielp je me dan ook vlot 
weer vanaf. Je liet me door je enthousiasmering dingen uitzoeken, berekenen 
en in grafieken zetten waarvan ik eerst dacht dat ik dat niet voor elkaar zou 
krijgen, maar iedere keer lukte het toch weer. Ik ben er trots op dat je mijn 
copromotor bent, bowlen kun je toch echt niet en graag zie ik je nog eens zingen 
op congres (ja, dat filmpje heb ik nog)! 
 
Dan hebben we Mathie, de flowcytometer-koning, stoere politieagent en 
natuurlijk dé klinisch chemicus en hematoloog in ons team. Je bent onmisbaar 
geweest en onze gesprekken bij kopjes koffie, soms wekelijks, soms wat 
intermitterender zijn me veel waard geweest. Je bent een binnenvetter en dat je 
daarin soms onleesbaar bent heeft me nog wel eens hoofdbrekens opgeleverd, 
en zo nu en dan een onder-vier-ogen gesprekje, maar ook daar zijn we goed 
uitgekomen. Je hebt me kritisch leren kijken naar flowcytometrie-werkwijzen en 
interpretaties, wat me geholpen heeft om alle metingen goed te verwerken. Je 
stimulerende woorden en het feit dat ik altijd bij je kon komen met een vraag (of 
veel vragen) hebben me door deze jaren heen gesleept. Als copromotor kon ik 
me geen betere wensen, dankjewel! 
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Meindert tot slot, mijn chirurgie-maatje, wat onwennig begonnen toen je zelf net 
in Heerlen was, maar al vlot een bruisend vat van energie die het woord 
stimulus zelf uitgevonden kon hebben. Ik heb me in het onderzoek in het begin 
altijd afgevraagd of je überhaupt wel snapte wat ik aan het doen was, maar 
gedurende overleggen met de anderen kon je dat eigenlijk vrij eenvoudig 
uitleggen, je snapte het technische deel echt niet. Het klinische deel 
daarentegen was jouw pakkie an en nu nog ga je er helemaal in op. Ik ben weet 
ik niet hoe vaak bij je langs geweest om te overleggen, advies te vragen en (ja 
ook hier) een bakkie te doen. Stimulerend ten top, altijd snel met reageren, ja 
ook soms irrelevante antwoorden, maar ach. Het is inderdaad zo dat wellicht de 
beste stimulans je woorden van vorig jaar waren, “dat het me in 2014 niet ging 
lukken om alles af te krijgen”. Daarin heb je in ieder geval ongelijk gehad, een 
prettige conclusie om te trekken. In je taak in dit traject was en ben je een 
chirurgisch copromotor van formaat, dank!! 
 
Dear thesis judging committee; thank you for taking the time to read all my work, 
judge it properly and provide me with proper feedback in time. I really appreciate 
the time and effort you all put in. Hope to see you all during the defence and in 
future research or other circumstances. 
 
Dan nog de overige begeleiders van het promotietraject: 
Lieve Patty, onze klinisch epidemiologe bij het team. Als ik een ding geleerd heb 
van je dan is het de onderzoeksvraag helder te hebben. Een tweede ding wat ik 
van je geleerd heb is dat je dat dan ook moet doen voorafgaand aan je data-
verzameling. In beide zijn we regelmatig niet geslaagd en dan kreeg ik weer een 
zuchtende en steunende Patty voor mijn neus, werd ik weer even stevig in de 
hoek gezet en konden we daarna constructief aan de slag met de gegevens die 
dan toch wel weer op een of andere manier grondig geanalyseerd konden 
worden. Je kennis is indrukwekkend en ik heb, ondanks je af en toe broodnodig 
pittige reacties, altijd met veel plezier je kamer bezocht. Dank daarvoor. 
 
Beste Geerard, Prof Beets onderhand, analytisch, kritisch op methode en inhoud 
en toch ook wel een beetje van je stuk te krijgen als ik “out of the box” roep dat 
de huidige follow-up van het rectumcarcinoom toch zo maar eens op de schop 
zou kunnen gaan. Immunologie kan een rol spelen, jij ziet en zag dat toch wat 
genuanceerder. Maar dat komt nog wel… Nu we gezamenlijk in de kliniek staan 
is het ineens iets anders allemaal, maar ook nu komen we er samen altijd uit. Ik 
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heb bewondering voor je voornoemde eigenschappen en hoopte de komende 
jaren nog veel chirurgisch van je op te steken, echter mag dat helaas niet zo 
zijn. Heel veel succes in je nieuwe positie noordelijker in het land. 
 
Dan een groep collegae zonder wie dit proefschrift er al helemaal niet zou zijn, 
mijn lieftallige WESP-studenten in volgorde van meedraaien in het project: Roy, 
Philip (ook keuzestage), Noortje, Jeroen, Kim, Nina, Tjitske, Jogien, Martine en 
David (ook keuzestage). Gedurende meerdere jaren maakten jullie in 
wisselende samenstelling deel uit van het team en dit vonden we allen geweldig. 
Ik vind het prachtig om te zien dat een deel van jullie ook in ons prachtige 
chirurgische vak terecht is gekomen naar aanleiding van jullie stage. Maar ook 
de rest is goed geland heb ik gezien. Wat een enorme lading buisjes hebben we 
met z’n allen weggewerkt, zeker meer dan 10.000 stuks… kun je het je nog 
herinneren, of heb je het stiekem ver weg gestopt… Jeroen en Tjits, jullie co-
auteurschappen staan als een huis, trots op jullie! 
 
Dan nog een aantal afdelingen in het Atrium: 
Allereerst mijn lab-collegae in het Atrium, iedereen was altijd zo vriendelijk en 
behulpzaam, we hadden het niet kunnen regelen zonder jullie. Met name de 
prikdienst in Heerlen, Kerkrade en Brunssum, maar ook de thuisprikdienst en 
alle laboranten in Heerlen. Met nadruk wil ik de trialanalisten noemen, maar ook 
de heren en de dames van de ICT op het lab en last but not least de lieve 
collegae op het beenmerglab, onder de bezielende leiding van Annie. 
 
Ook het pathologie lab in Heerlen is onmisbaar geweest voor het slagen van dit 
traject. Alle medewerkers daar, waaronder Math, Jack, Ludy en de andere 
analisten. En natuurlijk Nick, onze flowcytometrie en Mathlab kenner, hopelijk 
ben je al vergevorderd met jouw proefschrift, we hebben lol gehad met het 
geven van de flow-cursus voor dummies. 
 
Dan de afdeling chirurgie in Heerlen, Brunssum en Kerkrade.  
Allereerst de dames van het secretariaat, de polidames en heer, de verpleging 
van afdeling 11 en 12 en de andere etages; in het bijzonder Leintje, de 
afdelingssecretaresses van 11 en 12 en tot slot de OK-medewerkers die altijd 
klaar stonden om bloed te samplen voor mijn studie. 
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Niet te vergeten mijn steun en toeverlaat in de inclusies, de MDL-
verpleegkundigen Desiree, Ilse en Grietje, superbedankt! Verder, de dames en 
heren van de scopie kamer in Kerkrade, zonder jullie hadden we niet zo’n mooie 
controle groep gehad. 
 
Dan de afdelingen in het MUMC 
Allereerst de dames van het secretariaat Heelkunde, in het bijzonder Joyce, 
Sabeth en Evelien voor het regelen van alle zaken die we nodig hadden. Op de 
afdeling ook Marian en Mariëlle als kapiteins op het schip. Cees Dejong voor het 
geloven in mijn traject en het ondersteunen waar nodig.  
 
Het Heelkunde lab alwaar ik Wim, Mo, Sander en Kaatje het meest meegemaakt 
heb, maar ook alle andere lab collegae hartelijk dank voor jullie kritische noten 
gedurende mijn presentaties en literatuurbesprekingen. Maar ook mijn 
wisselende roomies in het afgelopen schrijfjaar, dank voor jullie gezelligheid en 
steun! 
 
Het klinisch chemisch lab, het was kort maar krachtig, dank voor jullie 
ondersteuning.  
 
Afdeling Pathologie in het MUMC; Adriaan, toen je er nog werkte, dank voor je 
scherpe blik, Math Rousch dank voor je flow-sort cursus en je vertrouwen in mij 
dat ik met je flow-sort-kindje mocht spelen. 
 
De afdeling Electronenmicroscopie, met name Fons en Hans, dank voor jullie 
input, tijd en inzet. Zonder jullie was dit boekje een hoofdstuk armer. 
 
Dan MAASTRO-clinic, Guido Lammering, Jeroen Buijsen en Ruud van Stiphout, 
soms kwamen we er niet helemaal uit waar artikelen over moesten gaan, maar 
dat is uiteindelijk helemaal goed gekomen. Dank voor het mede faciliteren van 
het onderzoek. Dat geldt ook voor de dames van het bloedafname-lab van de 
MAASTRO, die alle patiënten hebben ingelicht en geprikt. Zeker net zo 
belangrijk zijn de dames van het datamanagement (Ann Claessens, Sylvia 
Loffeld en anderen), zonder hen hadden we niet alle data op een rijtje gehad. 
Allen superbedankt! 
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Beckton & Dickinson, met name Frans Nauwelaers wil ik bedanken voor het 
ondersteunen van de onderzoeken die we verricht hebben. Ook je kritische 
opmerkingen, je behulpzaamheid en je vriendelijke belse tongval hebben ons 
altijd voorzien van de juiste stimulans om weer verder te kijken en door te 
pakken. Het boekje was er niet geweest zonder jullie. 
 
Johannes Coy en onze collegae onderzoekers van Tarvarlin en Tavargenix in 
Darmstadt. Ook de collegae laboranten Martina en Olaf van InVitaLab te Neuss. 
Allen dank voor de ondersteuning en het meedenken in de validatiestudies, wat 
een klus was dat. Veel succes met het vermarkten van het idee van de EDIM-
test. 
 
Dan honderdduizend maal dank voor wellicht de belangrijkste groep personen 
van het gehele traject: Onze patiënten, gezonde proefpersonen en patiënten 
met goedaardige darmaandoeningen zonder wie we het onderzoek nooit 
hadden kunnen doen. Hopelijk heeft dit proefschrift een aanzet geleverd voor 
toepassing van de gevonden resultaten in de kliniek en verder onderzoek, zodat 
de patiënten van de toekomst ervan kunnen profiteren. 
 
Peter, we hebben samengewerkt op een totaal ander gebied, de ICT, en we 
waren een topteam. In die anderhalf jaar die tezamen liep met mijn promotie 
hebben we elkaar en elkaars familie goed leren kennen. Ik heb je wijze lessen 
goed in mijn oren geknoopt en zal de “s” koste wat het kost wegpoetsen. Heel 
veel succes en sterkte in je werk- en privéleven, je bent een kanjer. 
 
Mijn schoonmoeder Marjo en schoonzussen An en Ien voor het tonen van 
begrip dat ik wel eens niet meekwam omdat ik geen tijd had. Dat is natuurlijk 
niet omdat ik jullie niet lief vind, maar juist niet wilde vermoeien met verhalen 
over dit traject en de totstandkoming van dit boekje. De momenten dat ik er wel 
was kon ik dit traject gelukkig makkelijk even parkeren door de gezellige 
positieve drukte die er altijd heerst als we samen zijn. Dank dat ik erbij hoor! 
 
Mijn zus, zwager en kinderen die ik de afgelopen jaren spaarzaam heb bezocht 
en heb kunnen bezoeken. Laten we hier in de komende jaren samen aan 
werken! 
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Mijn lieve ouders, die al zo vaak zeggen dat ze het fantastisch vinden wat ik 
gedaan heb en nu doe, ik voel me vereerd dat ik jullie zoon ben, heb veel van 
jullie geleerd. Over hoe in het leven te staan en wat je moet doen om iets te 
bereiken in het leven, nooit opgeven is het devies. In de afgelopen jaren hebben 
jullie me door dik en dun gesteund, waardoor het volbrengen van dit 
lijdenswegje me toch lichter is gevallen. Als ik er niet altijd over praatte was het 
meer dat ik dan blij was dat ik het even kon parkeren, en over andere zaken kon 
babbelen. Afschakelen is iets wat ik bij jullie prima kan, dank daarvoor. Hopelijk 
zien we elkaar nog lang wekelijks als jullie op ons lieve dochtertje passen. Ben 
heel blij met jullie! 
 
Sienna, mijn dochter, voor het lieve wondertje dat je bent ben ik jou maar vooral 
ook je mama dankbaar, maar in de korte periode dat je er bent, ben ik helemaal 
verknocht aan je geraakt. Papa’s kindje zeggen ze, en dat is ook zo, je bent het 
zonnetje wat al schijnt voor zonsopgang en je straalt totdat de echte zon allang 
is onder gegaan. Jouw papa zijn is een feest. Ben gek op je… 
 
Joëlle… sprakeloos ben ik door je, keer op keer, de mooiste vrouw van allemaal! 
Altijd lief en vergevingsgezind, ook als ik toch weer achter de computer moest 
kruipen. Als (saaie, NOT!) internipst met passie voor niertjes ben je niet alleen 
de mooiste internipst, maar ook nog eens een hele slimme. Zeker meer dan een 
wandelend kruidenalmanakje, nu ben je zeker al de luxe editie van de grote 
Winkler Prins, op weg naar je eigen ultieme versie. Dat gaat je lukken. Je 
creëerde mijn ideale werkomgeving, maar als je vond dat het te lang duurde 
kwam je me gewoon halen voor een stukje ontspanning. Nu kunnen we zonder 
dit soort obstakels verder op weg naar onze toekomst samen (dat ja-woord is 
onderweg, dat weet je). Eerst gaf je me al je hart en afgelopen februari gaf je me 
onze dochter, wat een wereldervaring zo met z’n tweeën. Lieverd, ik hou van 
je…. 
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diploma in 1995 haalde hij het Atheneum-diploma in 1997. Hij werd uitgeloot 
voor de studie geneeskunde en besloot daarom farmacie te gaan studeren in 
Groningen. Na nog 3 maal uitgeloot te zijn werd hij alsnog nageplaatst voor de 
studie Geneeskunde te Maastricht. Gedurende zijn studie verbleef hij tweemaal 
in het buitenland; allereerst een keuzestage Klinisch Immunologie in Linköping 
in Zweden alwaar zijn interesse voor het menselijk immuunsysteem werd 
gewekt en vervolgens nog een co-schap KNO in Pretoria in Zuid-Afrika. In het 
laatste jaar van zijn geneeskundeopleiding (2006-2007) heeft hij gedurende zijn 
gecombineerde klinische en wetenschapsstage de basis gelegd voor dit 
promotieonderzoek door een prospectieve studie op te zetten in het Atrium 
Medisch Centrum Parkstad, te Heerlen. Hij behaalde vervolgens in 2007 het 
artsexamen aan de Universiteit Maastricht. Voor zijn onderzoekswerk in het 
laatste jaar van de geneeskundestudie ontving hij de NVGE Student Award in 
2007. Na afloop van zijn studie werd hij ANIOS Heelkunde in het Atrium 
Medisch Centrum Parkstad, te Heerlen. Begin 2008 werd hij full-time 
onderzoeker, eerst alleen in Heerlen, later ook in het Maastricht University 
Medical Center. Het onderzoek vond plaats onder leiding van de co-promotores 
dr. Sosef (gastrointestinaal en oncologisch chirurg), dr. Nap (klinisch patholoog) 
en dr. Leers (klinisch chemicus en hematoloog), met als promotor Prof. dr. von 
Meyenfeldt (oncologisch chirurg). In 2009 volgde zijn eerste publicatie over het 
onderwerp van dit proefschrift en ontving hij de MAASTRO-Atrium grant. In 2010 
verwierf hij een AGIKO-subsidie van ZonMw. Begin 2011 startte hij met de 
gecombineerde opleiding tot chirurg en klinisch onderzoeker, met één jaar 
volledig onderzoek. In de jaren daaropvolgend publiceerde hij verschillende 
papers over het in dit proefschrift beschreven werk. In de periode 2012-2013 
rondde hij de eerste twee jaar van zijn chirurgische opleiding af, gevolgd door 
wederom een volledig jaar wetenschapsbeoefening in 2014. Per 1-1-2015 is hij 
begonnen aan zijn 2e periode van 2 jaar chirurgische opleiding, ditmaal in het 
Maastricht University Medical Center te Maastricht. Hij zal zijn opleiding tot 
chirurg afronden in het Atrium Medisch Centrum Parkstad te Heerlen 
aansluitend op de huidige periode in Maastricht. 
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Abbreviations 
AAD  Advanced adenomas 
AEC  3-amino-9-ethylcarbazole 
AJCC  American joint committee on cancer 
AM  Activated macrophages 
APC Allophycocyanin  
APC  Adenomatous polyposis coli 
AUC  Area under the curve 
BC  Blood capillairies 
bFGF  Basic fibroblast growth factor 
BGP  Biliary glycoproteins 
BRAF  Proto-oncogene B-Raf, serine/threonine kinase 
BSA  Bovine serum albumin 
CBC  Complete blood count 
CCR2  Chemokine receptor 2 
CD  Crohn's disease 
CD in CD14 or CD16 Cluster of differentiation  
CEA Carcinoembryonic antigen  
CEA-IM CEA in macrophages (CEACM) 
CEA-S Isomeric carcinoembryonic antigen 
CEACM  CEA-containing macrophages (CEA-IM) 
CGM  CEA gene family members 
CK  Cytokeratin  
CK-IM CK in macrophages 
CMP  Common myeloid progenitor 
CRC  Colorectal Cancer 
CRP  C-reactive protein 
CSF-1  Colony stimulating factor 1 
CTC Circulating tumour cells 
ctDNA  Circulating tumour DNA 
DAB  3,3'-Diaminobenzidine 
DC  Dendritic cells 
DFS Disease free survival 
dMMR  Defective mismatch repair 
EDIM  Epitope Detection In Macrophages  
EDTA Ethylenediaminetetraacetic acid 
EGF  Endothelial growth factor 
EGFR  Endothelial growth factor receptor 
EM Electron microscopy 
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ERUS  Endorectal ultrasound 
FAP Familial adenomateus polyposis 
Fcgamma  (FC: Fragment, crystallizable) region directed at IgG 
FI  Fluorescence intensity 
FIT  Faecal immunochemical test 
FITC  Fluorescein isothiocyanate  
FMO Fluorescence-minus-one  
FSC  Forward Scatter 
GA  Glutaraldehyde 
GDP  Gross domestic product 
gFOBT Guaca faecal occult blood test 
GFP  Green fluorescin protein 
H&E  Hematoxylin & eosin staining (HE) 
HNPCC  Hereditary non-polyposis colorectal cancer 
HSC  Haematopoietic stem cells 
IBD Inflammatory bowel disease 
ICC  Intra-class correlation coefficient 
IEM  Immuno electron microscopy 
iFOBT  Immunochemical feacal occult blood test 
IL10  Interleukin 10 
IL12  Interleukin 12 
IL8 Interleukin 8 
INF Immune cell influx 
KC  Kupffer cells 
KRAS  Kirsten rat sarcoma viral oncogene homolog (K-ras) 
LARC Locally advanced rectal cancer 
LM  Light microscopy 
LPS  Lipopolysaccharide 
M30  M30-neo-epitope  
M30-IM  M30 in macrophages 
MAP  MYH-associated polyposis 
MC  Methylcellulose 
MdnFI  Median fluorescence intensity 
mFMO Modified Fluorescence-minus-one  
MLH1  MutL homolog 1, colon cancer, nonpolyposis type 2 
(Lynch syndrome mutation) 
MMP  Matrix metallo proteinase 
MREC  Medical research ethics committee 
MSH2  MutS protein homolog 2 (Lynch syndrome mutation) 
MTA Membrane-associated tissular antigen 
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MTV  Metabolic tumour volume 
NCA  Non-specific crossreacting antigens 
nCRT Neoadjuvant chemoradiation therapy 
nm  Nanometer 
OR  Operating room 
PB  Phosphate buffer 
pCR  Pathological complete response 
PE  Phycoerythrin  
PFA Paraformaldehyde 
PIK3CA  Phosphatidylinositol-4,5-bisphosphate 3-kinase, 
catalytic subunit alpha 
PSA  Prostate specifice antigen 
PSG Pregnancy-specific β-1 glycoprotein 
RI  Response index 
ROC-curve  Receiver operating characteristic curve 
RT  Room temperature 
SD  Standard Deviation 
SOP  Standard Operating Procedure  
SSC  Side Scatter  
SUV Standard uptake value 
TAM  Tumour associated macrophages 
TEM  Transmission electron microscopy 
TFAP2E  Transcription factor AP-2 epsilon 
TGL Tumour gland lumen 
TIMP1  Metallopeptidase inhibitor 1 
TKTL1  Transketolase-like 1  
TKTL1-IM  TKTL1 in macrophages 
TM Tumormarkers  
TRG  Tumour regression grade 
UA  Uranylacetate 
UC  Ulcerative colitis 
ypTN  Tumour response 
  
224 
A 
 
 
 
